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Part I Menorrhagia and bleeding disorders
General introduction
Menorrhagia is a common problem among women. At least 5-10% of women in reproductive age 
seek medical attention for menorrhagia.1 The World Health Organization estimates that 18 million 
women worldwide are affected.2 Menorrhagia is objectively defined as greater than or equal to 80 
ml blood loss per menstrual cycle3 and is a common cause of iron deficiency anaemia.3 This can 
affect a woman’s quality of life, her study or work and family and social interactions.4 Historically, the 
causes of menorrhagia have focused on gynaecological and endocrinological conditions in terms of 
organic pathology (e.g. polyps and fibroids) and anovulation/ hormonal dysbalance. After excluding 
these conditions, the remaining aetiologies were systemic disorders such as hypothyroidism5 and 
iatrogenic causes including intrauterine devices and the use of anticoagulants.1 In the past, prior 
to broad haemostatic testing in patients with menorrhagia, no specific aetiology was identified in 
approximately 50% of cases, leading to the diagnosis of exclusion ‘dysfunctional uterine bleeding’.6 
Normal menstruation can be described in part as a haemostatic process given the necessity for 
monthly formation of a primary platelet aggregate with subsequent secondary fibrin formation 
with concurrent fibrinolytic modelling of the fibrin clot. For women with menorrhagia without 
gynaecological abnormalities, haemostatic evaluation for underlying bleeding disorders,7-9 including 
von Willebrand`s disease (VWD), platelet dysfunction and coagulation factor deficiencies has been 
advised.7, 8, 10 The prevalence of underlying bleeding disorders in women with menorrhagia varies from 
1 to 47%.11,12 The highest prevalence is reported for platelet dysfunction, but this is based on one 
single study12 and is yet not well established. For VWD the prevalence varies from 5 to 24% with 
an overall prevalence of 13% (95% confidence interval, 11-16%) based on a systematic review of 11 
studies comprising 988 women with menorrhagia.11 Furthermore, it is important to realize that most 
studies measured randomly in the menstrual cycle. This could give an over- or underestimation of the 
prevalence of bleeding disorders,11 because a cyclic variation of haemostatic variables with the lowest 
levels during menstrual and/or follicular phase have been found.13 Previous studies have focussed on 
women without gynaecological abnormalities. Whether women with menorrhagia and gynaecological 
abnormalities as uterine polyps and fibroids also have underlying bleeding disorders has not been 
assessed in earlier studies.
 
Haemostatic variables during menstrual cycle
A wide range of values for coagulation and clotting factors has been reported in both normal 
individuals and patients with bleeding disorders, with a considerable overlap between normal 
subjects and patients with mild disorders, especially in patients with VWD. In addition, a wide inter-
individual and intra-individual variability of these coagulation and clotting factors has been reported. 
This variability could be the effect of hormonal changes. Estradiol concentrations are lowest on cycle 
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days (cd) 1-3 and highest on cd 13-15, followed by a decrease. Progesterone concentrations are lowest 
on cd 1-8 and highest on cd 21-25.  Such hormonal variation could have important implications for 
the timing of haemostatic evaluation in women with menorrhagia. For that reason, we decided to 
summarize the evidence for the timing of haemostatic evaluation in women with menorrhagia. 
Women with von Willebrand`s Disease
 Theoretically, men and women are equally likely to be affected with VWD, but in women the 
disorder is more often clinically manifest because of the bleeding challenges that are associated 
with menstruation and childbirth.14 Most of the studies performed so far addressed these bleeding 
problems only in mild type 1 disease rather than the more severe VWD types, and most of these studies 
are small case series. In these studies women with VWD frequently have menorrhagia, with reported 
prevalence ranging from 74 to 92%.15-17 This may lead to impaired quality of life. Several medical and 
surgical treatment options are available for menorrhagia, and the appropriate choice of therapy can 
be tailored to the individual needs of the patient. Nevertheless, women with VWD are more likely to 
undergo a hysterectomy and they undergo this operation at a younger age,18  despite the increased 
risk of bleeding complications. The above mentioned studies may suffer from selection bias given the 
fact that patients seeking medical attention for bleeding and menorrhagia have predominantly been 
included. Therefore, we initiated an investigation on the gynaecological and obstetrical symptoms 
in a large unselected cohort of women who participated in the WiN-study, a nation-wide study on 
moderate and severe VWD in the Netherlands.
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Part II Bleeding issues in obstetrics
General introduction
 Low-molecular-weight heparins (LMWH) are the most commonly used anticoagulant during 
pregnancy for prevention or treatment of venous thromboembolism (VTE). Pulmonary embolism 
(PE) is the second cause of maternal mortality in the Western world, and deep vein thrombosis 
(DVT) in pregnancy is an important cause of maternal morbidity, also on the long term.19,20 Venous 
thromboembolism complicates 1 to 2 of 1000 pregnancies, and the risk increases with age, mode of 
delivery, and presence of comorbidities.19, 21, 22 In women with a previous episode of VTE, the risk of 
recurrence during pregnancy ranges from 2-6%.23,24 For these women, with either a current VTE or 
a high risk of recurrent VTE, LMWH is the most commonly used anticoagulant during pregnancy for 
prevention of a new thrombotic event. 
The usage of  LMWH during pregnancy
 The usage of LMWH during pregnancy may be associated with an increased risk of blood loss 
or postpartum haemorrhage (PPH), a common complication of childbirth and one of the causes of 
maternal morbidity and mortality. Few studies assessed the risk of PPH associated with usage of 
LMWH,25-32 but most studies are retrospective cohort studies, without a control group and describing 
only a small number of women on therapeutic dosage LMWH. 
Moreover, the optimal dosage of thromboprophylaxis in women with an increased risk of VTE 
during pregnancy and puerperium is not well established.33 Prophylactic, intermediate as well as 
therapeutic doses of LMWH are used.34, 35 Further, current guidelines recommend discontinuing 
LMWH at least 24 hours before labor,33 although no data are available whether this decreases the 
risk of PPH. In our hospital, all pregnant women with an indication for thromboprophylaxis received 
a therapeutic dosage of LMWH during pregnancy and the puerperium. We could therefore assess a 
relatively large cohort of pregnant women on full dose LMWH. First, we evaluate the risk of PPH in 
women who used a therapeutic dosage of LMWH. Second, we assess the bleeding risk in relation to the 
last injection of LMWH. Another well-known, but underreported complication of the usage of LMWH 
are hypersensitivity skin reactions. This could be an intolerance for heparin, but pregnancy seems to 
increase the incidence of these skin reactions. However, alternative choices for anticoagulation are 
limited and hypersensitivity skin reactions might recur when another preparation of LMWH is used.36 
A few studies reported on the incidence of hypersensitivity skin reactions on LMWH in pregnant 
women, but these studies had other primary outcomes and therefore hypersensitivity skin reactions 
are probably underreported.37-39 To evaluate the incidence of hypersensitivity skin reactions, we used 
the same cohort  as for the bleeding risk. 
Alternative anticoagulation is limited, but fondaparinux, a synthetic selective inhibitor of activated 
factor X (fXa), is commonly used as an alternative anticoagulant in non-pregnant patients who develop 
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heparin intolerance. However, data on the use of fondaparinux in pregnancy is limited to animal 
models and a few case reports.42-47 While we are collecting data about the usage of LMWH during 
pregnancy, we observed during clinical practice that some women had  hypersensitivity skin reactions 
to all preparations of LMWH. And most patients strongly wish to avoid vitamin K antagonists, even 
beyond the 12th week of pregnancy, because of the association with congenital and developmental 
abnormalities.40, 41 They used fondaparinux as an alternative anticoagulation. Because of the limited 
data in the literature, we described our experience of these 10 women. 
Reproductive choices and obstetrical experience in Dutch carriers of 
haemophilia A and B
 Haemophilia is an X-linked recessive inherited bleeding disorder that arises from reduced levels 
of functional coagulation factor VIII (haemophilia A) or factor IX (haemophilia B). Males inherit 
the condition whilst females are affected as carriers. Carriers of haemophilia are expected to have 
clotting factor levels around 50% of normal as they have only one affected chromosome. However, 
a wide range of values (0.05–2.19 IU mL)42 has been reported as a result of lyonization, e.g. random 
inactivation of one of both X chromosomes.43 Some haemophilia carriers may have very low factor 
levels and therefore have an increased tendency to bleed.42 
 In the Dutch obstetrical care system, women with low-risk pregnancies can choose between 
home and outpatient hospital delivery. About 30% of the deliveries take place at home.44 This means 
that in the past, and also presently in women with unknown carrier state of haemophilia, women 
with unknown levels of plasma factor could be at risk of bleeding during pregnancy and delivery in 
a low-tech environment. From 2000 onwards, national guidelines advise to refer all known carriers, 
irrespectively of factor levels and fetal sex, to the obstetric department of a hospital with a Haemophilia 
Centre. Despite advances in care, pregnancy and delivery seems to remain critical times for carriers 
of haemophilia, with previous studies reporting 9–38% bleeding complications.45-48 Therefore, we 
want to evaluate our experience with pregnancy and delivery in carriers of haemophilia during the 
last decennia and after the introduction of the national guideline in the Netherlands. Secondly, we 
evaluate the influence of the knowledge of carriership of haemophilia on reproductive choices.
Knol.indd   14 29-08-12   09:00
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Outline of this thesis
The first part of this thesis focuses on diverse aspects of haemostatic testing and clinical symptoms 
of women with menorrhagia. Menorrhagia can be associated with a wide range of haemostatic 
disorders.  In Chapter 1 we summarize the evidence for timing of haemostatic testing during the 
menstrual cycle in women with a suspected bleeding disorder. Chapter 2 investigates the work-up 
of menorrhagia in the University Medical Centre of Groningen, with a special interest in haemostatic 
evaluation. Secondly, the outcome of routine treatment in patients with unexplained menorrhagia 
is assessed. Because haemostatic testing was not routinely done in women with menorrhagia, we 
hypothesized that the identification of haemostatic disorders might improve care for these women. 
Therefore, we designed in Chapter 3 a prospective cohort study of women with menorrhagia to 
evaluate the prevalence of underlying bleeding disorders, including VWD, other coagulation disorders 
and platelet defects, in patients with unexplained and explained menorrhagia with testing in the 1st 
week after menstruation.  Women with von Willebrand`s disease have frequently bleeding episodes 
during menstruation and childbirth. To investigate this we assess in Chapter 4 the gynaecological 
and obstetrical symptoms in a large unselected cohort of women with moderate or severe VWD who 
participated in the WiN-study, a nation-wide cross-sectional study among patients with moderate and 
severe VWD in the Netherlands
The second part of this thesis focuses on different bleeding issues in the obstetrical practice. Low-
molecular-weight heparins are the most commonly used anticoagulation drugs  during pregnancy and 
puerperium for treatment and prevention of venous thrombo-embolism. This could be complicated 
by an increased bleeding risk and hypersensitivity skin reactions due to the daily injections.  Chapter 5 
assesses the bleeding risk of the usage of a therapeutic dosage low-molecular-weight heparins during 
pregnancy and delivery compared to controls. Second, this chapter assesses the bleeding risk in relation 
to the last injection of LMWH. Chapter 6 assesses the prevalence of hypersensitivity skin reactions 
of LMWH usage during pregnancy. When these skin reactions occur, alternative anticoagulation are 
limited. Chapter 7 evaluates the usage and safety of fondaparinux as an alternative anticoagulation 
during pregnancy. Chapter 8 evaluates the reproductive choices and obstetrical experiences in the 
current generation of carriers of haemophilia in our Haemophilia Centre. Chapter 9 addresses the risk 
of recurrent fetal loss in women with thrombophilic defects and high levels of TAFI.
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Background: for a number of haemostatic factors menstrual cycle variation has been studied. Such 
variation could have clinical implications for the timing of haemostatic testing in women. 
Objectives: systematically review the literature about evidence for timing of haemostatic testing 
during menstrual cycle.
Methods: we searched MEDLINE, EMBASE and the Cochrane library to identify studies that measured 
haemostatic variables (platelet function, von Willebrand factor, factor VIII, factor IX, factor XI, factor 
XIII, d-dimer, PAI-I, tPA, alpha-2-antiplasmin and fibrinogen during normal menstrual cycle without 
hormonal contraceptives. Two investigators independently selected studies, and abstracted data in 
duplicate. 
Results: we identified 1046 studies of which we included 30 studies (25 longitudinal and 5 cross-
sectional studies).  All studies reported on haemostatic variables during menstrual cycle. Overall, most 
of the studies found no cyclic variation in von Willebrand factor, FVIII, FXI, FXIII, fibrinolytic factors (PAI, 
t-PA, uPA, d-dimer and α2-antiplasmin) and fibrinogen.  However, in studies where any these variables 
showed any variation, they reached the lowest levels during menstrual and early follicular phase, 
especially for von Willebrand Factor, FVIII and platelet function tests. 
Conclusion: the optimal timing for haemostatic testing during menstrual cycle seems to be menstrual 
and early follicular phase. 
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Menorrhagia is a very common clinical condition affecting about 5% of women. For women with 
menorrhagia without gynaecological abnormalities haemostatic evaluation for underlying bleeding 
disorders,1,2 including von Willebrand`s disease (VWD), platelet dysfunction and coagulation factor 
deficiencies has been advised.3 The prevalence of underlying bleeding disorders in women with 
menorrhagia varies from 1 to 47%.4 The highest prevalence is reported for platelet dysfunction, but 
this is based on one study.5 For VWD the prevalence varies from 5 to 24% with an overall prevalence 
of 13% (95% confidence interval, 11-16%) based on a systematic review of 11 studies comprising 988 
women with menorrhagia.6  
Interestingly, a wide range of values for coagulation and clotting factors has been reported in both 
normal individuals and patients with bleeding disorders, with a considerable overlap between normal 
subjects and patients with mild disorders, especially in patients with von Willebrand`s disease. In 
addition, a wide inter-individual and intra-individual variability of these coagulation and clotting factors 
has been reported. This variability could be the effect of hormonal changes. Estradiol concentrations 
are lowest on cycle days (cd) 1-3 and highest on cd 13-15, followed by a decrease. Progesterone 
concentrations are lowest on cd 1-8 and highest on cd 21-25.  Menstrual cyclic variation has been 
studied for a number of haemostatic factors. Such variation could have important implications for the 
timing of haemostatic evaluation in women with menorrhagia. The aim of this systematic review is to 
summarise the evidence for timing of haemostatic testing during the menstrual cycle in women with 
a suspected bleeding disorder.
Methods
Search strategy and study selection 
 We identified haemostatic variables relevant to this review from previous knowledge and a non-
systematic review of the literature. Subsequently, we searched the MEDLINE database using the terms 
‘menstrual cycle’, ‘menstruation’, ‘menorrhagia’, ‘blood coagulation factors’, ‘aPTT’, ‘PT’, ‘blood platelet 
disorders’, ‘von Willebrand factor’, ‘factor VIII’, ‘factor IX’, ‘factor XI’, ‘factor XIII’, ‘d-dimer’, ‘fibrinolysis’, 
‘PAI’, ‘tPA’, ’plasmin inhibitor’, ‘alpha-2-antiplasmin’ and ‘fibrinogen’ as MeSH terms and as text words. 
A similar search was performed in the EMBASE database and the Cochrane Database of Systematic 
Reviews with the same terms. The reference lists of relevant articles were searched for additional 
studies. The literature search was performed in August 2010. After identifying relevant titles, abstracts 
of these studies were read to decide if the study was eligible. The full article was retrieved when the 
information in the title or abstract appeared to meet the inclusion criteria of this systematic review. All 
materials were reviewed independently by two investigators (HMK and RFJK). 
 We included all study designs (cross-sectional and longitudinal studies), if they included women 
with a normal regular menstrual cycle and/or women with menorrhagia, who did not use oral 
contraceptives, in whom haemostatic variables were tested during the menstrual cycle at two or more 
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moments. We excluded studies if they included less than 5 women. No language restrictions were 
applied; all papers included in the final selection were in English. We applied no restriction in time. 
Disagreements between the two primary reviewers were resolved by discussion. 
Analysis
 We present study characteristics and the days of sampling in different tables per (group of) 
haemostatic variable(s). A priori, we determined that if there was significant clinical, methodological 
or statistical heterogeneity among included studies we would not pool data. Although we did not 
measure heterogeneity quantitatively, the design, case mix and the different days of sampling 
haemostatic variables in the included studies were, as expected, so heterogeneous that statistical 
pooling of results was not justified. We fitted a figure with the vWF levels during the follicular (cd 5-9) 
and the luteal phase (cd 19-23) and with fibrinogen levels during follicular (cd 5-11) and luteal phase 
(cd 17-28).
Results
 A total of 1048 studies were identified with our search (figure 1). We excluded 998 studies after 
screening titles and abstracts by using the predefined inclusion and exclusion criteria. Forty-eight 
studies underwent full text review, 18 studies were excluded for the following reasons: measured 
haemostatic variables in all patients on only one moment during menstrual cycle (n=5), number of 
patients < 5 (n=1), did not address the question of interest (n=8) and had duplicate data (n=1). A 
search of the reference lists, EMBASE and Cochrane databases did not yield any more relevant articles. 
Therefore, we included 30 studies for this review. 
Platelets 
 We identified two studies that tested platelet function by platelet function analyzer (PFA) and one 
study that performed a thrombocytogram during the menstrual cycle. See also table 1.
 We found two longitudinal studies7,8 and one cross-sectional study.9 Both longitudinal studies 
sampled during follicular and luteal phase in the menstrual cycle. Roell et al.9 performed a cross-
sectional study and compared the platelet function of women in the follicular phase (n=27) and luteal 
phase (n=25). All studies established the menstrual cycle to be ovulatory by measuring hormones. 
The individual sample size varied from 10 to 52 healthy volunteers. Feuring et al.7 and Roell et al.9 
performed platelet function analyses by PFA-100 using collagen/epinephrine-coated and collagen/
ADP-coated cartridges. Both studies found an increased platelet function during luteal phase. Roell et 
al. al.9 also found an increase of vWF-levels in response to increasing progesterone  levels during the 
luteal phase of the menstrual cycle. Repina et al.8 performed a longitudinal study of aggregation tests 
with ADP, ristocetin and collagen during the follicular and luteal phase in 10 pre- and perimenopausal 
women and found no cyclic variation. 
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Figure 1: Study flow diagram
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Table 1: Platelet function during the menstrual cycle










Measurement (cd or phase)
1 2
Roell et al, 2007 52 PFA-100 Y F Mid F Mid L
Feuring et al, 2002 18 PFA-100 Y 8-11 8-11 18-21
Repina et al, 2002 10 aggregation Y NA F L
NA= not applicable (no cyclic variation) Y= yes; N= no; cd= cycle days
F= follicular phase; L= luteal phase PFA= platelet function analyzer
Von Willebrand factor
 Eleven studies were identified that tested vWF levels during the menstrual cycle, varying from two 
to sixteen times. The characteristics of the studies are presented in table 2. 
 We found 7 longitudinal7, 10-15 and 2 cross-sectional studies.9,16 One study had 2 designs, namely 
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a longitudinal and a cross-sectional part.17 The longitudinal studies measured vWF-levels on at least 
two moments during the follicular and luteal phase, but four studies measured it on more moments, 
varying from 3 to 6 times. In most of the studies the days of sampling were different. The cross-
sectional studies tested women on one moment and compared the levels by grouping the women in 
groups by time of sampling during the menstrual cycle. Individual study sizes ranged from 9 to 123 
women. All studies included healthy volunteers, except one study by Kadir et al., who performed a 
cross-sectional analysis in 123 women with menorrhagia.17 In total, 7 studies7, 9-13,15  established an 
ovulatory menstrual cycle by measuring hormones. 
 Overall, five out of eleven studies found a cyclic variation. All these five studies9, 11, 13, 16, 17 reported 
the lowest vWF levels during menstruation or early follicular phase (cd 1-7). One of these studies 
by Kadir et al.17 found in their longitudinal data of 19 normal menstruating volunteers a statistically 
significant decrease of vWF-Ag and vWF-Rcf concentrations during the first 3 days of the menstruation. 
In one study by Roell et al.9 the exact days of sampling are lacking, but they reported the lowest levels 
mid follicular. VWF-levels were mostly about 10% (range 2-24%) lower in menstrual/ early follicular 
phase compared to the luteal phase (see figure 2). The other six studies reported no cyclic variation.7, 
10, 12, 14, 15, 18 




















Roell et al, 2007
Koh et al, 2005
Giardina et al, 2005
Feuring et al, 2002
Miller et al, 2002 *
Onundarson et al, 2001
Kadir et al, 1999
He et al, 1999
Blomback et al, 1997 *
Jern et al, 1991 *
Mandalaki et al, 1980
* = significant variation of vWF-levels
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We identified 9 studies that tested FVIII levels during menstrual cycle. Study characteristics are 
presented in table 2.
 We found 7 longitudinal studies,8, 10, 11, 14, 15, 19, 20 1 cross-sectional16 and 1 combined study with a 
longitudinal and a cross-sectional part.17 Individual study sizes ranged from 9 to 123 women. The 
longitudinal studies measured FVIII two to six times during the menstrual cycle. In the cross-sectional 
study by Miller et al.16 women were tested on one moment and FVIII levels were compared by grouping 
the women in 6 groups by time of sampling during the menstrual cycle. The phase of the menstrual 
cycle was estimated for each subject by subtracting the date of the last menstrual period from date of 
blood collection. In total, 5 studies established an ovulatory menstrual cycle by measuring hormones.8, 
10, 11, 15, 20 Two out of nine studies16, 19 reported a cyclic variation of FVIII during menstrual cycle. The 
lowest levels were found during menstruation and early follicular phase. All other studies reported no 
cyclic variation.8, 10, 11, 14, 15, 17, 20 
Factor IX
 We found no studies that had tested cyclic variation of FIX during menstrual cycle. 
Factor XI
 Only Kadir et al.17 tested FXI levels during the menstrual cycle and found no cyclic variations of FXI 
levels.  See table 3.
Factor XIII
 We found one longitudinal study by Bolis et al.,21 which tested cyclic variation of FXIII during the 
menstrual cycle. They tested 10 healthy volunteers on 4 moments during the menstrual cycle. They 
found a highly significant decrease during the peri-ovulatory phase of FXIII. See table 3. 
Table 3: Other haemostatic variables during the menstrual cycle








1 2 3 4
Kadir et al, 1999 142 † FXI N NA 1-4 6-11 10-18 20-25
Bolis et al, 1982 10 FXIII N 13-15 6-10 13-15 20-23 27-29
NA= not applicable (no cyclic variation);  cd=cycle days   † = 123 of them were menorrhagia patients Y= yes; N= no
Fibrinolysis
We identified 15 studies that tested fibrinolytic parameters as plasmin activator inhibitor (PAI-I), 
tissue plasmin activator (t-PA), d-dimer and α2-antiplasmin during the menstrual cycle. PAI-I is the 
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principal inhibitor of t-PA and urokinase (uPA), the activators of plasminogen and hence fibrinolysis. 
See table 4 for detailed information about these studies.












Measurements (cd or phase)
1 2 3 4 5
Toth et al, 2007 27 d-dimer Y NA F L





1-3 5-9 10-14 21-26





Ricci et al, 2004 41 t-PA-ag, PAI-
I-act Y  -7 (t-PA) 1 7 14 21
Feuring et al, 2002 18 d-dimer Y NA 8-11 18-21
He et al, 1999 23 t-PA-ag, PAI-
act N NA 5-7 24-26
Chung et al, 1998 18 PAI-I, uPA Y F (PaI-I)/
O (uPA) 
F O L
Spona et al, 1997 20 d-dimer, t-PA, 
PAI N NA 7 14 21
Blomback et al, 1997 15 PAI-I, t-PA Y NA 5-7 20-25
Larsen et al, 1996 10 PAI, t-PA Y NA Twice weekly samples during 9 weeks 







Jern et al, 1991 9 t-PA (act +ag), 
PAI-I-act Y NA 2-8 18-26
Siegbahn et al, 1989 13 PAI-I Y NA early F late F Early L late L M
Jespersen et al, 1986 15 t-PA(act+I) Y NA 1-3 5-7 12-16 19-23 27-30







1-3 5-7 12-16 19-23 27-23
F= follicular phase; O= ovulation; L= luteal phase; M= menstruation; cd= cycle days; NA= not applicable (no cyclic 
variation) Y=yes; N=no; t-PA= tissue-plasmin activator; PAI-I=plasmin activator inhibitor; uPA= urokinase plasmin 
activator; Act= activity; ag= antigen; I=inhibitor
We found 13 longitudinal7, 11-14, 18, 20, 22-27 and 2 cross-sectional studies.28, 29 Twelve studies determined 
the cyclic variation of PAI-I, t-PA and/ or uPA,11-14, 18, 22-26, 28 five studies assessed the cyclic variation of 
d-dimer7, 12, 14, 26, 29 and one study determined α2-antiplasmin levels during the menstrual cycle.27 
All studies included healthy volunteers. Study sizes ranged from 9 to 41 women. The number of 
samples in the longitudinal studies varied from 2 to 9 during menstrual cycle and the days of sampling 
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were different between the studies.  In 11 out of 15 studies the menstrual cycle was established as 
ovulatory by measuring hormones.7, 11-13, 20, 22-25, 28, 29 
Two  out of 11 studies found cyclic variation of PAI-I.12, 22 Giardina et al.12 found the lowest levels 
during the luteal phase (day 28), whereas Chung et al.22 found the lowest levels during the follicular 
phase (days not specified). One out of 10 studies found cyclic variation of t-PA.25 Ricci et al.25 found the 
lowest levels of t-PA during the luteal phase (day 21). Two out of 3 studies found a cyclic variation of 
uPA.22, 28 Chung et al.22 found the lowest levels during the ovulatory phase (days not specified) and Dorr 
et al.28 during the post-ovulatory phase (day 19-22). Two out of five studies found a cyclic variation 
of d-dimer during the menstrual cycle.12, 14 Koh et al.14 found the lowest levels late follicular (day 10-
14) whereas Giardina et al.12 found the lowest d-dimer levels in luteal phase (day 28). Additionally, 
we found one study by Jespersen et al.,27 which described a longitudinal study about α2-antiplasmin 
during the menstrual cycle. They found significantly lower levels during the late follicular phase (day 
12-16).
 




















Roell et al, 2007
Koh et al, 2005
Giardina et al, 2005
Ricci et al, 2004 *
Dapper et al, 2002 *
Repina et al, 2002
Feuring et al, 2002 *
Kadir et al, 1999 *
He et al, 1999
Blomback et al, 1997
* = significant variation of fibrinogen levels
Fibrinogen
We identified 20 studies that tested fibrinogen during the menstrual cycle. See for detailed 
information about the studies table 5. We found 17 longitudinal studies,7, 8, 10-12, 14, 18, 20, 23-25, 30-35 one 
study with a cross-sectional and a longitudinal part,17, (17) one randomized controlled trial in which 
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the haemostatic variables were measured longitudinally during the menstrual cycle in the placebo 
group26 and one cross-sectional study.9 The study sample sizes varied from 10 to 350 women. In 
the longitudinal studies, women were sampled two to sixteen times. All studies included healthy 
volunteers, except the study by Kadir et al.17 which included also 123 patients with menorrhagia. In 
total, 12 studies determined the menstrual cycle by measuring hormones.7-12, 20, 23-25, 34, 35 
Six out of 20 studies reported the lowest levels of fibrinogen during the follicular or mid-cycle 
phase.7, 14, 17, 24, 32, 34 Two studies reported the lowest levels during luteal phase25, 35 and all other studies 
reported no cyclic variation.8-12, 18, 20, 23, 26, 30, 31, 33 Figure 3 shows variation of fibrinogen levels during 
follicular and luteal phase. 








Measurement (cd or phase)
1 2 3 4 5
Roell et al, 2007 52 Y NA F L
Koh et al, 2005 30 N 10-14 1-3 5-9 10-14 21-26
Giardina et al, 2005 20 Y NA F L
Ricci et al, 2004 41 Y 21 1 7 14 21
Dapper et al, 2002 350 N F M F O L
Repina et al, 2002 10 Y NA F L
Feuring et al, 2002 18 Y 8-11 8-11 18-21
Kadir et al, 1999 142 † N 11 1 11 26
He et al, 1999 23 N NA 5-7 24-26
Blomback et al, 1997 15 Y NA 5-7 20-25
Spona et al, 1997 20 N NA 7 14 21
Larsen et al, 1996 10 Y O Twice weekly samples during 9 weeks 
Blomback et al, 1992 15 Y NA unknown
Lebech et al, 1989 37 Y 10-12 6-8 10-12 24-26
Siegbahn et al, 1989 13 Y NA early F late F early L late L M
Solerte et al, 1988 15 Y 25 7 14 21 25 27
Jespersen et al, 1986 15 Y NA 1-3 5-7 12-16 19-23 27-30
Gaur et al, 1982 18 N NA 1-7 8-14 15-21 22-28
Buchan et al, 1980 12 N NA 1-7 12-16 18-21 26-28
Cederblad et al, 1977 18 N NA 1-2 5-9 12-16 19-23
Y= yes; N= no; NA= not applicable (no cyclic variation)  † = 123 of them were menorrhagia patients; F= follicular 
phase; O= ovulation; L= luteal phase; M= menstruation




In this study, we performed a systematic review of the variation of different haemostatic variables 
during the menstrual cycle. These studies yielded conflicting results. The majority of the studies 
observed no cyclic variation, but if there was a variation, the lowest levels were measured almost 
always during menstruation and early follicular phase. For increasing the sensitivity of haemostatic 
testing, we suggest, based on these data that the optimal timing for haemostatic testing during the 
menstrual cycle seems to be during menstruation or early follicular phase for vWF, factor VIII and 
platelet function tests. For fibrinolytic parameters we found in most of the studies no cyclic variation 
during menstrual cycle.  
To our knowledge, this is the first reported systematic review concerning the variation of different 
haemostatic variables during menstrual cycle. We focused on several haemostatic variables, including 
platelet function, von Willebrand factor, factor VIII, factor IX, factor XI, factor XIII, fibrinolytic factors 
(α2-antiplasmin, PAI, t-PA, uPA, d-dimer) and fibrinogen which may cause a bleeding tendency when 
women have lower levels during menstruation.
Both studies that performed PFA testing during the menstrual cycle, found the lowest platelet 
functioning during the follicular phase and an increase during the luteal phase.7, 9 This is probably due 
to an increase of vWF-levels in response to progesterone actions.9
Five out of eleven studies9, 11, 16, 17, 19 reported the lowest vWF levels during menstruation or early 
follicular phase (cd 1-7). For FVIII we found the same results, two out of nine studies reported the 
lowest levels during menstruation and early follicular phase16, 19 and the other studies reported no cyclic 
variation. In case of borderline vWF-levels measured randomly or independently of the menstrual 
cycle in a woman with menorrhagia, we suggest to repeat testing during menstruation, preferable 
during the first 3 days. In addition, this could give therapeutic options for these patients, because it is 
during those initial 3 days that the patient would be a candidate for intranasal desmopressin for raising 
low vWF levels.36 Lower levels of von Willebrand factor and FVIII levels during this phase are possibly 
due to the fact that most female hormones are at their baseline in the early follicular phase. 
We found 15 studies about fibrinolytic parameters during menstrual cycle. Menstrual bleeding is 
associated with an increase in local fibrinolysis due to elevated levels of endometrium derived plasmin 
and plasminogen activators.37 However, most of the studies (10 out of 15) reported no cyclic variation 
of fibrinolytic parameters in plasma. Two studies found cyclic variation of d-dimer, two studies of PAI-I, 
two studies of uPA and one study of t-PA. We found one study about α2-antiplasmin, in which the 
lowest levels were reported during late follicular phase.27 Therefore, we assume that most fibrinolytic 
parameters have no significant cyclic variation during the menstrual cycle. 
Our data about fibrinogen levels during the menstrual cycle showed conflicting results. Six out 
of the 20 studies reported the lowest fibrinogen levels during the follicular or mid-cycle phase. Two 
studies reported the lowest levels during the luteal phase and all other studies reported no cyclic 
variation. Fibrinogen is an acute phase reactant, which can increase 2-20 fold during inflammation 
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and stress with a peak elevation that occurs after 3-5 days of onset. The strong association between 
fibrinogen and the acute phase reaction could be an explanation for these conflicting results. 
 A limitation of the included studies is that the days of sampling in the menstrual cycle differed 
between most of the studies. All studies measured the haemostatic variables during the follicular 
and luteal phase, but some studies measured it on more different moments, varying from two to 
sixteen times per cycle. Accordingly, because of obvious heterogeneity we could not pool these data. 
Moreover, most of the studies had a longitudinal design, but we included also 4 studies9, 17, 28, 29 with 
a cross-sectional design and 1 retrospective study with a cross-sectional design.16 In addition, the 
haemostatic variables were not always correlated to estrogen and progesterone levels. Consequently, 
the menstrual cycle was not always confirmed to be ovulatory. 
Secondly, another limitation of our study is that most of the described studies on the variation 
of haemostatic variables studied small patient numbers. Thus, real differences between the different 
phases of the menstrual cycle may be missed, because of the wide inter- and intra-individual biological 
variation in haemostatic factor levels.10 Moreover, a small number of patients could lead to a high 
coefficient of variation (CV) of the used laboratory tests. If the difference in the level of the haemostatic 
variable was lower than the CV, it is possible that the reported significant difference is not a real 
difference, but a difference what is caused by the small number of patients. For example we calculated 
the CV of laboratory tests which were used for the vWF measurement in the different studies. VWF-
levels were mostly about 10% lower during menstrual/ follicular phase, while the CV was in almost all 
studies about 30%. On the other hand, five out of eleven studies observed the same results for vWF, 
which gives us support to perform haemostatic evaluation during menstrual and follicular phase in 
clinical practice. 
Thirdly, an important part of the wide variation in results is due to the use of a variety of laboratory 
assays for determining the different haemostatic parameters in the included studies. 
In only one study, by Kadir et al.17 also women with menorrhagia were included. They found no 
cyclic variation for VWF, FVIII, FXI and fibrinogen during menstrual cycle. In the future we need studies 
for evaluating haemostatic variables during normal menstrual cycle and in women with menorrhagia, 
because perhaps women with menorrhagia show more or less variation. This could give us more 
insight in the pathogenesis of menorrhagia. 
In conclusion, this systematic review of the literature shows that the optimal timing of haemostatic 
testing seems to be the menstrual and early follicular phase of the menstrual cycle for most haemostatic 
variables. Of note, most of the studies found no cyclic variation, but if they showed a variation, the 
lowest levels were measured during these phases. Physicians suspecting deficiencies in haemostatic 
factors should therefore test during these phases, thereby increasing the sensitivity of the test.
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Objective: unexplained menorrhagia can be caused by underlying bleeding disorders. Aim of this 
study was to investigate the current work-up of menorrhagia in routine gynaecological practice, with 
a special interest in haemostatic evaluation. Secondly, we investigated the outcome of individualised 
treatment in our centre.  
Study design: retrospective medical chart review of 112 consecutive patients referred for menorrhagia 
to a general gynaecology clinic of a university teaching hospital in the Netherlands between January 
2006 and January 2007. In April 2008 we performed a structured telephone interview evaluating the 
effectiveness of their therapy. 
Results: we included 112 patients, median age was 42 years. Twenty-nine percent were anaemic 
(hemoglobin<12.0 g/dL). Seventy-one (63%) patients had unexplained menorrhagia. Only two patients 
had haemostatic evaluation, both had no von Willebrand`s disease. Forty percent (29/71) needed 2 or 
more different therapies, 17% (12/71) needed 3 different therapies and 2 patients needed a total of 7 
different therapies. Eight patients underwent a hysterectomy, six of them after endometrial ablation. 
Most patients (80%) were medically or surgically successfully treated and were satisfied with their 
therapy during follow-up. Eleven patients declined therapy and accepted their heavy periods. 
Conclusion: haemostatic evaluation in women with unexplained menorrhagia in gynaecological 
practice is uncommon in our centre. Although most of the patients were satisfied with their treatment, 
a significant number had required hysterectomy and another important proportion had to accept their 
menorrhagia. We hypothesize that the identification of haemostatic disorders might improve care for 
these women.  
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Menorrhagia is a common problem among women in the reproductive age. At least 5-10% 
of women in reproductive age will seek medical attention for menorrhagia.1 The World Health 
Organization estimates that 18 million women worldwide are affected.2,3 Menorrhagia is a common 
cause of iron deficiency anaemia4, 5 and may affect a woman’s quality of life, her study or work and 
family and social interactions.6 Menorrhagia can be caused by a wide range of disorders.7,8 For women 
with menorrhagia without gynaecological abnormalities a haemostatic evaluation for underlying 
bleeding disorders,2,9 including von Willebrand`s disease, platelet dysfunction and coagulation factor 
deficiencies has been advised,10 although the impact of testing on patients treatment outcome 
parameters has not been studied.9, 11 In the absence of carcinoma or other significant pelvic pathology, 
medical treatment is generally the first line of therapy for women with menorrhagia.12 The aim of this 
study was to investigate the work-up of menorrhagia in the University Medical Centre of Groningen, 
with a special interest in haemostatic evaluation. Secondly, we assessed the outcome of routine 
treatment in patients with unexplained menorrhagia. 
 
Materials and Methods
We retrospectively identified all consecutive patients with menorrhagia referred to the general 
gynaecology clinic of the University Medical Centre of Groningen between January 2006 and January 
2007, by searching computerized hospital files for the Dutch diagnosis-and-treatment code (DBC 
code), G11, (menstrual cycle disorders, including post menopausal bleeding). For all thus identified 
patients, medical records were reviewed. National legislation and the ethical committee of our 
institution approve this type of retrospective study without the need for review of the protocol. 
Menorrhagia was defined as heavy regular menstrual bleeding.13 Patients with postmenopausal, 
irregular, postcoital and intermenstrual bleeding were excluded. Medical records contained detailed 
information on gynaecological history elicited by using a standardized form and reviewing past 
medical history. All patients had a gynaecological examination and a pelvic sonography. Saline infusion 
sonography, hysteroscopy, haemostatic evaluation and other tests were performed when clinically 
indicated. Patients with intracavitary polyps, submucosal myoma or intramural myoma more than 2 
cm in diameter were classified as having a gynaecological abnormality or explained menorrhagia. We 
collected data including age at presentation, onset of menorrhagia, menorrhagia since menarche, 
duration of menstrual period, previous history of anaemia, associated medical problems such as 
hypothyroidism, use of medications (including aspirin and vitamin K antagonists), abnormalities during 
gynaecological examination, anaemia during presentation, laboratory data on bleeding disorders, 
initiated treatments, effectiveness and satisfaction with treatment. Specifically, we recorded whether 
the gynaecologist had documented a bleeding history, included post-partum haemorrhage, nose 
bleedings and bleeding after dental or other procedures. In routine care, an individualized treatment 
plan was made for each patient with unexplained menorrhagia, mostly starting with medical therapy. 
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Choices depended on the preferences of the patient, the effectiveness of any previous therapy, 
fertility plans and contra-indications for a given drug. Options included hormonal treatment and 
non-hormonal treatment. Hormonal treatments were combined oral contraceptives (COCs), cyclical 
and continuous progestogens and a levonorgestrel-releasing intrauterine device (Mirena-IUD). Non-
hormonal treatments were non-steroidal anti-inflammatory drugs (NSAIDs) and tranexamic acid 
during menstruation. Surgical management (endometrial ablation or hysterectomy) was considered if 
previous treatments had failed or patients did not tolerate or choose medical treatments. 
In April 2008 we contacted all included patients with unexplained menorrhagia by telephone using 
a standardized questionnaire about symptoms and effectiveness (effective – partially effective – not 
effective) of both the initial and – if applicable – the most recently started therapy.  We classified 
a treatment as effective if a patient was satisfied, considered her periods as normal and wanted to 
continue the therapy.14 We analyzed the data with Statistical Package for the Social Sciences (SPSS) 
version 16.0.
Results
In the computer search, we identified 769 patients between January 2006 and January 2007 with the 
DBC code G11. We excluded 657 patients for postmenopausal, irregular, postcoital or intermenstrual 
bleeding. One hundred and twelve patients were identified with the diagnosis menorrhagia. All their 
medical records were reviewed with a standardized data form. Patient characteristics are shown in 
Table 1. Median age was 42 years (range 13-54 years) and the median age of the onset of menorrhagia 
was 39 years. Seven patients (6%) had menorrhagia since the menarche. The duration of the menstrual 
period varied, the median was 7 days. A previous history of anaemia was reported by 36 patients (32%). 
At the time of testing 29% (32/112) of the patients were anaemic (hemoglobin <12.0 g/dL). In seventy-
one patients (63%), no gynaecological abnormality was diagnosed (unexplained menorrhagia), 16 
patients (14%) had an intracavitary abnormality (endometrial polyp in 12, submucosal uterine myoma 
in 4) and 25 patients (22%) had intramural myoma. Personal history of bleeding after surgery, tooth 
extraction, delivery or miscarriage was reported in one patient, who had a postpartum haemorrhage. 
Five patients reported a family history of menorrhagia. A laboratory evaluation for underlying 
bleeding disorders was performed in two patients, one of whom had menorrhagia since menarche 
and the other had a postpartum haemorrhage. Von Willebrand`s disease was excluded in both. Six 
patients had a history of hypothyroidism, but all used thyroid replacement therapy. Four patients 
had menorrhagia while on antithrombotic therapy. Three patients used a vitamin K antagonist, two 
of them had also a gynaecological abnormality. One patient used dipyridamol, a platelet inhibitor in 
combination with a vitamin K antagonist. 
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Age at enrolment  (years) 42 (13-54) 41(13-51) 43 (26-54)
Menstrual period (days) 7 (4-17) 7 (4-17) 7 (4-16)
Menorrhagia since menarche 7 5 2
Anaemia 32 14 18
Antithrombotic therapy 4 2 2
Hypothyroidism (suppleted) 6 6 0
Haemostatic testing 2 2 0
Postmenopausal during follow-up 6 1 5
Continuous variables are denoted as median (range), categorical variables as number.
Initial therapy - unexplained menorrhagia
 In each case of unexplained menorrhagia (n=71) treatment was tailored to the individual patient. 
Of the patients with unexplained menorrhagia, fifty were initially treated with hormonal treatment. 
Seventeen of them were treated with cyclical or continuous progestogens, 20 patients with a Mirena-
IUD, twelve patients with COCs and one patient with danazol. Fifteen patients were initially treated 
with non-hormonal medicines; five patients with tranexamic acid, eight patients with NSAIDs and two 
patients with a combination of NSAIDs and tranexamic acid. One patient underwent an endometrial 
ablation and five patients declined therapy.  
Initial therapy - gynaecological abnormalities
 Of the patients with gynaecological abnormalities (n=41), 19 patients underwent a therapeutic 
hysteroscopy (polyp resection in 12, myoma resection in 7), one patient an uterine artery embolisation, 
one patient a myomectomy and one patient a hysterectomy. Twelve patients were initially treated 
with hormonal treatment, six of them with a Mirena-IUD, four with progestogens, one with COCs and 
one with danazol. Seven patients were initially treated with non-hormonal treatment, four of them 
with NSAIDs and three with tranexamic acid. 
Treatment and follow-up during telephone interview in patients with unexplained 
menorrhagia
 Outcome in all patients with unexplained menorrhagia (n=71) was assessed by a structured 
telephone interview. Eight patients of them were lost to follow-up. The follow-up period from the 
first clinic visit to the telephone interview ranged from fourteen to twenty-six months. Figure 1 shows 
the distribution of the therapies of patients with unexplained menorrhagia during follow-up. Of the 
patients with unexplained menorrhagia who were still on treatment 80% (33/41) were satisfied and 
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20% (8/41) were partly or not satisfied at follow-up.  Forty percent (29/71) needed 2 or more different 
therapies, 17% (12/71) needed 3 different therapies and 2 patients needed a total of 7 different 
therapies. Further, 15% (11/71) of the patients declined therapy and accepted their heavy periods, 
10% (7/71) had normal periods without current therapy and 17% (12/71) were pregnant, post-
menopausal or lost to follow-up.  Of the 14 patients with anaemia before therapy, nine patients had 
improvement in anaemia with therapy, one patient had still anaemia while she accepted her heavy 
periods, hemoglobin level with therapy was missing in one patient and three patients were lost to 
follow-up. A total of nine patients with unexplained menorrhagia underwent an endometrial ablation, 
in six of them followed by hysterectomy. In total, 8 (11%) patients underwent a hysterectomy. No 
patient needed a blood transfusion or developed excessive bleeding with surgery or during therapy.  
Figure 1: Treatment of patients with unexplained menorrhagia at follow-up
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Our study shows that routine haemostatic testing of patients with unexplained menorrhagia (no 
gynaecological abnormalities) referred to a university teaching hospital is uncommon. Only two 
patients of this cohort have had haemostatic evaluation for von Willebrand`s disease, which was 
negative in both. Despite the absence of haemostatic evaluation, most patients were satisfied with 
their treatment. 
 In our cohort two patients were tested for only von Willebrand`s disease and not for other 
bleeding disorders such as platelet dysfunction. In addition, two patients with menorrhagia without 
gynaecological abnormalities had menorrhagia while on antithrombotic therapy, one due to a platelet 
inhibitor in combination with a vitamin K antagonist and one due to a vitamin K antagonist.  In one of 
the two patients who had haemostatic testing a postpartum haemorrhage was recorded as a bleeding 
symptom and the other patient had menorrhagia since menarche. It is possible that gynaecologists do 
not routinely ask for other bleeding symptoms, so are not prompted to think of underlying bleeding 
disorders in women with menorrhagia, which could also explain the low frequency of haemostatic 
testing in our cohort. Another reason that testing for haemostatic disorders is still not widespread in the 
gynaecological setting is that first line therapy (i.e. combined oral contraceptives) is not influenced.15 
On the other hand specific therapies are available for von Willebrand`s disease (desmopressin) and 
fibrinolytic disorders (tranexamic acid).16 No studies have reported on the frequency of testing for 
haemostatic disorders in adult women with unexplained menorrhagia. One study is available in 
adolescents, which also reported that the majority (85%) of the adolescents were not screened for 
bleeding disorders.17 Sixty-three percent of the patients in our cohort had unexplained menorrhagia, 
which is comparable with several studies.7,8,13 However a proportion of these patients might have 
an underlying bleeding disorder. The prevalence of von Willebrand`s disease has been reported in 
approximately 1:1500 of the general population.18,19 In women with menorrhagia the prevalence 
of von Willebrand`s disease varies ranging from 5 to 24%,9, 11, 20 with an overall prevalence of 13% 
(95% confidence interval, 11-16%) based on a systematic review of 11 studies comprising 988 
women with menorrhagia.20 Philipp et al. demonstrated bleeding disorders in 47% of 115 women 
with menorrhagia. This study also suggested that the prevalence of platelet dysfunction may be even 
higher than von Willebrand`s disease in women with menorrhagia.21,22 They found no differences in 
prevalence between adolescents, reproductive-aged women and perimenopausal women.22, 23 
 We have chosen to take satisfaction as measurement of the effectiveness of the therapy. This is 
in line with a Cochrane systematic review which concludes that the definition of treatment success 
in patients with menorrhagia is perhaps best based on woman’s satisfaction level and willingness to 
continue a particular therapy.14 Outcomes measured by methods like the alkaline haematin technique24 
and the pictorial blood loss assessment chart (PBAC score)25 are less patient-important, although they 
are valuable from clinician’s point of view. In our centre the therapy was individualized per patient 
and depending on the preferences of the patient, the satisfaction and side-effects of any previous 
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therapy, but also on fertility plans and contra-indications for a given drug. So a wide range of routine 
medical treatments were used to reduce menstrual bleeding. Surgical management (endometrial 
ablation or hysterectomy) was considered if patients did not tolerate or choose medical treatments or 
where such treatments had failed. Of the patients who were treated for menorrhagia, most of them 
(80%) were satisfied. There are no recent studies of present care in general for women presenting 
with chronic menorrhagia. In general, progestogens are the most prescribed therapy for women with 
menorrhagia. A Cochrane systematic review showed that cyclical progestogens are less effective than 
other medical therapies such as danazol, tranexamic acid, NSAIDs and the Mirena-IUD.8 Progestogens 
for 21 days of the cycle resulted in a significant reduction in menstrual blood loss, although women 
found the treatment less acceptable than Mirena-IUD.8 Probably cyclical progestogens are a good 
option for short-term treatment.8 In our cohort most of the patients with a Mirena-IUD were satisfied, 
but the number of patients per treatment was too small to analyze. Although most of our patients 
were satisfied with their treatment, this required a hysterectomy in 8 patients. Also > 2 or > 3 different 
therapies were needed in 29/ 71 patients and 12/ 71 patients respectively. 
 In conclusion, haemostatic evaluation in patients with unexplained menorrhagia is uncommon 
in our centre. Managing unexplained menorrhagia without testing for haemostatic disorders does 
not compromise patient satisfaction. However, treatment is not optimally efficient, requiring often 
several lines of therapy, and more cases of hysterectomy should be avoided. We hypothesize that 
systematic haemostatic testing might improve patient care by identifying disorders that respond to 
specific therapies. Presently, we are undertaking a prospective study to test this hypothesis. 
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Objective: to assess the prevalence of underlying bleeding disorders in women with menorrhagia with 
and without gynaecological abnormalities. 
Design: single-centre prospective cohort study
Setting: a tertiary referral teaching hospital  
Population: hundred-and-two consecutive patients referred for menorrhagia with a PBAC-score >100 
were included. Controls are 28 healthy volunteers without menorrhagia. 
Methods: patients and controls had haemostatic testing in the 1st week after menstruation. Patients 
underwent gynaecologic evaluation. 
Main measure outcomes: prevalence of von Willebrand disease, FXI deficiency, platelet defects and 
other coagulation factor deficiencies.
Results: twenty-six percent of the patients had gynaecological abnormalities, sufficient to explain 
menorrhagia. An underlying bleeding disorder was found in 29% versus 11% (p=0.04) of patients 
versus controls, and in 31% vs 27% of the women with unexplained versus explained menorrhagia 
(p=0.75). We diagnosed 6 cases of VWD, 4 cases of FXI deficiency and one FVII deficiency. The only 
abnormalities found in controls were platelet aggregation defects (11% versus 23% in patients). 
Patients had a significantly longer aPTT compared to controls (26.5 vs 25.0 sec; p=0.001) caused by 
lower median levels of FXI (100 versus 124 IU/dL; p<0.001). 
Conclusion: bleeding disorders play an equally important role in the aetiology of menorrhagia with 
and without gynaecological abnormalities. A novel finding is the occurrence of low, but not deficient 
levels of factor XI.
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Menorrhagia is a common problem. At least 5-10% of women in reproductive age seek medical 
attention for menorrhagia.1 The World Health Organization estimates that 18 million women worldwide 
are affected.2 Menorrhagia is a common cause of iron deficiency anemia3 and can affects a woman’s 
quality of life, her study or work and family and social interactions.4 
Menorrhagia can be associated with a wide range of haemostatic disorders.5,6 Von Willebrand`s 
disease (VWD) has been recognized as an important aetiologic and/or contributory factor.7-9 About 13-
20% of the patients with menorrhagia without gynaecological abnormalities have VWD as underlying 
bleeding disorder.10 The prevalence in menorrhagia of underlying bleeding disorders other than 
VWD, for example platelet function defects, is yet to be established. Although a cyclic variation of 
haemostatic factor variables has been found11 with nadirs occurring during the menstrual and/ or 
follicular phase, most previously reported studies have measured variables randomly throughout 
the menstrual cycle. This may result in over- or underestimation of the prevalence of a bleeding 
disorder.10 Previous studies have focussed on women without gynaecological abnormalities. Whether 
women with menorrhagia and gynaecological abnormalities as uterine polyps and fibroids also have 
underlying bleeding disorders has not been assessed in earlier studies.10
We studied the prevalence of underlying bleeding disorders, including VWD, other coagulation 
disorders and platelet defects, in patients with menorrhagia with and without gynaecological 
abnormalities with testing in the 1st week after menstruation in routine Dutch gynaecological practice. 
Methods
Patients
This is a single-centre prospective cohort study, including consecutive patients referred to the 
gynaecology clinic at the University Medical Centre of Groningen between March 2007 and December 
2010, with a history of heavy, regular (every 23–39 days) menstrual periods. Exclusion criteria were: 
PBAC-score <100, known bleeding disorders, use of any intrauterine device in the past 2 months, and 
treatment with anticoagulants, antifibrinolytics, non-steroidal anti-inflammatory agents, combined 
oral contraceptives, or progestagens. Referred patients who were potentially eligible received a 
structured questionnaire by mail to obtain information about baseline characteristics; medical, 
obstetrical and gynaecological history and previous treatment for menorrhagia. After reviewing the 
completed questionnaire, we excluded women with intermenstrual, irregular and postcoital bleeding. 
Thereafter they had a gynaecological examination and pelvic ultrasonography in the first week after 
menstruation. One interviewer (HMK) took the menstrual history, recorded the number of other 
bleeding symptoms such as easy bruising, nose, gum, postoperative, and postpartum bleeding, and 
bleeding after tooth extraction, and asked about a family history of bleeding disorders. Women with 
submucous uterine fibroids more than 2 cm in diameter and/or uterine polyps were classified as 
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menorrhagia with gynaecological abnormalities, or explained menorrhagia. 
The study was approved by the Institutional Review Boards of the University Medical Centre of 
Groningen. Informed consent was obtained from all patients and controls.
Controls
We also recruited 28 healthy volunteers in our hospital; women without menorrhagia (defined 
as subjectively normal menstruation) and without the use of hormonal treatment or intra-uterine 
device, for comparison of haemostatic test results in the first week after menstruation during follicular 
phase. Exclusion criteria were: known bleeding disorders, and treatment with anticoagulants or non-
steroidal anti-inflammatory agents. Controls completed the same questionnaire as the women with 
menorrhagia, but had no gynaecological examination. We did not exclude controls on the basis of 
their PBAC score.
Pictorial bleeding chart assessment of menorrhagia
Patients were informed about the pictorial bleeding assessment chart (PBAC)12,13 by an information 
letter with standard instructions before the first hospital visit and completed it in the menses before 
the first hospital visit. Women were instructed to use maxi tampons and pads. The chart consisted of a 
series of diagrams representing lightly, moderately and heavily soiled pads and tampons. The patients 
recorded each discarded item during an entire cycle. Scoring of pads and tampons was done by the 
interviewer (HMK) as previously described 12, 13 with tampons scored 1, 5 and 10 and pads scored 1, 
5, 20 for lightly, moderately and heavily soiled, respectively. Menorrhagia was defined as a pictorial 
bleeding assessment chart (PBAC) score of 100 or more based on the scoring system of Higham et 
al.12 The healthy volunteers also completed the pictorial chart, in the first menses after blood samples 
were taken. 
Laboratory measurements
A venous citrated blood sample was taken from all patients and controls in the first week after 
menstruation. In patients the blood samples were taken before the gynaecological examination. Blood 
samples were also obtained for ABO blood group typing, complete blood cell counts, ferritin and liver, 
kidney and thyroid function measurements. 
We measured activated partial thromboplastin time (aPTT) with reagents (Dade® Actin ®FS Reagent) 
obtained from Siemens (Marburg, Germany), prothrombin time (PT) with reagents (Dade® Innovin® 
Reagent) obtained from Siemens, fibrinogen with Dade® Thrombin Reagent from Siemens. The one-
stage factor VIII, IX, XI and XII assays were performed with APTT reagents (Dade® Actin ®FS Reagent) and 
factor deficient plasmas, obtained from Siemens. α
2
-antiplasmin (PI) measurements were performed 
with Berichrom® and PI reagents were obtained from Siemens. All assays were measured on a CA-
7000® system (Sysmex Corporation, Siemens). Von-Willebrand-factor antigen (vWF:Ag) was measured 
Knol.indd   50 29-08-12   09:00




by ELISA using polyclonal antiserum from DakoCytomation (Glostrup, Denmark), von-Willebrand-
factor ristocetin cofactor activity (vWF:Rco) was measured with Von Willebrand Reagent (lyophilized 
stabilized platelets and ristocetin) from Siemens in an optical aggregometer from Chrono-Log Corp 
(Haverton, PA, USA). 
Induced platelet aggregation measured by light transmission aggregometry (LTA; Chrono-Log 
Corp) was performed at 37.8°C in platelet-rich plasma with 5 different agonists;  ADP 3.3 micromol/mL 
(Sigma-Aldrich B.V., Zwijndrecht, the Netherlands), ristocetin 1.2 mg/mL (Sigma-Aldrich), arachidonic 
acid 1.5 mmol/L (Chron-Log Corp), epinephrine 1 microgram/mL (Pharmachemie B.V., Haarlem, the 
Netherlands), and collagen 1 microgram/mL (Chro-Log Corp). In a subgroup (n=48), we also performed 
LTA with lower ADP concentrations of 1.0, 1.5, and 2.0 micromol/mL. Aggregation tracings were 
performed for 10 minutes and maximal percent aggregation was recorded. Reference values (mean 
+/- 2SD) were estimated in the control group on log transformed data and a decreased aggregation 
was defined as a maximal percent aggregation below the mean-2SD. Lower limit of normal reference 
values (mean-2SD) were for ADP (3.3 micromol/mL) 64%; ristocetin 72%; epinephrine 70%; collagen 
70% and arachidonic acid 69%. 
For the other haemostatic parameters the normal ranges in our laboratory were: PT 9-12 sec; aPTT 
23-33 sec; fibrinogen 1.7-4.0 g/l; FVIII:C 50–150 IU/dL; FIX 50-150 IU/dL; FXI 70–130 IU/dL; FXII 65-150 
IU/dL; vWF:Ag 50–150 IU/dL; vWF:Rco 50–150 IU/dL and PI 75-125 IU/dL. 
Values below the lower limit of normal reference range were confirmed by a second, independent 
sample. A diagnosis of von Willebrand’s disease was made if vWF:Ag or vWF:Rco was less than 50 IU/
dL in two measurements. 
Statistical analysis
Continuous variables, expressed as medians (ranges) were used for age, age of menarche, 
duration of period and number of days of heavy menstrual bleeding. To analyse differences in levels of 
hemoglobin, platelet count, MCV and ferritin in women with menorrhagia and controls Mann Whitney 
U tests were used. The chi-square test was performed to analyse differences between the prevalence of 
bleeding disorders of women with unexplained menorrhagia and explained menorrhagia, respectively. 
Because the levels of all haemostatic variables and percentage of maximal aggregation were non-
normally distributed, we log transformed them. Differences in log transformed means between 
women with menorrhagia and controls were evaluated by t-tests. ANOVA test was used to analyse 
differences in the number of decreased maximal aggregation in patients and controls. A P-value of less 
than or equal to 0.05 was considered statistically significant. 





We included 102 consecutive patients with menorrhagia and 28 healthy volunteers. We excluded 
139 patients with PBAC <100, irregular periods, postcoital bleeding, usage of contraceptives or 
anticoagulants. Median age was 42.5 yrs (range 17-55) in patients and 40.0 yrs (range 25-55) in controls 
(p=0.06). Ninety-five percent of the patients were Caucasian. Median PBAC score was 271 in patients 
vs 126 in controls (p<0.001). Anaemia (Hb < 7.5 mmol/L) was more prevalent in patients compared 
to controls (46 vs 9%, p<0.000). Patients had a lower median Hb (7.7 vs 8.4 mmol/L; p<.001), a lower 
median MCV (84 vs 89 10-15L, p<0.001), lower median ferritin levels (12 vs 34 ng/mL; p<0.001) and a 
higher median  platelet count (289 vs 251 109/L, p<0.001). Seventy-four percent had unexplained and 
26% of patients had explained menorrhagia (with a gynaecological abnormality), respectively. See for 
detailed information table 1.






Median age, yrs (range) 43 (17-55) 40 (25-55) 0.06
Median age of menarche, yrs (range) 13 (9-17) 13 (11-14) 0.68
Median age first symptom menorrhagia 33 (9-54)
Median duration period, days (range) 7 (3-15) 5 (3-14) <0.001
Median length of cycle, days (range) 28 (22-37) 28 (23-34) 0.48
Median duration menorrhagia, months (range) 79 (3-436)
Race, n (%)
   White 97 (95) 28 (100) 0.58
   Black 1 (1) 0
   Asian 4 (4) 0
PBAC-score, median (range) 271 (106-823) 126 (41-290) <0.001
Hemoglobin < 7.5 mmol/L, n (%) 47 (46) 2 (9) <0.001
Ferritin < 15 ng/mL, n (%) 62 (61) 2 (9) <0.001
Gynaecological abnormalities, n (%) 26 (26)
Bleeding disorders
Overall, we found in 29% of the patients vs 11% of the controls an underlying bleeding disorder 
(p=0.04). The only bleeding disorder identified in controls was decreased maximal platelet aggregation 
with one or more agonists. Thirty-one percent of the patients without  vs 27% with gynaecological 
abnormalities had an underlying bleeding disorder (p=0.48). VWD was diagnosed in 7 vs 4%, 
respectively (p=0.58). Low FXI levels (<70%) were found in 4% of the women with unexplained and in 
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4% of the women with explained menorrhagia. One patient with unexplained menorrhagia exhibited 
a FVII deficiency (FVII = 49 IU/dL). Decreased maximal platelet aggregations with  one or more agonists 
were found in 21% women with unexplained vs 27% with explained menorrhagia (p=0.36). See also 
table 2.







Bleeding disorder overall 23 (31) 7 (27) 0.48
Von Willebrand Disease 5 (7) 1 (4) 0.58
Low FXI (<70%) 3 (4) 1 (4) 0.73
Other deficiencies * 1 (1) 0 0.75
Platelet defect 16 (21) 7 (27) 0.36
* factor VII deficiency
Haemostatic variables 
Patients had the same PT values as controls (10.9 vs 10.8 sec, p=0.8) but significantly longer 
aPTT values (mean: 26.5 vs 25.0 sec; p=0.001, table 3), probably caused by lower levels of FXI (mean: 
100 vs 124 IU/dL; p<0.001). The levels of  coagulation factors IX and XII, which could also influence 
aPTT values, were comparable in patients and controls, while factor VIII levels tended to be higher in 
patients (mean: 133 vs 120 IU/dL, p=0.11). VWF:Ag levels were significant lower in patients compared 
to controls (mean: 91 vs 109; p= 0.024), in line with lower VWF:Rco values, although the latter did 
not reach statistically significance. Fibrinogen and PI levels were both higher in patients compared to 
controls. See also table 3.






PT, sec 10.9 10.8 0.5
aPTT,sec 26.5 25.0 0.001
FVIII:C, IU/dL 133 120 0.11
FIX, IU/dL 110 105 0.24
FXI, IU/dL 100 124 <0.001
FXII, IU/dL 96 98 0.84
vWF:Ag, IU/dL 91 109 0.024
vWF:Rco, IU/dL 94 102 0.19
Fibrinogen, g/L 2.8 2.4 0.002
PI, IU/dL 105 97 <0.001




Overall, 23% (23/102) of the patients and 11% (3/28) of the controls had decreased maximal 
aggregation with one or more agonists (p=0.17). Fourteen patients (14%) and 2 controls (7%) had 
decreased aggregation with one agonist, 3 (3%) vs 1 (4%) with two agonists, 1 (1%) vs 0 with three 
agonists, and 5 (5%) vs 0 with four agonists, respectively (p=0.14). See also figure 1. Similar mean 
maximal aggregation was found in patients vs controls for ristocetin (both 77%); epinephrine (both 
80%); collagen (82 vs 80%, respectively) and arachidonic acid (80 vs 82%, respectively). Mean maximal 
aggregation with 3.3 micromol/mL ADP was higher in patients than in controls (81 vs 77%, p=0.037). 
We attempted to increase the sensitivity of LTA by using lower ADP concentrations, but this did not 
distinguish patients from controls: i.e. 1.0 micromol/mL ADP (49 vs 62%, p=0.76), 1.5 micromol/mL 
ADP (67 vs 64%, p=0.62) and 2.0 micromol/mL ADP (73 vs 71%, p=0.65). 
Figure 1: Histogram of number of decreased maximal aggregations (0,1 or >1) with different agonists 
in patients with menorrhagia (grey) and controls (black)





























Patients experienced significantly more often easy bruising than controls. Overall, 22% of the 
women with menorrhagia had any bleeding after surgery, tooth extraction or delivery compared to 0% 
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in controls (p=0.007). The number of bleeding symptoms was the same in women with and without a 
bleeding disorder (20% vs 22%, respectively, p=0.80). See table 4.















Menorrhagia since menarche 27 (37) 8 (27) 0.21 0 (0) 35 (34) <0.001
Epistaxis 11 (15) 1 (3) 0.08 1 (4) 12 (12) 0.18
Easy bruising 18 (25)  8 (27) 0.86 2 (7) 26 (25) 0.027
Excessive bleeding with procedures 2 (3) 3 (10) 0.15 0 (0) 5 (5) 0.30
Post partum haemorrhage (PPH)* 13 (18) 5 (17) 0.60 0 (0) 18 (18) 0.044
Bleeding with tooth extraction 2 (3) 0 (0) 0.51 0 2(3) 0.48
After any surgery, tooth extraction, PPH 16(22) 6(20) 0.80 0 22 (22) 0.007
* only women who had given birth; # FXI <70% vWF:ag or vWF:Rco < 50%, factor VII < 50% or decreased maximal 
platelet aggregation with >1 agonist.
PBAC 100 vs 185
Of the women with menorrhagia, 79 had a PBAC score above 185 vs 4 of the controls.  Restricting 
analyses to patients with a PBAC score above 185 did not change the results. The number of bleeding 
symptoms in women with and without bleeding disorder was still the same. However, in this 
subgroup analysis, women with menorrhagia experienced more often easy bruising and a postpartum 
haemorrhage compared to controls. 
Discussion
In this single-centre prospective study we found bleeding disorders in 29% of unselected women 
with an objectified menorrhagia. We demonstrated that bleeding disorders play an equally important 
role in the aetiology of both unexplained and explained menorrhagia in this consecutive cohort. The 
prevalence of bleeding disorders was equally high in menorrhagia with and without gynaecological 
abnormalities. Women with menorrhagia had significantly lower vWF:Ag and FXI levels than controls. 
Decreased platelet aggregation was often seen in patients, but also in controls.
Although women with menorrhagia exhibited easier bruising and more bleeding after surgery, 
tooth extraction or after delivery, non-menorrhagia bleeding symptoms did not predict an underlying 
bleeding disorder in our cohort. 
To our knowledge this is the first cohort that included an unselected cohort of women referred for 
menorrhagia (PBAC>100). All women had a gynecological examination after which we classified the 
women as unexplained menorrhagia or due to gynecological abnormalities. All women had haemostatic 
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testing for underlying bleeding disorders. Moreover, we also included healthy volunteers to compare 
the haemostatic levels between patients and controls during the 1st week after menstruation. 
Our study demonstrated a significantly longer aPTT in patients compared to controls. An increased 
aPTT with normal PT reflects deficiencies of factors VIII, IX, XI, and/or XII. 14 In our cohort, FIX and FXII 
were comparable between both groups and FVIII tended to be even higher in patients. Only FXI was 
significantly lower in patients. Accordingly, the longer aPTT in patients is probably due to lower FXI 
levels. The clinical relevant lower limit of the normal range for FXI is controversial and varies between 
50 IU/dL and 72 IU/dL.15 Although only a few women had levels below the lower limit of normal, 
our finding could be relevant as the correlation between FXI concentrations and bleeding symptoms 
is poor.15,16 Women with either homozygous or heterozygous FXI deficiency are more likely to have 
menorrhagia than their unaffected relatives.16 Previous studies were not designed to find lower but 
not deficient levels of FXI, as they did not include the appropriate cycle controlled controls. 
Patients had higher FVIII and fibrinogen levels compared to controls. This could be the effect of 
stress due to the anticipation of the gynaecological examination. The prevalence of von Willebrand 
disease in our cohort is 7% in unexplained menorrhagia and 4% in women with menorrhagia due to 
gynaecological abnormalities. The prevalence in women with unexplained menorrhagia is comparable 
to some other (American) studies,9,17 but most studies reported a higher prevalence.8,10 Ethnicity might 
be one factor, as our cohort was almost exclusively Caucasian. The diagnosis of VWD is complex and 
the diagnosis of mild forms can be difficult.18 Furthermore, we performed in our cohort haemostatic 
evaluation in the early follicular phase (1st week after menstruation), because of fluctuation of 
haemostatic variables during menstrual cycle. In a previous systematic review,11 which summarizes the 
evidence that haemostatic variables vary during the menstrual cycle, we reported that vWF and FVIII:C 
had their lowest levels during the menstrual and early follicular phase. Most other studies which 
evaluated the prevalence of underlying bleeding disorders in menorrhagia patients tested randomly 
and took no account of cyclic variations.7, 8, 17, 19 Accordingly, we expected that the prevalence of VWD 
in our cohort is not underestimated, because by measuring in the 1st week after menstruating, we 
increased the sensitivity of finding an underlying bleeding disorder as VWD.20-22 Furthermore, vWF:Ag 
was significantly lower in patients compared to the controls. This could not be explained by the blood 
group O effect, because this was equally divided in both groups. 
The number of defects in platelet aggregrometry seems to be comparable between patients 
and controls (23 vs 11%; p=0.17), but the number of decreased maximal aggregations with different 
agonists per women was higher in patients (Figure 1). It is possible that statistical significance was not 
attained in our cohort due to the small numbers of controls we had involved. Also the prevalence in 
women with unexplained and explained menorrhagia seems to be comparable. Only one other study 
by Philipp et al23 evaluated the prevalence of platelet aggregation defects specifically. They reported in 
47% a decreased aggregation with one or more agonists in women with menorrhagia, which is much 
higher compared to our cohort. One possible explanation for the different prevalence rates could be 
the test itself. Laboratory tests for platelet function disorders are not well standardized due to test 
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complexity and the need to rapidly process freshly collected blood samples.24 
We cannot identify a specific or combination of non-menorrhagia bleeding symptoms as a predictor 
for an underlying bleeding disorder in our cohort. Some other studies suggest that symptoms, like 
bleeding after tooth extraction, post-operative bleeding and postpartum bleeding, may be more 
valuable to predict an inherited bleeding disorder.25 Although in our study patients with menorrhagia 
more often had additional bleeding symptoms than controls, there was no difference between patients 
with and without bleeding disorders. We suggest that clinicians consider haemostatic evaluation 
in patients with menorrhagia, independent of presence or absence of other bleeding symptoms or 
gynaecological abnormalities. 
Our study has some limitations. First, we performed the platelet aggregometry only once in all 
patients and controls. This is supported by Quiroga et al,26 who reported that most repeated tests by 
LTA confirm initial findings. Nonetheless, repeat testing is recommended to rule out pre-analytical 
or analytical false positive abnormalities. Second, a proportion of the controls had also a PBAC score 
above 100 although we only included healthy volunteers with a subjective normal menstruation. 
Apparently, not all Dutch women with heavy menstruation consider their menstruation pattern 
abnormal. This is also known from the literature, the correlation between the observed PBAC score 
and the subjective menstrual blood loss is poor.27 
Our study confirms the results of other studies that haemostatic disorders play an important role 
in the aetiology of menorrhagia. A new finding is that this is also true in women with concomitant 
gynaecological abnormalities. To our knowledge this is the first reported study that found significantly 
lower levels of FXI in women with menorrhagia compared to controls. This together with its clinical 
relevance must be confirmed in a larger cohort of women with menorrhagia.
Recognizing and diagnosing underlying bleeding disorders like VWD in women with menorrhagia 
can have important clinical implications because it enables effective medical treatment of menorrhagia 
with desmopressin nasal spray and antifibrinolytic agents in addition to oral contraceptive pill28 used 
alone or in combination, and recognition of increased bleeding risk during major surgical intervention. 
Further, most underlying bleeding disorders like VWD are inherited disorders, which could lead to 
screening of family members when a case is identified.  
In conclusion, underlying bleeding disorders play an important role in the aetiology of unexplained 
as well as menorrhagia with gynaecological abnormalities. Haemostatic testing must be considered, 
independently of other bleeding symptoms and gynaecological abnormalities. 
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A nation-wide cross-sectional study was initiated to assess gynaecological and obstetrical symptoms 
in an unselected cohort of women with moderate and severe VWD in the Netherlands. 423 women 
aged ≥16 years were included. Bleeding severity was measured using the Tosetto Bleeding Score (BS). 
Menorrhagia, defined as occurrence of ≥2 menorrhagia symptoms, was reported by 81%. Of all VWD 
women, 78% received any kind of treatment for menorrhagia and 20% underwent a hysterectomy 
predominantly because of severe menstrual bleeding. Over half of the women reported more blood 
loss than can be expected with a normal delivery. In 52% of reported pregnancy losses curettage 
was needed because of bleeding. Mean number of live births was 1.9, which is comparable with the 
general Dutch population. 
In conclusion, women with moderate or severe VWD frequently have menorrhagia in need of 
treatment and 20% of the VWD women underwent a hysterectomy. Bleeding complications occurred 
in over 50% of the women after childbirth or pregnancy loss. Progeny seems not to be affected in 
women with moderate or severe VWD.
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Von Willebrand Disease (VWD) is caused by defects in or reduced levels of Von Willebrand Factor 
(VWF). It is the most common inherited bleeding disorder and affects 0.5-1% of the population, 
although not all patients with low VWF levels have clinically relevant bleeding episodes.1, 2 
Patients with VWD frequently have bleeding episodes, varying from gum bleeds and epistaxis 
to intestinal bleeding. In theory, men and women are equally likely to be affected, but in women 
VWD is more often clinically manifest because of the bleeding challenges that are associated with 
menstruation and childbirth.1 Tosetto et al. have developed a bleeding score (BS) to quantify the 
number and severity of bleeding symptoms.2 Two of the 12 items of the BS include menorrhagia and 
postpartum haemorrhage. We used the BS, a validated and commonly used instrument, to determine 
the severity of menorrhagia and postpartum haemorrhage.
The majority of published studies investigating the prevalence of gynaecological symptoms 
in women with VWD are case series of a relatively small number of women.3-7 In addition these 
women had predominantly type 1 or mild VWD. In these studies women with VWD frequently have 
menorrhagia with reported prevalence ranging from 74-92%, which may impair quality of life (QoL).4,5,8 
Also increased absence from school or work during menstruation is reported.5,6,9-11 One study reported 
that women with VWD more often underwent hysterectomy than women without VWD.12 The above 
mentioned studies may suffer from selection bias given the fact that patients seeking medical attention 
for bleeding and menorrhagia have predominantly been included.
Therefore the aim of our study was to assess gynaecological and obstetrical symptoms in a large 
unselected cohort of women with moderate or severe VWD who participated in a nation-wide study.
Methods 
Participants
We performed a nation-wide cross-sectional study among patients with moderate and severe 
VWD in the Netherlands, the “Willebrand in the Netherlands” (WiN) study. Data on gynaecological 
and obstetric bleeding were obtained retrospectively. Patients were recruited at all 13 Hemophilia 
Treatment Centers (HTCs) in the Netherlands. We included patients diagnosed with type 1, type 2 and 
type 3 VWD who fulfilled both of the following inclusion criteria: 1) hemorrhagic symptoms or a family 
history of von Willebrand disease; 2) historic levels of VWF antigen (VWF:Ag) ≤ 30 U/dL and/or VWF 
activity (VWF ristocetin cofactor activity (VWF:RCo) and/or VWF collagen binding assay (VWF:CB)) 
≤ 30 U/dL and/or FVIII:C ≤ 40 U/dL at least once. Classification of VWD into type 1, 2 and 3 was 
based on VWF parameters measured in laboratories of the various HTCs and according to classification 
guidelines.9,10 Patients with mild VWD were excluded, as were patients with other congenital disorders 
of hemostasis resulting in a hemorrhagic diathesis.
For the present analyses we selected all women aged 16 years and older. Data were obtained 
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between October 2007 and October 2009. The Medical Ethical Committees at all participating HTCs 
approved this study, and written informed consent was obtained from all study participants.
Figure 1: Flow chart of study inclusion.
261 patients did not 
participate
140 children <16 years and
243 males were excluded
45 women: no plasma
available
1067 eligible patients identified in the 
Netherlands
806 patients participated, of whom 
clinical data are available
423 women >16 years participated, of 
whom clinical data are availabie
378 women of whom plasma and 
clinical data are availabie
Assessment methods 
All participants completed an extensive questionnaire, which contained questions on bleeding 
episodes, treatment of VWD, side effects of treatment, concomitant disease, and employment.13 The 
Bleeding Score was incorporated into this questionnaire. 
The Bleeding Score was used as previously described for bleeding severity in type 1 VWD by Tosetto 
et al.2 It systematically evaluates bleeding symptoms, and accounts for both the number and severity 
of the bleeding symptoms. The severity and frequency of 12 items are scored on a scale ranging from 
-1 to 4 points. Higher scores reflect more severe/frequent bleeding. The total for all 12 items results 
in a Bleeding Score (range 3 to 45). 
Definitions 
Severe VWD was defined as the presence of at least one of the following laboratory abnormalities: 
VWF:Ag ≤ 10 U/dL, and/or VWF:RCo ≤ 10 U/dL, and/or FVIII:C ≤ 20 U/dL. Moderate VWD was defined 
as VWF:Ag 10-30 U/dL, and/or VWF:RCo 10-30 U/dL, and/or FVIII:C 20-40 U/dL.11
Menorrhagia was defined as the occurrence of at least two of the symptoms listed in table 1A.14-16 
Severity of menorrhagia was determined according to the menorrhagia items of the Tosetto Bleeding 
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Score (BSmenorrhagia).2 The score for this item ranges from 0 to 4 (table 1B). 
Severity of bleeding complications following childbirth was determined according to the 
postpartum haemorrhage (PPH) item of the Tosetto Bleeding Score (BS-PPH).2 The score for this item 
ranges from -1 to 4 (table 1B). 
Fetal loss was defined as spontaneous miscarriages, fetal death and intrauterine death. 
Table 1: A) Definition of menorrhagia and B) classification of severity of menorrhagia and postpartum 
haemorrhage, according to the Tosetto Bleeding Score
A)  Menorrhagia: ≥2 symptoms at the time of study or in the past 
     •  subjective excessive menstrual bleeding
     •  loss of blood clots during menstrual bleeding
     •  requirement of oral iron therapy or blood transfusion
     •  heavy menstrual flow that interferes with daily life
     •  menstrual period that lasts longer than 7 days
B)  Severity of bleeding symptoms*
     Severity of menorrhagia (BSmenorrhagia)
     Score 0: No menorrhagia
     Score 1: Consultation only
     Score 2: Antifibrinolytics or pill use
     Score 3: Dilatation and curettage or iron therapy
     Score 4: Blood transfusion, FVIII/VWF concentrate, desmopressin or hysterectomy
     Severity of PPH (BS-PPH)*
     Score -1: No bleeding in at least two deliveries
     Score 0: No deliveries or no bleeding in one delivery
     Score 1: Consultation only
     Score 2: Dilatation and curettage, iron therapy, antifibrinolytics
     Score 3: Blood transfusion or FVIII/VWF concentrate or desmopressin
     Score 4: Hysterectomy
* BS=Bleeding Score, scores are derived from the Tosetto Bleeding Score18
Laboratory measurements of VWD
Historic measured VWF and FVIII levels in the Hemophilia Treatment Centers were used as 
inclusion criteria for the WiN study, and patients with at least one measurement of VWF or FVIII below 
30 U/dL or 40 U/dL respectively were included.
Peripheral venous blood was collected at inclusion of the study. Plasma levels of VWF antigen 
(VWF:Ag), VWF Collagen Binding (VWF:CB), VWF activity (VWF:Act) and FVIII activity (FVIII:C) were 
measured centrally in the Erasmus university Medical Center, Rotterdam, The Netherlands. VWF:Ag 
level was measured with an in-house ELISA using a polyclonal rabbit anti-human VWF antibody 
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(DakoCytomation, Glostrop, Denmark) for capturing and a HRP-conjugated anti-human VWF antibody 
(DakoCytomation, Glostrop, Denmark) for detecting. VWF:CB level was measured with an in-house 
ELISA using collagen type 1 (Sigma-Aldrich, St Louis, USA) for capturing and a HRP-conjugated anti-
human VWF antibody (DakoCytomation, Glostrop, Denmark) for detecting. To assess VWF activity we 
have used an VWF:Act assay that measures the ability of VWF to bind GpIbα. The VWF:Act assay uses 
latex particles coated with a monoclonal murine antibody direct against the GpIbα binding domain of 
VWF (Instrumentation Laboratory B.V, Breda, The Netherlands). These latex particles were incubated 
with the patient plasma  and agglutination of the particles, proportionally to the GpIbα binding activity 
of VWF, was measured.17 In the Erasmus university Medical Center Rotterdam we have validated this 
test and compared it with the VWF:RCo activity test. We obtained a Spearman correlation coefficient 
of 0.942 FVIII:C was measured in a one-stage clotting assay (TriniCLOT, Biomerieux, Marcy l’Etoile, 
France) with FVIII-deficient plasma (Biopool, Umea, Sweden). Multimeric pattern was evaluated by 
low resolution 0.9% agarose (Bio-Rad Laboratories, Hercules, CA, USA) gel electrophoresis followed 
by capillary Western blotting.13 VWF multimer patterns were evaluated by two independent reviewers 
(HCJE and FWGL). VWF multimers were classified as either abnormal, normal or absent by comparison 
with the commercial reference plasma (Normal reference plasma, Precision biologic, Kordia, Leiden, 
Netherlands). Abnormal multimers were defined as a deviation from a normal distribution; according 
to the MCMDM-1VWD study.18 
Determination of type of VWD into type 1, type 2 and type 3 VWD and subclassification was based 
on the centrally determined VWF and FVIII parameters, according to ISTH guidelines.9, 10, 19 
Statistical methods 
Continuous variables, expressed as medians (ranges) were used for age of menarche, duration of 
period, number of days of heavy menstrual bleeding, and data on deliveries and PPH. The chi-square 
test was performed to analyse differences between the prevalence of symptoms and bleeding scores 
between subgroups. ANOVA test was used to analyse differences in age and duration of menstrual 
bleeding, and for data on deliveries and PPH. Significant differences were defined as a p-value ≤0.05. 
Results
A total of 423 women were included in the study, see figure 1. Table 2 represents the patient 
characteristics. Median age was 46 (range 16-83) years. A total of 242 (64%) women had type 1 VWD, 
120 (32%) had type 2 VWD, and 16 (4%) had type 3 VWD. 
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Table 2: Patient characteristics of the women included in the study (n=423)
age median, range 46 16-83
VWD type* 1 (n,%) 242 64%
 2 (n,%) 120 32%
      2A 83  
      2B 15  
      2M 14  
      2N 8  
 3 (n,%) 16 4%
VWF:Ag* median U/dL, IQR 33 21 to 47
VWF:CB* median U/dL, IQR 28 11 to 57
VWF:Act* median U/dL, IQR 28 12 to 59
FVIII:C* median U/dL, IQR 56 37 to 80
VWD severity* severe VWD 121 32%
 moderate VWD 257 68%
Bleeding Score median, range 12 -1 to 35
*n=378 based on patients of whom plasma was available
IQR: interquartile range
Menorrhagia in women with moderate or severe VWD
Median age of menarche was 13 years (interquartile range 12-14), table 3. The median duration 
of menstrual bleeding of the women included in this study was 7 days. Menorrhagia, defined as 
occurrence of ≥2 menorrhagia symptoms, was reported by 81% of the women (table 3). The two 
most frequent symptoms were excessive menstrual bleeding (82%) and loss of blood clots (80%). No 
differences were observed for type 1, type 2 and type 3 VWD. 
Eighty-five percent of all VWD women had consulted their general practitioner or gynaecologist 
because of menorrhagia, including 24 women who did not qualify as menorrhagia according to our 
strict definition. 
Treatment of menorrhagia in patients with moderate or severe VWD
Nearly all women with menorrhagia (99%) had used some treatment for menorrhagia. Figure 2 
shows which treatment women with moderate or severe VWD received because of menorrhagia. 
Most women with menorrhagia use or have used hormonal contraceptives (hormone therapy, oral 
contraceptives, or levonorgestrel intrauterine device) to control menstrual blood loss (68%). In 10% 
of the women desmopressin was ever given because of menorrhagia. Eleven percent of the women 
received a blood transfusion at least once because of anaemia due to menorrhagia. Fifty-six percent 
of the women with type 3 VWD received a blood transfusion, FVIII/VWF concentrate, or underwent a 
hysterectomy because of menorrhagia.
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Of all included women with VWD, 20% (n=84) underwent a hysterectomy. In the group of 
women >40 years 28% underwent a hysterectomy. Of the women with type 1, type 2, and type 3 
VWD respectively 24%, 14% and 13% underwent a hysterectomy. In 31 (37%) of the women VWD was 
diagnosed after the hysterectomy, in 29 (35%) before hysterectomy, whereas in the other women this 
was unknown. The median age at the time of hysterectomy was 37 years (range 26-54). Median age 
at the time of hysterectomy did not differ for women who were diagnosed before (38, range 27-51) or 
after (37, range 26-53) the hysterectomy, p= 0.358. Data on surgery-related bleeding was available in 
50 hysterectomies, of which 29 were complicated by a bleeding (58%). A hysterectomy was more often 
complicated by bleeding if VWD was not yet diagnosed before the hysterectomy. A hysterectomy was 
performed in 68% of the women because of menorrhagia. In the other women it is unknown whether 
bleeding was the cause of the hysterectomy. Two women underwent endometrial ablation.
Figure 2: Treatment of menorrhagia in women with moderate or severe VWD (n=342). 
* hormone therapy, oral contraceptives, hormone releasing IUD patients may have used more than one treatment 
option
Pregnancies and bleeding in patients with moderate or severe VWD
Of the total cohort of 423 women 314 (74%) had ever been pregnant. The mean number of live 
births per woman with moderate or severe VWD above the age of 40 years is 1.9. The 314 women 
had 691 deliveries. Of the 314 women 159 (51%) reported more blood loss than can be expected with 
a normal delivery, see table 4. This was not different in women who gave birth recently or decades 
ago. In women aged 16-40 years, 41 to 60 years and >60 years a PPH occurred in 46%, 51% and 55% 
respectively (p=0.610). In 77 (11%) of the 691 deliveries a blood transfusion was given because of 
postpartum haemorrhage (PPH). 
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Twenty-seven percent of the primary PPHs (within 24 hours after childbirth) occurred in women 
who received prophylactic FVIII/VWF concentrate or desmopressin. The severity of PPH is reflected in 
Tosetto bleeding score on PPH (BS-PPH). Of the 314 women who have been pregnant, 101 (33%) had 
a BS-PPH of ≥2, indicating that they were treated for PPH. A blood transfusion, FVIII/VWF concentrate 
or desmopressin was needed in 90/314 (29%) women, and 3 women (1%) underwent a hysterectomy 
because of a massive PPH. 
BS-PPH was significantly different between women with moderate and severe VWD: women with 
moderate VWD had a median BS-PPH of 0 (interquartile range -1 to 4), whereas women with severe 
VWD had a median BS-PPH of 1 (range -1 to 3) (p=0.046). We found an association between VWF 
levels, FVIII level and BS-PPH. Patients with the lowest VWF and FVIII levels had the highest BS for the 
item PPH. Women with VWF:Ag, VWF:Act or FVIII levels <10 IU/dL compared to women with levels 
≥10 IU/dL, had a 1.0 (0.3-1.7), 0.5 (0.0-0.9), and 1.8 (0.6-3.0) point BS-PPH increase respectively.
Spontaneous abortion, fetal death and intrauterine death in moderate or severe VWD
We collected data on elective abortions, spontaneous miscarriages and fetal deaths. Twenty 
women did not fill in this part of the questionnaire, therefore data were available for 294 of the 314 
women who have been pregnant. Of these, 115 women (39%) had a total of 201 pregnancy losses 
(elective abortions, spontaneous miscarriages and fetal deaths). In 52% of the pregnancy losses 
curettage was needed because of bleeding.   
Discussion
In this nationwide study of a large unselected cohort of 423 women with moderate to severe VWD 
in the Netherlands, we have demonstrated a very high prevalence of menorrhagia. Nearly 80% of all 
the VWD women had used medication or underwent an intervention because of menorrhagia. Of all 
included women with VWD, 20% underwent a hysterectomy. Moreover, a high incidence of bleeding 
complications associated with pregnancies was observed. Thirty-nine percent of these women had 
a pregnancy loss, half of the women needed curettage because of bleeding after pregnancy losses. 
Progeny was comparable with the general Dutch population.
In this largest cohort of women with VWD described so far, including the majority of all women 
with moderate to severe VWD in the Netherlands, 81% reported the occurrence of 2 or more 
symptoms of menorrhagia and 85% sought medical attention for menorrhagia. This is comparable 
with other, smaller studies about menorrhagia in women with VWD.4,5,8,20 These are very high numbers 
in comparison to the general population in which 5-10% of women in reproductive age has sought 
medical attention for menorrhagia.21 There is a discrepancy between the percentage of women 
consulting a physician for menorrhagia (85%) and the percentage of women with menorrhagia (81%). 
Probably most of the women have menorrhagia, but did not fulfil the strict definition of menorrhagia 
we used in our study. In addition, women may subjectively perceive their menses as normal when 
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mothers or sisters also have menorrhagia. 
The high number of hysterectomies (20%) in our VWD cohort is of particular concern. The 
proportion of hysterectomies is nearly twice as high as previously reported in a Dutch study on women 
with chronic menorrhagia. In this study 11% of the women underwent a hysterectomy at a median 
age of 42.22 The women in our study underwent the hysterectomy at a younger age (median 38 years), 
which is comparable with other studies on women with VWD.4, 6, 8, 20 A hysterectomy was complicated 
by bleeding more often if VWD was not yet diagnosed. It is therefore of utmost importance that 
gynaecologists consider inherited bleeding abnormalities including VWD, because in these women 
other treatment options, i.e. intranasal desmopressin and/or tranexamic acid, might have resulted 
in less menstrual blood loss. In case surgery is still needed, desmopressin or FVIII/VWF concentrate 
can be given perioperative to prevent bleeding complications. Fortunately the high proportion of 
hysterectomies does not seem to reduce the progeny, as the number of children is similar to the 
general population.
Despite the increased awareness of bleeding problems in women with VWD in the last 
decades,14,23,24 postpartum haemorrhage is still a major concern in these women. Treatment options 
like FVIII/VWF concentrate became available, nevertheless we observed no reduction in postpartum 
haemorrhage over the last decades. A blood transfusion after delivery was more often needed in 
VWD women (11% of all deliveries) compared to the general population in which the incidence of 
blood transfusion after vaginal delivery and caesarean section is 1% and 1-7%, respectively.25 In our 
study we used retrospective data, therefore it is impossible to definitely confirm the diagnosis of 
postpartum haemorrhage, furthermore it is known that surveys on postpartum haemorrhage show 
higher numbers than discharge summaries.26 Remarkable, improvement of care and guidelines has 
not decreased the frequency of postpartum haemorrhage. The cause of postpartum haemorrhage in 
women who received prophylactic treatment was unknown. Prospective studies are needed in order 
to improve outcome and to optimize current treatment guidelines.27 
A main concern of many women with VWD is whether they have lower rates of conception 
or a higher chance of miscarriages or spontaneous abortions. Our study revealed a mean number 
of live births of 1.9 per woman above the age of 40, which is comparable with the general Dutch 
population (1.8).28 Therefore, we concluded that having VWD does not result in fewer children. Our 
questionnaire did not distinguish between early and late fetal loss, therefore it is not possible to draw 
firm conclusions about the prevalence of fetal loss in our cohort. A very high number of women (52%) 
needed curettage because of bleeding after pregnancy losses. This is in line with a previous study, in 
which also a high incidence of post-abortal bleeding was observed.29 In the general population the 
number of curettage after pregnancy loss was only 2-20%.30 The high number of bleeding can partly 
be explained by the low FVIII and VWF levels in VWD, which do not rise significantly until the second 
trimester by which stage many fetal losses have already occurred.31, 32 
Our study has some limitations. First the study design, we performed a retrospective study in which 
data were gathered using a self-completed questionnaire, and we have only self-reported data about 
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menorrhagia and postpartum haemorrhage. Recall bias may be a potential problem. We determined 
the severity of menorrhagia and PPH using the Tosetto Bleeding Score and did not quantify blood loss 
for instance with the pictorial blood loss assessment chart (PBAC) score. However data on the need of 
blood transfusion seem to be reliable and showed an increase in the VWD women compared to the 
general population. We defined menorrhagia as the presence of ≥ 2 symptoms (see table 1), based 
on available literature and recommendation of an international expert panel.14-16 Second, the Tosetto 
Bleeding Score used in this study was designed as a physician-administrated questionnaire and not 
for self-administration. However, patients with severe VWD and type 3 had higher bleeding scores, 
compared to patients with type 1 VWD and moderate VWD, suggesting that this self-completed 
questionnaire revealed reliable results. A third limitation is that the Tosetto Bleeding Score was 
originally developed only to distinguish between adult type 1 VWD patients and patients without 
VWD.2, 33 However recently also others have successfully used the Bleeding Score in type 2 and 3 
VWD,34,35 and we think that this also reflects severity of bleeding phenotype in our cohort of patients.
The strength of our study is the large number of unselected women included. Our study covers 
almost all women with moderate and severe VWD in the Netherlands, since the large majority of all 
individuals who were diagnosed with moderate or severe VWD in any of the 13 Dutch Haemophilia 
Centres participated in the study. Therefore referral bias is limited, especially since our cross-sectional 
study included all women, regardless of the presence of menorrhagia. Finally, central laboratory 
testing of VWF and FVIII levels was performed, excluding bias by inter-laboratory differences.
In conclusion, women with moderate or severe VWD frequently have menorrhagia in need 
of treatment and a large proportion of the VWD women underwent a hysterectomy. Bleeding 
complications occur in over half of the women after childbirth or pregnancy loss. Progeny seems not 
to be affected in women with moderate or severe VWD.
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Background: Low-molecular-weight heparins (LMWH) are the most commonly used anticoagulant 
during pregnancy for prevention or treatment of VTE. However, the size of the associated risk of 
postpartum haemorrhage (PPH) is unknown. 
Objective: to assess the bleeding risk of high dose LMWH, also in relation to the time between last 
dose LMWH and delivery. 
Material and methods: from 1999 to 2009, we followed 88 pregnant women who were started on 
therapeutic anticoagulation. Controls were pregnant women without LMWH, matched 1:4 for parity, 
mode of delivery, age, gestational age and delivery date. PPH was defined as >500 ml blood loss for 
vaginal delivery (severe PPH in vaginal delivery as >1000 ml) and >1000 ml for cesarean section (CS). 
Women were divided into subgroups by the interval between last dose of anticoagulation and delivery 
(<12, 12-24hrs, >24hrs). 
Results: Risk of PPH after vaginal delivery was 30% and 18% for LMWH-users and non-users, 
respectively (OR 1.9, 95%CI 1.1-3.5). Risk of severe PPH after vaginal delivery was not different (5.6 
vs 5.0%; OR 1.1; 0.4-3.6). Risk of PPH after CS was 12% in LMWH-users and 4% in non-users (OR 2.9; 
0.5-19.4). Both events of LMWH-users occurred after emergency CS. The risk of PPH associated with 
delivery within 24 hours after last dose of LMWH was 1.2 fold higher (95%CI 0.4-3.6) compared to a 
larger interval. 
Conclusion: high dose LMWH carries an increased risk of more than 500 mL blood loss after vaginal 
delivery. However, this results not in more clinical relevant severe PPHs. The interval between last 
dose of LMWH and delivery does not influence the risk of PPH.   
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In the general population, 0.5 in 1000 pregnancies1 is complicated by a venous thrombo-embolism 
(VTE), with a predominance in the puerperium.2,3 In women with a previous episode of VTE, the risk 
of recurrence during pregnancy ranges from 2.4-6.2%.4,5 For these women, with either a current 
VTE or a high risk of recurrent VTE, low molecular weight heparin (LMWH) is the most commonly 
used anticoagulant during pregnancy. The optimal dosage of thromboprophylaxis in women with an 
increased risk of VTE during pregnancy and puerperium is not established.6 In our hospital, all pregnant 
women with an indication for thromboprophylaxis received a high dose intended as a therapeutic 
dosage of LMWH during pregnancy and the puerperium. 
Usage of LMWH during pregnancy may be associated with an increased risk of blood loss or 
postpartum hemorrhage (PPH), a common complication of childbirth and a leading cause of maternal 
morbidity and mortality. Few studies assessed the risk of PPH associated with usage of LMWH,7-14 but 
most studies are retrospective cohort studies, without a control group and describing only a small 
number of women on therapeutic dosage LMWH. 
Further, current guidelines recommend discontinuing LMWH at least 24 hours before labor,6 
although no data are available whether this influences the risk of PPH. This is challenging as labor may 
start unplanned. 
We performed a retrospective cohort study in our hospital to evaluate our treatment protocol 
to assess the bleeding risk with high dose therapeutic dosage LMWH during delivery compared to 
controls and to assess the bleeding risk in relation to the last injection of LMWH.
Methods
Patients
This is a retrospective cohort  study, including as cases consecutive women who started with a 
therapeutic dosage LMWH during pregnancy at our hospital between 1999 and 2009. These women 
were followed prospectively during pregnancy in a combined obstetric/ coagulation clinic and seen 
by a thrombosis specialist every 2 months until 6 weeks post-partum.  Indications for anticoagulation 
were a history of idiopathic, provoked or pregnancy related VTE, recurrent fetal loss or asymptomatic 
thrombophilic defects (protein C, S or AT deficiency). For a given woman, we included only the first 
ongoing pregnancy in which she used anticoagulation, to avoid selection bias. Pregnancies with 
early fetal loss were not included. Detailed information on episodes of VTE, external risk factors for 
thrombosis, obstetric history, anticoagulant treatment and delivery was collected using a standardised 
questionnaire. Data on labor was collected retrospectively by reviewing medical records. National 
legislation and the ethical committee of our institution approve this type of studies without the need 
for review of the protocol. 




Women were started on a therapeutic dosage of nadroparin once daily in early pregnancy with 
bodyweight adjusted therapeutic dosage (175 anti-Xa IU kg−1 day−1), as soon as a pregnancy test was 
positive or when a VTE occurred during pregnancy. All women were followed by a thrombosis specialist 
every 2 months until 6 weeks post-partum. Anti-fXa levels were not routinely monitored and doses of 
LMWH were not adjusted for increasing bodyweight or increasing renal clearance. If hypersensitivity 
skin reactions developed, we switched to another preparation, fondaparinux, danaparoid or 
acenocoumerol. The women had no planned induction of labor with withholding of anticoagulation, 
but all women switched to divided (twice daily) dosing of their LMWH in the 37th week to minimize 
the bleeding risk. Women who used acenocoumerol switched to a twice daily dosing LMWH in the 
37th week. Second, LMWH or another preparation was stopped at the start of spontaneous or induced 
labor and restarted 4-8 hours after delivery (when blood loss was normal) and stopped six weeks 
postpartum. Women with a current VTE during pregnancy were treated for six months, but at least 
until six weeks postpartum. 
Controls
Controls were women who delivered in our hospital and did not use LMWH or another 
anticoagulant during pregnancy. LMWH users were matched 1:4 to controls (non-users) by random 
electronic selection for parity, mode of delivery, age, gestational age, and date of delivery (+/- 2 years). 
Exclusion criteria for the controls were a history of VTE or PPH.
Definitions
The amount of blood loss was a visual estimation.  According to the WHO guidelines, we defined 
>500 ml as definition of PPH for vaginal delivery and >1000 ml for a cesarean section. Severe PPH was 
defined as >1000 ml for a vaginal delivery. Primary and secondary PPH were defined as a bleeding 
within 24 hours after delivery and after 24 hours, respectively.15
Statistical analysis
Continuous variables were expressed as mean or median values and standard deviations or ranges 
depending on normality, categorical data as counts and percentages. Differences between groups 
were evaluated by the student t test or Mann-Whitney U test, depending on the normality of data 
for continuous data, and by Fisher exact test for categorical data. A two-tailed p-value of less than 
0.05 was considered statistically significant. Women were divided into subgroups by the various 
intervals between last dose of LMWH and delivery (<12 hrs, 12-24 hrs, >24 hrs). Logistic regression 
was performed for calculating odds ratios for PPH in users and non-users and in relation to timing of 
last injection of LMWH with adjustment for known risk factors for PPH, such as age, parity and birth 
weight >4000 gram. Statistical analyses were performed using PASW version 18.0 (IBM SPSS, Chicago, 
Illinois, United States).
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We followed 143 pregnancies in 88 women. We included 88 first pregnancies in which women 
used full dose anticoagulation. Baseline characteristics are shown in table 1. Median age was 30 yrs 
(range 20-43 yrs), 66% was nulliparous. All women started with nadroparin. Sixty-eight percent (n= 
60) used LMWH during the whole pregnancy,  17 (19%) women switched to acenocoumarol between 
16 and 36 weeks, 9 (10%) switched to fondaparinux, 2 (2%) switched to danaparoid and one woman 
switched to unfractionated heparin during labor. The reason for switching was mostly hypersensitivity 
skin reactions or (for VKA) the wish to avoid injections. All women used a  dosage of anticoagulation 
intended as therapeutic during pregnancy. 
Modes of deliveries were vaginal in 81% and cesarean section (CS) in 19% (9% elective, 10% 
emergency). Labor was induced in 26 of 88 women: this was in 17/71 (24%) women who had a 
vaginal delivery, 1/9 (11%) of the women who had an emergency CS and 8 women who had a primary 
CS. Median gestational age was 39 0/7 weeks (28 3/7-42 3/7). One late fetal loss in the 30th week 
due to abruptio placenta was reported in this cohort. In total, 3 pregnancies were complicated by 
preeclampsia and 3 by HELLP syndrome.





Median age at pregnancy, years 30 30
Median gestational age at delivery, weeks 39 0/7 39 4/7
Median birthweight, gram 3360 3360
Aspirin use 0 0
Indication for anticoagulation, n(%)
   History of VTE 64 (73)
   Recurrent fetal loss 5 (6)
   Asymptomatic thrombophilic defects‡ 14 (16)
   VTE in current pregnancy 5 (6)
Mode of delivery, n 
    Vaginal, normal delivery 65 260
    Vaginal, assisted 6 24
    Cesarean section, primary 8 32
    Cesarean section, secondary 9 36
‡ Antithrombin, protein C and protein S deficiency
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Bleeding complications during pregnancy
Of the 88 patients, 5 (6%) had vaginal blood loss during pregnancy without gynecological 
abnormalities. All these women used LMWH. One patient had epistaxis around the 20th week and 10% 
had hematoma due to injection of the LMWH. No other bleeding episodes were reported. 
Figure 1: Blood loss after vaginal delivery in users vs non-users 
Bleeding complications during and after delivery
Risk of PPH after vaginal delivery was 30% vs. 18% for LMWH-users and non-users, respectively 
(OR 1.9; 95%CI 1.1-3.5; p=0.029). Risk of severe PPH (>1000 ml) after vaginal delivery was comparable 
between both groups (5.6 vs 5.0%; OR 1.1; 95%CI 0.4-3.6; p=0.83). Of the LMWH-users who had a 
severe PPH after vaginal delivery (4/71), 2 had uterine atony, one had retained placenta and one had 
a PPH after vacuum extraction due to uterine atony. Risk of PPH in women who delivered by CS was 
12% (2/17) in LMWH-users and 4% (3/67) in non-users (OR 2.9; 95%CI 0.5-19.4; p=0.26). Both events 
in LMWH-users occurred after emergency CS, but both had their last injection of LMWH > 12 hours 
before the CS.  See also table 2. The reasons for emergency CS were fetal distress (n=5), prolonged 2nd 
stage of labor (n=1) and a prolonged 1st stage of labor. (n=3). None of the women with a pregnancy 
complicated by HELLP-syndrome or pre-eclampsia experienced a severe PPH.
Of the women who used danaparoid (n=2) and unfractionated heparin (n=1) during delivery, none 
experienced a PPH. Of the women who used fondaparinux during delivery (n=9), one experienced a 
PPH, but she had her last injection 48 hours before. 
The amount of blood loss after vaginal delivery is presented in Figure 1, showing an increased 
percentage of women with PPH (blood loss 500ml or more), but not of severe PPH (over 1000 ml). Of 
note, the median blood loss was comparable after primary (350 vs 325ml; p= 0.79) and emergency CS 
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(425 vs 400 ml; p=0.29) in users vs non-users, respectively.  
In total, 8% (2/26) of LMWH users vs 11% (8/73) of the non-users who experienced a PPH, needed 
red blood cell (RBC) transfusion (p=0.46). 
Finally, one woman who used LMWH experienced a secondary PPH (>24 hrs).








    500 ml 29.5 23.6 0.08 1.6 (0.9-2.7)
    1000 ml 6.8 4.8 0.46 1.4 (0.5-3.8)
Vaginal delivery (overall)
    500 ml 29.6 17.8 0.029 1.9 (1.1-3.5)
    1000 ml 5.6 5.0 0.83 1.1 (0.4-3.6)
Vaginal delivery (spontaneous)
    500 ml 26.1 15.8 0.058 1.9 (1.0-3.6)
    1000 ml 4.6 3.8 0.79 1.2 (0.3-4.5)
Vaginal delivery (assisted)
    500 ml 66.7 37.5 0.21 3.3 (0.5-22.0)
    1000 ml 16.7 16.6 1.0 1.0 (0.1-11.1)
Cesarean section (overall)
    1000 ml 11.7 4.4 0.26 2.9 (0.5-19.4)
Cesarean section (primary)
    1000 ml 0 6.3 0.45
Cesarean section (emergency)
    1000 ml 22.2 2.8 0.06 11.3  (1.0-145.5)
Timing of last injection LMWH and risk of bleeding
Of the 88 women with anticoagulation during first pregnancy (LMWH users), 10 women delivered 
within 12 hours after the last injection of LMWH, 37 women within 12-24 hours and 26 women after 
24 hours. In 15 women (17%), the timing was unknown. The time between last injection and delivery 
of the women who delivered within 12 hours ranged from 5 to 11 hours, with a median of 6 hours. 
Median blood loss in women who delivered before 12 hours after last dose of LMWH was comparable 
to 12-24 hours and after 24 hours (275 vs 350 vs 325 ml; p=0.30). Risk of a PPH after vaginal and CS 
delivery was 30%, 38% and 27% for intervals of <12, 12-24 and >24 hours, respectively (p=0.36). Risk 
of a severe PPH was 0%, 11% and 4% for intervals of <12, 12-24 and >24 hours, respectively (p=0.58). 
Overall, the risk of PPH within 24 hours after the last injection of LMWH did not significantly differ 
from the risk in  women who delivered more than 24 hours after the last injection (OR 1.4; 95% CI 0.5-
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3.9; p=0.56). After adjustment for age, birthweight >4000 gram and parity, OR was 1.2 (95% CI 0.4-3.6; 
p=0.73). See for detailed data table 3. In 17% of the women (n=15) we had missing data about the 
timing of last injection of LMWH, but their median blood loss was comparable with the women who 
delivered within and after 24 hours (300 vs 350 vs 249 ml; p=0.21). 
Of the women who had a planned induction of labor, 50% delivered within 24 hours after the last 
dose of LMWH and of the women who had spontaneous onset of labor 58% delivered within 24 hours. 
After adjustment for parity, age and birthweight >4000 gram, LMWH-users who had a spontaneous 
onset of labor had a 1.9 fold increased risk for PPH compared to women who had a planned induction 
of labor (95% CI 0.6-5.8; p=0.29).
Table 3: Risk of PPH based on interval between last injection of LMWH and delivery
< 24 hrs > 24 hrs OR (95%CI) OR (95%CI)‡ p ‡
Overall
    MBL, ml 300 350
    PPH, % 34.7 28.0 1.4 (0.5-3.9) 1.2 (0.4-3.6) 0.73
Vaginal delivery 
    MBL, ml 300 300
    PPH (>500 ml), % 35.0 26.3 1.5 (0.5-5.1) 1.3 (0.4-4.8) 0.68
Cesarean section
    MBL, ml 400 400
    PPH (>1000ml), % 11.1 16.7 0.7 (0.03-12.4) 0.4 (0.1-21.4) 0.67
‡ adjusted for age, parity and birthweight >4000 gram; MBL: median blood loss
Thrombo-embolic complications
No recurrent VTE was reported in the women who used therapeutic dosage LMWH because of a 
history of VTE. Five women had a current VTE during the pregnancy, one woman had a recurrent VTE 
in the 8th week and one woman in the 34th  week of pregnancy while they had not yet started their 
thromboprophylaxis. Three patients had a first VTE in 8th, 10th and 37th week of pregnancy and started 
with therapeutic dosage of LMWH. 
Comments
In this study, we analysed the bleeding risk of high dose LMWH during pregnancy and the 
puerperium in 88 pregnancies. We showed that women who used LMWH had a 1.9-fold increased risk 
for PPH, but this did not result in more RBC transfusions. We observed no increased risk for a severe 
PPH after vaginal delivery. The PPH risk was not increased in women who delivered within 24 hours 
after the last injection of LMWH as compared to women who delivered more than 24 hours after the 
last dose LMWH.
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Overall, we reported 30% PPH (>500 mL) and 6% severe PPH after vaginal deliveries in women 
who used LMWH. There are a few studies who also reported the bleeding risk of high dose or 
therapeutic dosage of LMWH.7, 10, 13, 16 Kominiarek et al.7 reported no increased bleeding risk in a case-
control study of 49 women using LMWH during pregnancy. Sixty-seven percent used a therapeutic 
dosage of LMWH, but they did not analyse the risk of therapeutic dosages separately. Furthermore 
70% had more than 24 hours between last dose of LMWH and delivery. Voke et al13 reported a 5% 
incidence of primary PPH (>500 mL) in 126 women with a VTE during the current pregnancy followed 
by therapeutic dosage LMWH, but there was no control-group. Rowan et al10 described no bleeding 
complications in 32 pregnancies with therapeutic dosage of LMWH, but 26 of these women had a 
planned induction of labor. Lepercq et al.16 described 624 pregnancies of which 49 women used a 
therapeutic dosage of enoxaparin. They found no increased bleeding risk, but did not analyse the 
pregnancies with therapeutic dosage separately. 
We observed 18% PPH and 5% severe PPH in our matched controls after vaginal delivery. This is 
comparable with findings of a population-based cohort analysed in the Netherlands, which showed a 
risk for PPH (>500 ml) and severe PPH (>1000 ml) of 19% and 4.2% after vaginal delivery, respectively.15 
There is no single, satisfactory definition for PPH worldwide. In the Netherlands a PPH is defined as 
>1000 ml blood loss for a vaginal delivery and a cesarean section. Because different countries and 
the WHO define PPH as more than 500 ml blood loss after vaginal delivery, we also used these cut-
off values for the analysis. We observed no increased risk for a severe PPH after a vaginal delivery. 
Moreover, figure 1 shows that the distribution of the amount of blood loss lies mainly below 1000mL. 
This amount of blood loss is usually not clinical relevant, because this leads mostly not to a RBC 
transfusion and an extension of the hospital stay.  
In our cohort women started with a therapeutic weight-adjusted once daily dosage of LMWH in the 
beginning of their pregnancy until 37 weeks of gestation. During pregnancy LMWH requirements may 
alter because the glomerular filtration rate increases in the 2nd trimester and the volume of distribution 
of LMWH changes. Given these physiologic changes, Crowther et al.17 suggested that the dosage of 
LMWH should be increased in proportion to the change in body-weight. However, adjustment of the 
dose of LMWH according to anti-fXa levels and increasing body-weight is controversial. Some small 
studies showed that periodic (every 1-3 months) dose-adjustment to maintain therapeutic anti-fXa 
levels is essential.18, 19 However, other studies demonstrated that only a few women require dose 
adjustment when therapeutic doses of LMWH are used.20,21, 22 Therefore, in the absence of large studies 
with clinical end-points of optimal dosage during pregnancy we decided to not routinely monitor anti-
fXa levels and not to adjust the doses for increasing bodyweight or increasing renal clearance.
The women who received their last injection of LMWH within 24 hours before delivery had no 
increased bleeding risk compared to women who delivered after 24 hours. The ACCP guidelines 
recommend a weight-adjust twice-daily dosage LMWH and discontinuation of LMWH at least 24 hours 
prior to elective induction of labor (Grade 1C).6 In our hospital women who use anticoagulation for 
(prevention of) VTE have no standard planned induction of labor, but all women switched to divided 
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therapeutic weight-adjusted dosing of LMWH in the 37th week to minimize the bleeding risk. However, 
dividing the LMWH dose into twice daily doses and stopping at start of labor may decrease the 
anticoagulant effect at delivery. In total, only 30% of the women in our cohort had a planned labor. 
The incidence of PPH in the women who had a spontaneous labor seems to be higher compared to 
women with a planned labor, (OR 1.9; 95% CI 0.6-5.8; p=0.29) but not reaching statistical significance. 
This difference cannot be explained by a longer duration between delivery and the last dose of 
LMWH, because the number of women who delivered within 24 hours was comparable in both 
groups. Reassuringly, in women who delivered within 12 hours after last dose of LMWH, no severe 
PPH occurred and no woman needed a RBC transfusion. One study by Maslovitz et al.8 described the 
bleeding risk postpartum related to the timing of last injection of LMWH. They found no increased 
bleeding risk in the women who delivered within 24 hours, but most of these patients (84%) had only 
a prophylactic dosage of enoxaparin. 
Our study has some limitations. Firstly, the amount of blood loss was not objectively measured, 
but as in common clinical practice the blood loss was a visual estimation. It is known that this gives 
mostly an underestimation of the amount of blood loss,23-25 in particular a higher estimated blood 
loss (>500 ml) is associated with a greater underestimation.26 In our cohort we observed an increased 
risk for a >500 ml blood loss in vaginal delivery but no increased risk for >1000 ml. The latter could 
be explained by visual underestimation of especially the higher amounts of blood loss. Secondly, the 
obstetricians attending the birth were not blinded and may have managed the third stage of labor 
differently in an anticoagulated patient either by administering prophylactic agents (i.e. oxytocics) 
or intervening earlier to prevent PPH. However, all women (users and non-users) who deliver in our 
hospital have an active management of the third stage of labor, including oxytocin. Thirdly, we did not 
evaluate the therapeutic anticoagulant effect with objective laboratory analyses. Therefore, it may be 
possible that a proportion of patients did not reach therapeutic levels of LMWH in the third trimester. 
Finally, the collecting of data about the delivery and timing of last dose of LMWH retrospectively is 
a limitation. Consequently, we had 17% missing data about the timing and two women with missing 
data had a PPH. However, the median blood loss of these women was comparable with the women 
without missing data. 
Given the increased risk of PPH for vaginal and emergency CS delivery in women using full dose 
LMWH for prevention of VTE during pregnancy, the individual risk of VTE and PPH should be balanced. 
We will reconsider our treatment protocol, maybe in a subgroup of patients a prophylactic dose of 
anticoagulation during pregnancy might result in more net benefit.27 A randomized trial comparing full 
dose LMWH with prophylactic dose LMWH in pregnant women with an increased risk of VTE is needed 
to improve patient care. 
In conclusion, high dose LMWH carries an increased risk of PPH after vaginal delivery. However, it 
does not lead to an increased risk for a severe and clinical relevant PPH. It is unknown whether this risk 
is offset by a lower risk of (recurrent) VTE. Secondly, PPH risk seems to not be increased after deliveries 
within 24 hours after the last injection of LMWH compared to women who delivered after 24 hours.
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Background: Low-molecular-weight heparins (LMWH) are the most commonly used anticoagulants 
for the treatment and prophylaxis of venous thrombo-embolism in pregnancy. Hypersensitivity skin 
reactions associated with the use of LMWH are frequently seen, but are probably underreported.
Objective: to evaluate the incidence of hypersensitivity skin reactions due to the use of LMWH in 
pregnancy, and the subsequent management of anticoagulation. 
Patients and methods: from 1999 to 2009, we followed consecutive women who used therapeutic 
anticoagulation for venous indications. Women visited a combined obstetric/ coagulation clinic and 
were seen by a thrombosis specialist every two months until six weeks post-partum. All women were 
started on nadroparin. 
Results: we included 135 pregnancies in 88 women. Overall, in 52 of 135 pregnancies (39%), women 
switched at least once to another anticoagulant due to the development of hypersensitivity skin 
reactions. Switching to another preparation of LMWH was effective in 77% of the cases. In 23% of the 
cases skin reactions recurred and another switch had to be made.   
Conclusion: in almost half of the pregnancies, women had to switch at least once to another 
anticoagulant preparation due to the development of hypersensitivity skin reactions on LMWH. In 
most cases, skin reactions did not recur after switching to a second preparation of LMWH. 
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For pregnant women with either a current venous thrombo-embolism (VTE) or a high risk of 
recurrent VTE, low molecular weight heparins (LMWH) are the most commonly used anticoagulant. 
However, hypersensitivity skin reactions are a recognized complication in pregnant patients who use 
LMWH. Moreover, when this heparin intolerance occurs, alternative choices for anticoagulation are 
limited and hypersensitivity skin reactions might recur when another preparation of LMWH is used.1 
Vitamin K antagonist (VKA) could be an alternative anticoagulant, but this drug crosses the 
placenta and its use in pregnancy is associated with significant fetal risks, particularly teratogenesis 
and fetal hemorrhage.2-5 The use of VKA in pregnancy might also be associated with mild neurological 
dysfunctions in children of school age.6 Fondaparinux is another alternative anticoagulant treatment, 
but data on the use in pregnancy are limited.7 
Rates of mild hypersensitivity skin reactions due to LMWH use in the general population range 
from 2-7,5%.8,9 Risk factors for the development of hypersensitivity skin reactions are female sex, 
obesity and long duration of heparin therapy.9 It has been hypothesized that the hormonal status 
may be of influence in the pathogenesis of the delayed hypersensitivity skin reaction to LMWH.10 
Pregnancy also seems to increase the incidence of these skin reactions, ranging from 0.6% to 29%.1,11-
13 These reactions may present as erythematous, well circumscribed lesions without necrosis, usually 
secondary to a delayed type IV hypersensitivity reactions. An urticarial rash (type I immediate 
hypersensitivity reaction), skin necrosis and heparin-induced thrombocytopenia have also been 
reported, although these types of reactions are rare.10  
A few studies report on the incidence of hypersensitivity skin reactions on LMWH in pregnant 
women, but these studies had other primary outcomes and therefore hypersensitivity skin reactions 
are probably underreported.11-13 
We performed a cohort study in our hospital to assess the safety of the use of a full dose of LMWH 
in pregnancy. Here, we report the prevalence of hypersensitivity skin reactions of LMWH usage during 
pregnancy and the subsequent management of anticoagulation.
Patients and methods
Patients
This is a single-centre cohort study, including 88 consecutive women who received a therapeutic 
dosage of LMWH during pregnancy and the puerperium. All women visited the University Medical 
Centre Groningen and were followed between 1999 and 2009. We included 135 ongoing pregnancies 
of these 88 women. Early fetal losses (< 22 weeks of gestation) were not included, due to lack of 
information on these pregnancies. Indications for anticoagulation were a history of idiopathic, 
provoked or previous pregnancy related venous thrombo-embolism, a VTE in the current pregnancy, 
recurrent fetal loss or asymptomatic severe thrombophilic defects (protein C, S or antithrombin 
deficiency).
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Women visited a combined obstetric/ coagulation clinic and were seen by a thrombosis specialist 
every two months until six weeks post-partum. Information on hypersensitivity skin reactions, episodes 
of VTE, bleeding, external risk factors for thrombosis, obstetric history, anticoagulant treatment, 
delivery and pregnancy outcome were collected using a standardised questionnaire and by reviewing 
medical records. Additional data were added retrospectively. National legislation and the ethical 
committee of our institution approve this type of studies without the need for review of the protocol. 
Treatment protocol
Women were started on a LMWH in early pregnancy, as soon as a pregnancy test was positive or 
when a VTE occurred. They were all treated with a body weight adjusted therapeutic dosage, during 
pregnancy and until six weeks post partum. Women with a current VTE during pregnancy were treated 
for six months, but at least until six weeks post-partum. Women started with a once daily dosage of 
LMWH, and from the 37th week of pregnancy all women switched to a twice daily dose to minimize 
the bleeding risk during delivery. Women were instructed about self injection by a research nurse and 
received an information letter; most women actually injected themselves, but a few were injected by 
home-care nurses. Anti-fXa levels were not routinely measured and doses of LMWH were not adjusted 
for increasing bodyweight or increasing renal clearance. 
Switch protocol
All women started in the first pregnancy on nadroparin in a weight adjusted therapeutic dosage 
(175 anti-Xa IU kg−1 day−1). When a woman developed hypersensitivity skin reactions, she was switched 
to tinzaparin in a weight adjusted therapeutic dosage. If the hypersensitivity skin reactions recurred 
again, the woman was switched to VKA (only during second trimester), dalteparin, danaparoid or 
fondaparinux. In subsequent pregnancies women started with the preparation that was used without 
complications during their previous pregnancy.
Definitions
Red pruritic injection infiltrates: itchy, erythematous, well circumscribed lesions without necrosis, 
subcutaneous, usually secondary to a delayed type IV hypersensitivity reaction. 
Generalized rash: rash not restricted to the site of injection.
Mild symptoms: symptoms of skin reactions, (including hematomas, pruritic injection infiltrates and 
non pruritic injection infiltrates) not severe enough to switch treatment (dependent on patient and 
doctor’s preferences)
Statistical analysis
Descriptive statistics were used. The statistical analysis was performed in PASW version 18.0 (IBM 
SPSS, Chicago, Illinois, United States).
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Eighty-eight women had 135 pregnancies between 1999 and 2009. Twelve of these women (=12 
pregnancies) were also included in a study of Bank et al.1 Median maternal age was 30 years (range 
20-43). Indications for anticoagulation were previous VTE in 98 (73%) pregnancies, a current VTE in 
5 (4%) pregnancies, an asymptomatic thrombophilic defect in 23 (17%) pregnancies and recurrent 
fetal loss in 5 (4%) pregnancies. In four (3%) pregnancies therapeutic dosage of LMWH was given for 
other reasons (strong positive family history for VTE). In 66 (49%) of the pregnancies women were 
nulliparous. None of the patients had a history of thrombocytopenia or an allergy to a LMWH. Baseline 
characteristics are displayed in table 1. 
Table 1: Baseline characteristics of study population
Women, n 88
Pregnancies, n 135
Maternal age (median, range) 30 (20-43)
Parity        
           Nulli- 66 (49)
           Multi- 69 (51)
Gestational age at delivery in weeks (median, range) 39.4 (27.5-42.3)
Birthweight in gram (median, range) 3372 (750-4890)
Indication for anticoagulation during pregnancy
             VTE in current pregnancy, n (%) 5 (4)
             Previous VTE, n (%) 98 (73)
             Asymptomatic thrombophilia, n (%) 23 (17)
             Recurrent fetal loss, n (%) 5 (4)
            Other (strong positive family history for VTE) 4 (3)
Pregnancy outcome
             Liveborn 129
                      Congenital birth defects 4
             Stillborn 1
             Late fetal loss (>22 weeks) 3
            Termination due to severe fetal anomalies 2
Pregnancy outcomes
Hundred-and-thirty-five pregnancies, including one twin pregnancy, resulted in 129 live infants. 
Median gestational age of live infants was 39.4 weeks, ranging from 27.5 to 42.3 weeks. Median birth 
weight was 3372 gram, ranging from 750 to 4890 gram. Three late fetal losses (23-27 weeks) were 
observed. In one of these three pregnancies VKA was used during the second trimester. In addition, 
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one infant was stillborn due to placental abruption at 31 weeks and two pregnancies were terminated, 
for severe fetal anomalies (trisomy 18 and severe cardiac defect). Four live born infants had congenital 
defects: a cleft palate, clubfeet and a (genetic form of) retinoblastoma: no VKA were used in these 
pregnancies. One male infant was born with an epispadia, in this pregnancy VKA were used during the 
second trimester.  Results are also displayed in table 1. 
Figure 1: Switches of anticoagulation treatment during pregnancy










Overall, in 52 out of 135 pregnancies (39%), women switched at least once to another treatment 
due to the development of hypersensitivity skin reactions. In 44 pregnancies (34%) women switched 
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to another LMWH, thereafter in 77 % (n=34) no other switch in treatment was required. In two 
pregnancies (2%) women switched twice to a different LMWH and in eight pregnancies (6%) women 
switched to VKA in the second trimester, due to the recurrence of hypersensitivity skin reactions. 
In 19 pregnancies (14%) women switched to VKA for other reasons, such as aversion to injections 
or patients’ preferences. In sixty-two pregnancies (46%) women continued using LMWH during their 
whole pregnancy and puerperium without hypersensitivity skin reactions, or with only mild reactions 
not severe enough to switch. (see also figure 1)
Four women used danaparoid, one of whom developed a generalized rash, while one woman 
developed mild symptoms but continued using danaparoid. 
Fondaparinux was used in fifteen pregnancies (11%) because of hypersensitivity skin reactions to 
at least one type of LMWH in the current or previous pregnancy. No skin reactions were observed with 
the use of fondaparinux. These results were described elsewhere.7 
Taking into account only the first pregnancies (n=88), all women started on nadroparin. Overall, in 
37 (42%) first pregnancies, women were switched at least once to another anticoagulation treatment 
for hypersensitivity skin reactions. In the subsequent pregnancies, this incidence was lower: in only 13 
pregnancies (28%) women were switched to another anticoagulation treatment for hypersensitivity 
skin reactions.
Type of skin reactions
LMWH were used in 131 pregnancies. Pruritic erythematous infiltrates on the site of injection 
due to the use of LMWH were observed in 38% (n=50) of pregnancies. Mild symptoms, which did 
not require a switch in treatment occurred in another 25% (n=33) of the pregnancies. Results are 
displayed in table 2.
Table 2: Reported side effects of pregnancies on LMWH
LMWH-users
(n= 131)
No side effects, n(%) 46 (35)
Pruritic injection infiltrates, n(%) 50 (38)
Rash (generalized), n(%) 2 (2)
Mild symptoms, n (%) 33 (25)
A more generalized rash was observed in 2% (n=2) of the pregnancies. One woman developed a 
rash on the sites of injection, in the groin, armpits, elbows and knees on nadroparin. No complications 
were observed with the subsequent use of dalteparin. The second woman developed erythematous 
pruritic injection infiltrates on both thighs, which expanded during the use of nadroparin and 
dalteparin. The woman was switched to danaparoid, but developed red itchy expanding infiltrates 
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again. Finally, the delivery was initiated and post partum she received a vitamin K antagonist. In the 
next pregnancy she was treated with compression stockings during the first trimester, VKA during the 
second trimester and fondaparinux during the third trimester without complications.
Discussion
In this study, we evaluated the use of a therapeutic dosage of LMWH during pregnancy. Overall, 
in 39% of the pregnancies, women had to switch at least once to another LMWH, acenocoumarol, 
danaparoid or fondaparinux for the development of hypersensitivity skin reactions. In the first 
pregnancies with a full dose anticoagulation (n=88) the rate was even higher; 42% switched at least 
once to another anticoagulation treatment. Switching to another preparation of LMWH seems to have 
a good effect, because in 77% of these pregnancies no second switch was needed.
Compared to other studies our rate exceeds the highest reported rate of 29% by Bank et al.1 
They reported a prospective, observational study, including 66 pregnant women. They found a skin 
complication rate of 29%, these skin complications consisted of itching (20%), local redness (23%), 
subcutaneous infiltrates at the injection site (11%), pain during injection (3%) and a generalized rash 
(3%). To maintain a consecutive cohort, data of 12 pregnancies included in the study of Bank et al1 were 
also included in our study, but excluding these pregnancies did not change our results. Other studies 
that assessed the usage of LMWH during pregnancy had mostly bleeding or thrombotic complications 
as a primary outcome. Two reviews evaluated the complication rate of LMWH and reported also skin 
reactions as a secondary outcome. First, Sanson et al12 performed a review of 21 studies, including 486 
pregnancies. They found only three cases (0.6%) of diffuse skin reactions, which led to cessation or 
change of treatment. Second, in a review by Greer and Nelson-Piercy,11 64 reports were included with in 
total 2777 pregnancies. They found that 1.8% of women using LMWH in pregnancy developed allergic 
skin reactions. We think that the high rate of skin complications we report here is real. Wütschert et 
al10 also suggested in a review that the incidence of hypersensitivity skin reactions on LMWH might be 
underreported. In our hospital women were followed with a focus on adverse events, which may be 
an explanation for the higher incidence of reported hypersensitivity skin reactions. However, the true 
percentage of hypersensitivity skin reactions in this cohort seems to be even higher, because some 
women did develop mild skin reactions, but did not switch to another treatment. 
Different types of hypersensitivity skin reactions are described.10 Most common is the delayed 
type IV hypersensitivity reaction, other reactions include type I immediate hypersensitivity reactions, 
skin necrosis and heparin-induced thrombocytopenia.10 In our study the delayed type IV reaction was 
also most commonly observed. 
Fondaparinux was used in 15 pregnancies in our study. No hypersensitivity skin reactions were 
observed, but the use of this drug is limited by the fact that it crosses the placenta.14 The use of 
fondaparinux in this study population was already described elsewhere.7 
Schindewolf et al9 described an increased risk for developing hypersensitivity skin reactions for a 
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body mass index greater than 25, duration of heparin therapy longer than nine days and female sex. 
They reported an overall incidence of 7.5%, but they included only a few pregnant women. However, 
our cohort of women had at least two of these risk factors. Unfortunately, we had no information 
about the BMI, so we could not analyze this relation.
A limitation of our study was the clinical diagnosis of the skin reactions. The interpretation and 
the decision to switch to another anticoagulant was based on a clinical diagnosis made by different 
doctors, and was not objectified by skin tests. On the other hand, there is also no consensus in the 
literature about how to test skin allergy to LMWH.10 Wütschert et al10 recommended switching to 
another LMWH without prior skin tests. Another review by Bircher et al,15 concluded that in some 
anticoagulant-associated hypersensitivity reactions detailed allergologic investigation may help to 
identify safe treatment alternatives. However, several tests may be needed, and the procedures are 
usually time-consuming. Although the interpretation of the hypersensitivity skin reactions was based 
on a clinical diagnosis in our cohort, symptoms were troublesome enough to change therapy. 
Because of the study design, we cannot compare the different preparations of LMWH. There is 
a bias by indication; all women were started on nadroparin and other preparations were only used 
when a woman already had shown hypersensitivity skin reactions to nadroparin.  Switching treatment 
seems to have a good effect, but we cannot exclude that longer duration of exposure to LMWH might 
also decrease the development of hypersensitivity skin reactions.
Our findings should lead to an altered view of hypersensitivity skin reactions during pregnancy. 
Physicians should be aware that patients receiving LMWH have a high risk of developing a delayed type 
IV hypersensitivity reaction. Therefore, we recommend monitoring pregnancies with anticoagulant 
treatment to recognize skin reactions. This might help patients to adhere to anticoagulant therapy. 
In conclusion, we report here a rate of 39% hypersensitivity skin reactions in women on LMWH 
during pregnancy. These reactions can primarily be managed by changing therapy to another 
preparation of LMWH, which is successful in 77% of the patients. In a subgroup of women, it is 
necessary to ultimately switch to VKA or fondaparinux.
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Low-molecular-weight heparins (LMWHs) are widely used in pregnant women in whom anticoagulant 
therapy is indicated, but they frequently cause hypersensitivity skin reactions. Choices of alternative 
anticoagulation are limited. In our hospital, experience with fondaparinux as an alternative in 
pregnant patients has accumulated. This report describes ten patients who used fondaparinux during 
12 pregnancies between 2003 and the present. All women were followed prospectively. They initially 
used LMWH but developed hypersensitivity skin reactions. Two patients used fondaparinux during 
two pregnancies, both started in the 1st trimester of the 2nd pregnancy. In all other pregnancies, 
fondaparinux was started in the 2nd or 3rd trimester. Fondaparinux was not associated with skin 
reactions or other side-effects. None of the 13 infants had congenital abnormalities or neonatal 
bleeding. We report here an alternative anticoagulant treatment with fondaparinux in 12 pregnancies 
who had allergic skin reactions to LMWH. 





Hypersensitivity skin reactions are frequently seen in pregnant patients who use low-
molecular-weight heparin (LMWH).1 When this heparin intolerance occurs, alternative choices for 
anticoagulation are limited. Hypersensitivity skin reactions often recur when another preparation 
of LMWH is substituted.1 Danaparoid is another preparation of choice which does not pass the 
placenta,2 but it is not consistently available. Most patients strongly wish to avoid vitamin K 
antagonists, even beyond the twelfth week of pregnancy, because of the association with congenital 
and developmental abnormalities.3,4 Fondaparinux, a synthetic selective inhibitor of activated factor X 
(fXa), is commonly used as an alternative anticoagulant in non-pregnant patients who develop heparin 
intolerance. Fondaparinux has been extensively studied for use in surgery prophylaxis and treatment 
of thromboembolic diseases.5 However, data on the use of fondaparinux in pregnancy is limited to 
animal models and a few case reports.6-10 Although it has been shown that transplacental passage can 
occur resulting in low measurable fXa activity in cord blood,11 no adverse outcomes in pregnancy have 
been reported in these four women. The other six separately published cases reported no adverse 
events to mother and child either.6-10 In our hospital, experience with fondaparinux as an alternative 
in pregnant patients has accumulated. The aim of our study was to evaluate the use and safety of 
fondaparinux during pregnancy.  
From 2003 until the present, we prospectively followed a consecutive cohort of 133 women in 
our university hospital who used anticoagulant therapy during their pregnancy and puerperium. The 
indication for anticoagulant therapy was a history of idiopathic, provoked or previous pregnancy-
related venous thrombo-embolism (VTE) or recurrent fetal loss. Recurrent fetal loss was defined as 
2 or more fetal losses. In all women thrombophilia screening was performed. Applied assays have 
been described elsewhere.12 All women were started on a LMWH (nadroparin or tinzaparin) in early 
pregnancy with body weight adjusted therapeutic dosage (175 anti-Xa IU kg−1 day−1), as soon as a 
pregnancy test was positive. All women were followed in a combined obstetric/ coagulation clinic 
and seen by a thrombosis specialist every 2 months until 6 weeks post-partum. Anti-fXa levels were 
not routinely monitored in maternal and cord blood and doses of LMWH were not adjusted for 
increasing bodyweight or increasing renal clearance. If hypersensitivity skin reactions developed, we 
either switched once to another preparation (tinzaparin or nadroparin), acenocoumarol or started 
fondaparinux 2.5 mg subcutaneously twice daily. Fondaparinux 7.5 mg once daily (therapeutic dosage) 
is not available in the Netherlands, and we wished to avoid thrice daily injections. The women had 
no standard planned induction with withholding of fondaparinux, but anticoagulation was stopped 
at start of spontaneous labour and restarted 4-8 hours after delivery (when blood loss was normal) 
and stopped six weeks post partum. Data were systematically collected by the thrombosis physicians 
during pregnancy on indication for anticoagulant therapy; start date of LMWH; trimester of switching 
to another LMWH, vitamin K antagonist or fondaparinux; bleeding and thrombo-embolic complications 
during pregnancy, delivery and post-partum period; side-effects of anticoagulants; gestational age of 
delivery; blood loss during delivery; birth-weight and neonatal bleeding/congenital abnormalities. 
National legislation and the ethical committee of our institution approve this type of studies without 
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the need for review of the protocol. All women were informed about the risks of the off label use 
of fondaparinux during pregnancy and agreed with it. In this letter, we report on the 12 out of 190 
pregnancies in 133 women in which fondaparinux was used. 
We treated 10 patients with fondaparinux during pregnancy and the puerperium in our institution, 
two of them during two pregnancies. Their median age was 30 yrs (range 26-34 yrs). Six of them had 
a history of VTE during combined oral contraceptive use, three patients had a history of an idiopathic 
VTE and one patient had a history of recurrent fetal loss. None of the patients had a history of allergy 
to LMWH. Eight patients were switched to fondaparinux in the 2nd trimester and 2 patients during the 
3rd trimester. All patients were started initially on nadroparin or tinzaparin, two used both preparations 
and one patient used a vitamin K antagonist during the 2nd trimester before switching to fondaparinux. 
See for detailed information Table 1. In all cases, the indication for switching to fondaparinux was 
hypersensitivity skin reactions to LMWHs, consisting of itching, local redness or subcutaneous 
infiltrates localized at the injection sites. Two patients were treated during two pregnancies, both 
started fondaparinux in the first trimester of their second pregnancy. No hypersensitivity skin reactions 
to fondaparinux were seen and patients reported no other side effects. No early or late fetal losses 
occurred. The median gestational age at delivery was 39 weeks (range 33 5/7-42 0/7 weeks). One 
patient delivered preterm twins due to preterm prelabour rupture of the membranes. The median 
blood loss during delivery was 450 ml (range 200-2000 ml), three patients had more than 1000 ml 
blood loss. The patient with 2000 ml blood loss had an atony of the uterus, she received her last 
injection of fondaparinux more than 12 hours before delivery. One patient had 1200 ml blood loss 
during a secondary section caesarean, she received her last injection 48 hours before delivery. The 
third patient had 1000 ml blood loss due to atony of the uterus and a preterm delivery of a twin, she 
received her last injection 7 hours before delivery. None of these women with more than 1000 ml 
blood loss needed a blood transfusion. Postpartum, 4-8 hours after cessation of the bleeding, these 
patients restarted on fondaparinux 2.5 mg twice daily. No bleeding recurred after restarting the drug. 
None of the 13 infants had congenital abnormalities or neonatal bleeding. Their median birth-weight 
was 3685 gram (range 1795-4330 g). No minor or major bleedings or thromboembolic events were 
reported during pregnancy or post-partum period. 
We report on all 12 pregnancies in our centre in which fondaparinux was used during the past six 
years. These data are derived from a prospective cohort study. We show that fondaparinux was not 
associated with increased bleeding, thromboembolic complications or fetal abnormalities. 
To our knowledge, this is the largest prospective study that reports on the use of fondaparinux 
during pregnancy. In concurrence with others,6-11 we did not observe hypersensitivity skin reactions on 
fondaparinux, although all women had had hypersensitivity skin reactions to LMWHs. Recurrence of 
hypersensitivity skin reactions when switching to another preparation of LMWH in pregnant women 
is a known phenomenon.1
Fetal safety is an important issue when considering a new anticoagulant therapy in pregnancy. 
LMWHs do not cross the placenta, so cannot cause teratogenicity or neonatal bleeding.13-15 A study by 





Dempfle et al. demonstrated that fondaparinux passes the placental barrier in vivo, resulting in low 
measurable anti-fXa levels in umbilical cord blood.11 That study described five pregnant women, in four 
of whom low anti-fXa levels were measured. These levels were approximately 1/10 the concentration 
in maternal plasma, which is well below the concentration required for effective anticoagulation.16 
Neonatal bleeding did not occur in the infants of these women. In the fifth woman, no elevated anti-
fXa level was measured, probably because she received her last injection of fondaparinux 22 hours 
before delivery. Based on these data, fondaparinux has the potential to affect the fetus. In a recently 
published retrospective study by Winger et al.,17 29 women with a history of unexplained recurrent 
fetal loss and infertility using fondaparinux 2.5 mg once daily during the 1st trimester of pregnancy 
were described. They reported no adverse events, in particular no fetal abnormalities. In the 13 infants 
in our study, no congenital abnormalities or bleeding occurred. Our data are obviously limited by the 
size of our study, although it is the largest prospective series reported. Of note, only 2 infants were 
exposed during the first trimester. A limitation of our study is the missing of anti-fXa levels in maternal 
and cord blood during labour because of the possibility of passage through the placenta and the 
potential side-effects for mother and child. Nevertheless, none of the children had neonatal bleeding 
or fetal abnormalities.
In conclusion, we report here an alternative treatment with fondaparinux in 12 pregnancies in 10 
women who had hypersensitivity skin reactions to LMWH. Fondaparinux did not cause hypersensitivity 
skin reactions and was not associated with bleeding or other complications in mother and child. 
However, given the limited data, the use of fondaparinux during the first trimester should still be 
avoided. 
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Introduction: reproductive choices, pregnancy and childbirth are influenced by culture and traditions. 
This probably also plays a role in carriers of haemophilia. 
Aim: to evaluate the reproductive choices and obstetrical experiences in the current generation of 
carriers of haemophilia in our Haemophilia Centre in the north of the Netherlands, a largely secular 
country with liberal abortion laws and a unique tradition of home births.
Methods: retrospective survey among haemophilia carriers. 
Results: we sent a questionnaire to 74 carriers, 65 were available, 75% responded. Median age was 
41 (range 20-83) years. 46/49 women had 120 pregnancies: 25 resulted in fetal loss, two in pregnancy 
termination (one for haemophilia) and 93 in live births. No woman had chosen not to start a family. 
Mean number of children was 2.0, 2.4 vs 1.8 in women with and without sons with haemophilia 
(p=0.008), respectively. Twenty women (20/46) were unaware of their carriership during 1st pregnancy, 
they were younger at 1st pregnancy than known carriers (25 vs 29 years, p=0.03). Twenty-three percent 
reported bleeding complications during the first delivery. Overall, 10% versus 3% of deliveries was 
complicated by a primary and secondary postpartum haemorrhage (PPH), respectively. 
Conclusion: in our Haemophilia Centre, carrier state has not influenced reproductive choices in the 
past, other than older age at first pregnancy. Carriers of haemophilia have an increased risk of primary 
PPH.
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Culture and customs play an important role in reproductive choices, pregnancy and childbirth. 
This is probably also true in carriers of haemophilia. Until not very long ago, carriers of haemophilia 
hardly had options regarding reproduction other than accepting the birth of affected sons. In the 
Netherlands, the widespread use of contraceptives started in 1960 when the ‘pill’ became available. 
Of the women aged 16-49 years 40-50% used oral contraceptives between 1990 and 1999 in the 
Netherlands.1 Of the women aged 20-29 years even 69% used oral contraceptives.1 More than 90% 
percent of pregnancies in the general population are planned.1 Testing for carriership of haemophilia 
and consequently prenatal diagnosis by chorionic villous biopsy became available in the mid 1980s.2,3 
Elective pregnancy termination for social and medical reasons has been widely accessible since 1984. 
More recently, advances in molecular science and ultrasound technology have provided more prenatal 
diagnostic options for carriers of haemophilia. Preimplantation genetic diagnosis for haemophilia has 
been available to our patients since 1995. Preimplantation genetic testing (PGD) is an alternative to 
conventional prenatal diagnostic techniques (amniocentesis, chorionic villus sampling) that allows 
couples to avoid intrauterine transfer of male embryos and consequently the possibility of an affected 
embryo. It is an adjunct to assisted reproductive technology, and requires in vitro fertilization to obtain 
oocytes or embryos for evaluation.
In the Dutch obstetrical care system, women with low risk pregnancies can choose between home 
and out-patient hospital delivery. About 30% of the deliveries take place at home.4 This means that 
in the past, and also presently in women with unknown carrier state, women with unknown levels of 
plasma factor could be at risk of bleeding during pregnancy and delivery in a low-tech environment. 
From 2000 on, national guidelines advise to refer all known carriers, irrespective of factor levels and 
fetal sex, to the obstetric department of a hospital with a Haemophilia Centre. Despite advances in 
care, pregnancy and delivery remain critical times for carriers of haemophilia, with previous studies 
reporting 9-38% bleeding complications.5-8 The aim of this study was to evaluate the reproductive 
choices and obstetrical experiences in the current generation of carriers of haemophilia in our 
Haemophilia Centre in the north of the Netherlands.
Material and methods
We identified all carriers of haemophilia A and B registered in our Haemophilia Centre in 2007. 
A standardised questionnaire was sent to all carriers above 18 years of age. The questionnaire 
contained questions about their experience of pregnancies, deliveries and reproductive choices.  The 
questionnaire was split into three sections describing: carrier state, complications during pregnancy 
and delivery and influences of reproductive choices. We recorded data about pregnancies, number of 
fetal losses and termination of pregnancy, place of delivery, complications during delivery; knowledge 
of carrier state during 1st pregnancy and experiences that influenced their reproductive choices. The 
questionnaire included yes/no, multiple choice and open-ended questions. Clinical details including 
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type (A or B), severity of haemophilia in the family and non-pregnant factor VIII and IX levels were 
obtained from medical records. National legislation and the ethical committee of our institution 
approve this type of retrospective study without the need for review of the protocol. Primary and 
secondary postpartum haemorrhage (PPH) was defined as a bleeding within 24 hours after delivery 
and after 24 hours, respectively.9,10 We classified a family as complete if the youngest child was older 
than five years. 
We analysed the data with Statistical Package for the Social Sciences (SPSS) version 16.0. 
Descriptive statistics were used; results were compared between carriers of a known and unknown 
carrier state during 1st pregnancy. Differences between groups were evaluated by the student t test or 
the Mann-Whitney U test; carriers who have never been pregnant were excluded from this analysis.
Figure 1: Flow diagram cohort





























We sent the questionnaire to 74 carriers. Two women were deceased, seven had moved and the 
other carriers did not respond. Of 65 women, 49 (75%) women responded.  See also Figure 1. The 
median age was 41 (range 20-83) years. All carriers were Caucasian.  Eighty percent were carrier of 
haemophilia A and 20% were carrier of haemophilia B. Twenty-three, 11 and 15 carriers had a family 
with severe (<1%), moderate (1-5%) and mild (>5%) haemophilia, respectively. The median non-
pregnant value of factor VIII and IX was 0.52 IU/ml (range 0.17-1.44) and 0.49 IU/ml (range 0.16-0.87 
IU/ml), respectively. See also table 1.
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Median age (range) 41 (20-83)
Median number of pregnancies (range) 2 (0-9)
Mean number of live births (SD) 2.0 (1.0)
Carrier state (n (%))
   Haemophilia A 39 (80)
   Haemophila B 10 (20)
   Carrier state known at 1st pregnancy 26 (57)
Median non-pregnant factor level (IU/ml)
   Factor VIII (range) 0.52 (0.17-1.44)
   Factor IX (range) 0.49 (0.16-0.87)
Pregnancy outcome (n)
   Pregnancies 120
   Live births 93
   Fetal losses 25
   Termination of pregnancy 2
Pregnancy outcomes
Forty-six carriers had 120 pregnancies between January 1956 and November 2007. Twenty-five 
resulted in fetal loss, two in terminations of pregnancy and 93 in live births. One carrier delivered a 
twin. Three of the carriers had never been pregnant, because they had not yet a child-wish during 
survey (aged 23, 26 and 36). Three women (7%) experienced two or more fetal losses. Two women 
had a pregnancy termination, one for haemophilia. Forty-six women (94%) had been pregnant at least 
once, 43 of them had at least one ongoing pregnancy. Of the carriers 32 had a completed family during 
survey. Of the infants born 59% were male, 53% of them were confirmed to have haemophilia. Of the 
43 women 63% had one or more affected sons. The mean number of children was 2.0 (SD 1.0), 2.4 vs 
1.8 in women with and without sons with haemophilia (p=0.008), respectively. 
Reproductive choices
Twenty women (20/46) were unaware of being a carrier of haemophilia during their 1st pregnancy. 
Carriers with an unknown state were younger at their 1st pregnancy compared to carriers with a known 
state (25 vs 29 years, p=0.03). The number of pregnancies and live births were comparable in known 
and unknown carriers. See also Table 2. The mean number of live births were comparable in carriers 
with a family history of severe, moderate and mild haemophilia. (2.0 vs 2.5 vs 1.9, p=0.25) Two known 
carriers decided to termination of one pregnancy, one for fear of passing haemophilia on to a child 
and one for social reasons. None of the carriers had made the conscious choice to have no children. 
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Five women chose to have no more children, four because of the concern for an affected son and one 
because of the bleeding risk during delivery. Two women in a family with severe haemophilia used 
preimplantation genetic diagnosis for gender selection before pregnancy, leading to the birth of twins 
in one woman. 








Mean age at 1st live birth (yrs) 29 25 0.03
Median number of pregnancies 2 3 0.23
Mean number of live births 1.8 2.3 0.13
Termination of pregnancy (n) 2 0
Delivery location, n
   At home 6 17
   General hospital 16 25
   Haemophilia centre 23 6
Complications, n
  Bleeding after fetal loss 0 0
  Postpartum bleeding 7 7
    primary 4 5
    secondary 1 2
    unknown 2 -
Mode of delivery, n
   Vaginal 44 41
   Section caesarean 4 4
Delivery and complications
None of the women who experienced one or more fetal losses reported bleeding complications. 
The modes of delivery were vaginal delivery in 85 (91%) and caesarean section in 8 (9%) pregnancies (2 
elective and 6 emergency). The mode of delivery was comparable between the carriers with a known 
and unknown state. (See for detailed information Table 2). Births took place at home in 23 cases, in 
a general hospital in 41 cases and in a Haemophilia Centre in 29 cases, respectively. The deliveries 
at home took place between 1956 and 2000. Eleven of the 43 women (26%) reported bleeding 
complications during one or more deliveries. Overall, 15% (14/93) of the deliveries was complicated 
by a primary or secondary PPH. Twenty-three percent (10/43) reported bleeding complications during 
or after the first delivery. Nine of them had a vaginal delivery and one a secondary section caesarean. 
Six of them had a primary PPH. None of these women received prophylactic factor VIII or IX. Bleeding 
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complications during the 2nd delivery was reported by 12% (4/33), 3 of them had a primary PPH, all 
delivered vaginally. One woman received postpartum administration of factor VIII concentrate. None 
of the 17 women reported bleeding complications during the 3rd and 4th delivery. Overall, 10% versus 
3% of the deliveries was complicated by a primary and secondary PPH, respectively. The timing of two 
PPHs was unknown. Of the carriers who delivered at home, in a general hospital and in a Haemophilia 
Centre, 4% versus 21% versus 10% experienced a PPH. Of our cohort, 16 carriers had non-pregnant 
factor VIII or IX levels below 0.50 IU/ml. The incidence of PPH was comparable between the carriers 
with non-pregnant levels below 0.50 IU/ml and carriers with a non-pregnant factor level above 0.50 
IU/ml. The median non-pregnant factor levels of the carriers with a history of PPH and no bleeding 
complications were comparable, 0.56 versus 0.52 IU/ml, respectively (p=0.82). 
Discussion
In the present study we evaluated the reproductive choices and obstetrical experiences of carriers 
of haemophilia A and B. We reported that in our Haemophilia Centre, the knowledge of carrier state 
has not influenced reproductive choices in the past except for older age at first pregnancy. Known and 
unknown carriers had the same number of children. The self-reported risk of PPH was increased in 
carriers of haemophilia. 
The mean number of live births in our cohort was 2.0 and the mean number of live births was 
comparable between known and unknown carriers (1.8 vs 2.3). The mean number of live births per 
woman is comparable with the general Dutch population in which the mean number of live births 
is 1.8 per woman.11 Despite the social acceptance and legalization of provoked abortion in the 
Netherlands, only one woman in our cohort had decided to termination of one pregnancy because 
of the concern of an affected son. The mean number of children in women with an affected son was 
significantly higher compared to women without an affected son. (2.4 vs 1.8, p=0.008). Having a son 
with haemophilia was apparently not a reason to have no more children. On the other hand, known 
carriers were older at the 1st pregnancy compared to unknown carriers, which is in line with a Swedish 
study about reproductive choices in carriers of haemophilia.12 
Bleeding complications after one or more deliveries were reported by 26% of the women in 
our cohort. Another assessment by questionnaire of PPH in carriers reported also an incidence of 
22%.13 We demonstrated an increased incidence of primary PPH (10%). This is comparable with other 
studies of carriers of haemophilia who reported also an increased risk of bleeding complications 
primary post-partum.5,6 In the general Dutch population the incidence of a primary PPH (>1000ml) 
during the first delivery is 4%.9 The incidence of a secondary postpartum haemorrhage in the general 
Dutch population is 2%, this is comparable with our cohort.14 The tendency to bleed in carriers of 
haemophilia could be explained by low plasma levels of factor VIII and IX. In our cohort there is no 
difference between the median non-pregnant factor levels of the carriers with a PPH compared to the 
women without bleeding complications, 0.56 versus 0.52 IU/ml, respectively. The incidence of PPH in 
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carriers of haemophilia is higher in a general hospital compared to a haemophilia centre (21 vs 10%).
This study had some limitations. Firstly, in the self-reported questionnaire, bleeding symptoms 
might have been overreported as well as underreported. In some cases, oozing might have been 
reported as bleeding. On the other hand, in families where blood loss is a well-known and accepted 
phenomenon, abnormal bleeding might not have been recognized as such. The response rate in our 
study was 75%, therefore the results may not represent an overview of experiences of all carriers. 
Probably, the response rate of carriers with negative experiences is higher compared to women with 
no complications during pregnancy and delivery. Secondly, the inclusion of older women limits its 
applicability to future patients when we consider more advanced prenatal diagnostic options like 
chorionic villous biopsy and PGD. However, most options were already available to the majority of 
known carriers in our cohort.  
In conclusion, in our Haemophilia Centre carrier state has not influenced reproductive choices 
in the past, other than older age at first pregnancy. We confirm that carriers of haemophilia have an 
increased risk of primary PPH, but not of secondary PPH. 
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Fetal loss may be induced by apoptosis of trophoblasts due to high levels of fibrin degradation products. 
Consequently, high TAFI levels would reduce this risk, especially in women with thrombophilia who 
generate more thrombin. This hypothesis was tested in women from 4 family cohorts, originally 
designed to estimate the risk of venous thromboembolism, associated with either hereditary 
deficiencies of antithrombin, protein C or protein S, prothrombin 20210A, factor V Leiden, high factor 
VIII levels or hyperhomocysteinemia. We retrospectively assessed fetal loss rates in women with high 
TAFI levels (> 75th percentile, i.e. 115 U/dl), compared to women with normal TAFI levels. Of 1557 
women, 843 (probands and relatives) were evaluable of whom 213 had high TAFI levels. Women with 
high TAFI levels and women with normal TAFI levels were comparable for age at time of first pregnancy 
(24 vs 24 years) and mean number of pregnancies (2.9 vs 3.0). Thrombophilic defects were equally 
distributed, excepted for high FVIII levels (48.1% vs 34.9%; p < 0.001). Fetal loss rates were lower 
in women with high TAFI levels. Total fetal loss rates were 22.5% vs 27.9% (odds ratio 0.72; 95% CI, 
0.49-1.07); early fetal loss rates 19.2% vs 24.9% (0.71; 0.48-1.05); total recurrent fetal loss rates 3.8% 
vs 7.9% (0.43; 0.19-0.96); and recurrent early fetal loss rates 2.8% vs 7.0% (0.38; 0.15-0.92). Our data 
provides evidence that high TAFI levels may protect against early and recurrent early fetal loss in 
women from families with thrombophilia. 
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Trombin-activatable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase which suppresses 
fibrinolysis by removing carboxy-terminal lysine residues from partially degraded fibrin.1 These 
residues are involved in binding of plasminogen and tissue-type plasminogen activator, and in plasmin 
formation. TAFI is activated by thrombin, mainly in complex with thrombomodulin, and by plasmin. 
TAFI inhibits tissue plasminogen activator-induced fibrinolysis.2 High TAFI levels might enhance the 
development of thrombosis, and consequently fetal loss as result of placental thrombosis. Recently, 
we demonstrated that high TAFI levels are not associated with an increased risk of fetal loss.3 On the 
contrary, our data suggested a decline of this risk at increasing TAFI levels. We hypothesized that high 
TAFI levels during normal pregnancy protect against fetal loss.4,5 This effect might be more pronounced 
in pregnant women who are at increased risk of fetal loss due to thrombophilic defects. Here we 
present the results of an additional analysis of data from our previously reported study, to test this 
hypothesis.
The study population contained female subjects from four pooled retrospective family cohort 
studies.6-9 These studies were designed to estimate the absolute risk of venous thromboembolism 
(VTE), associated with either hereditary deficiencies of antithrombin, protein C or protein S, the 
prothrombin 20210A mutation, elevated factor VIII:C levels, or hyperhomocysteinemia. Probands in 
each of these studies were consecutive patients with documented VTE or premature atherosclerosis 
(age < 50 years), and one of these thrombophilic defects. Relatives, who were 15 years of age or older 
were identified by pedigree analysis and were enrolled after informed consent was obtained. The 
studies were approved by the institutional review boards of the participating hospitals. In addition to 
above mentioned thrombophilic defects, subjects were tested for factor V Leiden, and TAFI activity 
was measured. Applied assays have been described elsewhere.3 Detailed information on obstetric 
history was obtained, using a questionnaire and reviewing medical records. Clinical data was collected 
prior to blood sampling. Women were evaluable if they had been pregnant before the end of the 
study. Women with only terminated or ectopic pregnancies were excluded from analysis. 
Fetal loss was defined as early fetal loss if it had occurred within 22 weeks of gestation, or as 
late fetal loss after more than 22 weeks of gestation, according to the criteria of the World Health 
Organisation.10 Recurrent fetal loss was defined as 2 or more fetal losses.  Fetal loss rates were 
expressed as percentages of women with fetal loss. Fetal loss rates in women with TAFI levels above the 
75th percentile (i.e. > 115 IU/dl) were compared to those in women with lower levels. Pregnancies after 
prior VTE were excluded from analysis, considering that thromboprophylaxis might have influenced 
the outcome of these pregnancies. Differences between groups were evaluated by the student t test 
or Mann-Whitney U test for continuous data, and by Fisher exact test for categorical data. Odds ratios 
were adjusted for family clustering by random effects logistic regression. A two-tailed p-value of less 
than 0.05 was considered to indicate statistical significance. Statistical analyses were performed using 
SAS software, version 9.1. (SAS-institute inc., Cary, North Carolina, USA)
The study cohort contained 1557 women, both probands and relatives. Of these women, 175 were 
excluded because they were younger than 15 years of age, had deceased or did not consent; 409 who 
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had never been pregnant or had had only terminated pregnancies; 35 who had experienced VTE prior 
to their first pregnancy; and 95 because of missing TAFI measurements. The remaining 843 women 
were analyzed; 213 had high TAFI levels. 
Their characteristics are summarized in Table 1. Age at time of first pregnancy was comparable 
in women with high TAFI levels and women with normal TAFI levels. Venous thromboembolism had 
occurred in 13 women with high TAFI levels (6.1%) and in 50 women with normal TAFI levels (7.9%; 
p=0.38). Thrombophilic defects were equally distributed among both groups, excepted high factor VIII 
levels that were more prevalent in women with high TAFI levels. Total numbers of pregnancies were 
608 in women with high TAFI levels (median 3) and 1864 in women with normal TAFI levels (median 
3). The number of early fetal losses per woman ranged from 1 to 8 in women with normal TAFI levels 
(median 1), and from 1 to 4 in women with high TAFI levels (median 1), respectively. 










Age at 1st pregnancy,
median (range), yr
24 (17-40 ) 25 (11-42) 0.14
VTE, n (%) 13 (6.1) 50 (7.9) 0.38
TAFI levels, U/dL, mean (SD) 127 (11) 96 (11)




      Antithrombin deficiency 2.4 (209) 1.8 (625) 0.56
      Protein C deficiency 2.8 (211) 4.0 (627) 0.53
      Protein S deficiency type I 4.9 (206) 3.9 (615) 0.55
      Prothrombin G20210A 10.9 (212) 13.0 (625) 0.47
      Factor V Leiden 12.7 (212) 11.7 (625) 0.71
      Any thrombophilic defect 30.2 (205) 30.9 (611) 0.93
Acquired/ genetic defect
      Factor VIII:C > 150 IU/dL 48.1 (206) 34.9 (619) <0.001
Total fetal loss, n (%) 48 (22.5) 176 (27.9) 0.72 (0.49 -1.07) 0.128
     Early 41 (19.2) 156 (24.9) 0.71 (0.48-1.05) 0.093
     Late 9 (4.2) 22 (3.5) 1.18 (0.52-2.66) 0.674
Total recurrent fetal loss, n (%) 8 (3.8) 50 (7.9) 0.43 (0.19-0.96) 0.041
     Early 6 (2.8) 44 (7.0) 0.38 (0.15-0.92) 0.028
     Late 0 (0) 2 (0.3) - 1.00
*Adjusted for family clustering
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Of women with high TAFI levels, 48 experienced any fetal loss (22.5%), i.e. early or late fetal loss, 
compared to 176 women with normal TAFI levels (27.9%; p=0.128). Early fetal loss was observed 
less frequently in women with high TAFI levels than in women with normal TAFI levels (19.2% versus 
24.9%; p=0.093). Six women (2.8%) versus 44 women (7.0%) had experienced recurrent early fetal 
loss (p=0.028). Recurrent late fetal loss was observed in 0 versus 2 women (0.3%). Lower recurrent 
fetal loss rates in women with high TAFI levels versus women with normal TAFI levels were observed in 
subgroups of women with established persistent thrombophilic defects (i.e. hereditary deficiencies of 
antithrombin, protein C or protein S, factor V Leiden, and prothrombin G20210A mutation) and women 
without these defects, respectively (Table 2). Differences in fetal loss rates were similar, comparing 
women with high factor VIII levels to women with normal factor VIII levels, and considering that these 
levels were measured at enrolment (i.e. end of follow-up) and therefore might be different from factor 
VIII levels at time of pregnancy (Table 3). Differences in these subgroup analyses were not statistically 
significant. Of 35 women who were excluded from analysis, because they had had VTE prior to their 
first pregnancy, 29 women had any thrombophilic defect. None of 4 excluded women with high TAFI 
levels had recurrent fetal loss, compared to 1 of 31 women (3.2%) with normal TAFI levels. 














Total recurrent fetal loss, n (%) 3 (4.8) 14 (7.4) 5 (3.5) 35 (8.3)
 Early 2 (3.2) 11 (5.8) 4 (2.8) 32 (7.6)
Late 0 (0) 1 (0.5) 0 (0) 1 (0.2)
* Hereditary deficiency of antithrombin, protein C or protein S, factor V Leiden or prothrombin G20210A
















Total recurrent fetal loss, n (%) 4 (4.0) 13 (6.0) 3 (2.8) 34 (8.4)
Early 3 (3.0) 10 (4.6) 2 (1.9)  
 31 (7.7)
Late 0 (0) 1 (0.5) 0 (0.0) 1 (0.25)
This study showed a lower risk of fetal loss in women with high TAFI levels, compared to women 
with normal TAFI levels. Overall, the risk of fetal loss was declined with 28%, mainly due to a 29% 
risk reduction in early fetal loss. This apparently protective effect of high TAFI levels was most 
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pronounced for early recurrent fetal loss (risk reduction 62%). Our findings are in agreement with the 
only previous study on this issue.11 That study addressed the association between single nucleotide 
polymorphisms (SNPs) and recurrent fetal loss in 86 women with recurrent fetal loss and in 72 controls 
with uncomplicated pregnancies. Two SNPs (+505A/A and + 1583 A/A) were associated with increased 
TAFI levels and a lower risk of recurrent fetal loss. On the other hand, the +505 G/G polymorphism, 
leading to lower TAFI levels, was more frequently demonstrated in women with recurrent fetal loss.11 
Experiments in mice provided evidence that fibrin degradation products may induce apoptosis of 
trophoblasts, resulting in fetal loss.12 Inhibition of fibrinolysis by TAFI is a possible explanation for the 
lower fetal loss rate in women with high TAFI levels in our study. If the protective effect of high TAFI 
levels is due to less apoptosis of trophoblasts, it will especially reduce the risk of early fetal loss, as we 
demonstrated. Considering that thrombophilic defects are associated with an increased risk of fetal 
loss,13-15 we speculated that this might be due to the generation of more thrombin and consequently, 
more fibrin and fibrin degeneration products in pregnant women with thrombophilic defects, 
compared to pregnant women without these defects. However, we observed no difference in recurrent 
fetal loss rates between women with thrombophilic defects and women without a defect, though 
the protective effect of high TAFI levels was consistently observed in these subgroups. By exclusion 
of pregnancies after prior VTE, overall recurrent fetal loss rates may have been reduced, especially 
in women with thrombophilic defects, who are at higher risk of VTE. It is likely that anticoagulant 
thromboprophylaxis during pregnancies after prior VTE, also decreases thrombin generation and 
levels of fibrin degeneration products. It should be emphasized that these subgroup analyses were 
not powered to demonstrate differences in fetal loss rates. 
Our observations are of clinical interest, because they suggest that another mechanism than 
placental thrombosis is involved in fetal loss. Thereby, a new perspective is opened for anticoagulant 
treatment in the prevention of early and late fetal loss. 
Some limitations of this study warrant comments. First, selection bias may have been introduced 
by excluding pregnancies after prior VTE. As mentioned before, this would have declined the benefit 
of high TAFI levels, especially in women with thrombophilic defects, who may be at increased risk of 
both VTE and fetal loss. Second, although a systematic search for other causes of early and late fetal 
loss was not performed, due to the retrospective design of our study, it is likely that these were equally 
distributed. Finally, recall bias regarding fetal loss may have been introduced by the retrospective 
study design, but probably remained limited as clinical data was collected prior to thrombophilia 
testing and measurements of TAFI levels. 
In conclusion, our data provides evidence that high TAFI levels may protect against early and 
recurrent early fetal loss.   
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Part I Menorrhagia and bleeding disorders
Part 1 of this thesis described that the frequency of an undiagnosed bleeding disorder, such as von 
Willebrand`s disease (VWD), in women with menorrhagia suggests that haemostatic testing should be 
added in the diagnostic work-up, prior to surgical intervention. Menorrhagia is often the first clinical 
manifestation in women with bleeding disorders, frequently beginning at menarche. Therefore, many 
affected patients initially visit their gynaecologist. A recent survey in the UK found that only 4% of 
the gynaecologists routinely considered VWD in the differential diagnosis in women of reproductive 
age.1  We found in our clinic similar results. In the evaluation of the diagnostic work-up in women 
with menorrhagia in only 2 of 112 (2%) patients with menorrhagia a haemostatic evaluation was 
performed. Failure to diagnose bleeding disorders, such as VWD, may result in anaemia, impaired 
quality of life during menstruation, and unnecessary surgical interventions. Another important point 
of diagnosing an underlying bleeding disorder is that most of these disorders like VWD are inherited 
disorders, which could lead to screening of family members when a case is identified.
Until now, most studies excluded women with gynaecological abnormalities for the evaluation 
of the prevalence of underlying bleeding disorders.2,3 However, in our study we found just as often 
haemostatic abnormalities in women with gynaecological abnormalities. These uterine abnormalities 
as fibroids may unmask a bleeding tendency. Hence haemostatic testing should also be considered in 
these cases.  In our cohort of women with menorrhagia we could not identify a specific or combination 
of non-menorrhagia bleeding symptoms as a predictor for an underlying bleeding disorder. On the 
other hand, Philipp et al developed a screening tool to select women with menorrhagia for haemostatic 
testing.4 However, they validated their screening tool in a population with a high prevalence of 71% 
of coagulation disorders.5 This remarkably high prevalence limits the generalizability of their tool in 
another population.6 Studies in the general population suggested that symptoms, like bleeding after 
tooth extraction, post-operative bleeding and postpartum bleeding, may be valuable to predict an 
inherited bleeding disorder.7 In our cohort these non-menorrhagia bleeding symptoms did not predict 
for an underlying bleeding disorder. We suggest therefore that clinicians have to consider haemostatic 
evaluation in patients with menorrhagia, independently of the presence or absence of other bleeding 
symptoms or gynaecological abnormalities.
VWD is the most common bleeding disorder in the general population, but testing for other 
haemostatic disorders than VWD should also be considered. As we showed, women with menorrhagia, 
with and without gynaecological abnormalities have also an increased prevalence of low FXI levels or 
platelet defects. 
Although 5-10% of the women of the general population have menorrhagia, there is no consensus 
on optimal management, even not for women with VWD. The goal of treatment is to improve quality 
of life by reducing the amount of blood loss during menstruation. Medical therapies for menorrhagia 
should be the first choice, including oral contraceptives, desmopressin, and antifibrinolytic agents, 
alone or in combination. However, it is not well studied what the benefits are of one formulation or 
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dosing strategy compared with another in the reduction of heavy menstrual bleeding especially in 
women with bleeding disorders. Kouides et al8 suggest that both DDAVP and tranexamic acid reduce 
the menstrual blood loss in women with bleeding disorders. When medical therapies fail, surgical 
options as endometrial ablation and hysterectomy are possible suitable options/choices when fertility 
is no longer desired. Until comparative studies become available, treatment should be based on the 
bleeding disorder, gynaecological abnormalities, age, contraceptive needs, reproductive plans and 
personal preference of the individual patient. 
 
Part II Bleeding issues in obstetrics
Part 2 of this thesis mainly described the clinical concerns and side-effects of the use of 
anticoagulants during pregnancy. Women with a history of a venous thrombo-embolism (VTE) have 
an increased  risk for a recurrent VTE during pregnancy.9, 10 These women have to use anticoagulants 
throughout the pregnancy and puerperium. This means that they have to inject themselves daily for 
about 10 months. Many of these women develop an aversion to these injections, often because of 
the hypersensitivity skin reactions. As we reported in our cohort of women who used LMWH during 
pregnancy, almost half of them developed hypersensitivity skin reactions during the use of nadroparin 
and had to switch to another preparation. Secondly, women on therapeutic dose of LMWH during 
pregnancy had an increased risk of PPH during vaginal and emergency caesarean section (CS) delivery. 
Taking these side-effects into account, it is important for each woman to make a good individual 
balance between the risk of VTE and the burden associated with anticoagulant therapy. Probably, 
a prophylactic or low dose instead of a therapeutic dose of anticoagulation during pregnancy might 
result in more net benefit in a subgroup of patients. The ACCP guidelines provide recommendations for 
VTE prophylaxis with LMWH for women who have an increased risk of VTE. However, these guidelines 
are mostly based on data from observational cohort studies in which the dosages of VTE prophylaxis 
were diverse and comparative groups were mostly lacking. 10-12 The optimal management for these 
patients is unknown and the guidelines offer different options. Therefore, it is not surprising that local 
hospitals use different treatment protocols. Consequently, it is important to have a treatment protocol 
in the local hospitals with  good collaboration between gynaecologists and haematologists to improve 
patient care. 
Implications for future research
The investigations described in this thesis support that bleeding disorders play an important 
role in the aetiology of women with menorrhagia. A novel finding of Chapter 3 is that women with 
menorrhagia have a significantly longer aPTT in patients compared to controls, apparently due to lower 
levels FXI in women with menorrhagia.  FXI is a coagulation protein essential to normal haemostasis, 
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which acts by cleaving coagulation factor IX. Women with low levels FXI (<70%) are prone to excessive 
bleeding during menstruation. Bleeding manifestations do not correlate well with the plasma levels 
of FXI activity and bleeding episodes can vary widely among patients with similar FXI levels. Recent 
studies suggest that the incidence of mild FXI deficiency in Caucasians may be higher than expected. 
Until now, more than 90 FXI gene mutations, associated with a FXI deficiency have been reported. 
Most of these mutations are found in the Jewish population, which has a relatively high prevalence 
of FXI deficiency. The presence of mutations in FXI gene in women with menorrhagia could probably 
lead to lower levels of FXI. In the future, we want to investigate the prevalence of FXI gene mutations 
or polymorphisms in women with menorrhagia and a control group of healthy female volunteers 
matched by age with normal menstrual blood loss without hormonal treatment.   
Another important function of FXI activation is to reduce fibrinolysis by promoting activation of 
thrombin activatable fibrinolytic inhibitor (TAFI). Loss or reduction of this normal pathway of inhibition 
in FXI deficiency fits well with the observation that FXI deficient individuals are prone to excessive 
bleeding after surgery or injuries to areas with high levels of fibrinolysis. But some individuals could 
have multiple defects, probably also in the fibrinolytic pathway. Therefore, it is conceivable that women 
with low levels of TAFI and FXI could have an increased bleeding tendency such as menorrhagia. In the 
future we want to investigate the role of the different fibrinolytic factors in women with menorrhagia. 
Because haemostatic testing is expensive and impractical to routinely perform in gynaecological 
practice, it would be useful to develop a screening tool to select women with a high a priori risk of 
a bleeding disorder. In our cohort, the subgroups of patients are now too small to reach statistical 
significance, therefore we want to enlarge our cohort of women with menorrhagia. Second, it would be 
useful to standardize the treatment of women with menorrhagia, especially in women with bleeding 
disorders. Therefore, we need more comparative studies to evaluate the different treatment options. 
Given the absence of studies about the optimal dosage of LMWH as thromboprophylaxis for women 
with an increased risk of VTE, a comparative trial of two different dosages of LMWH will improve 
patient care. Consequently, this will lead to more standardization in the treatment protocols of the 
different local hospitals and consequently national and international protocols. The main outcome 
of such a trial should be the effectiveness of the anticoagulation and the risk of VTE. The second 
outcomes should be the risk of side-effects like PPH and hypersensitivity skin reactions. Accordingly, 
the individual risk of side-effects as PPH and allergic skin reactions should be balanced with the risk of 
VTE. Maybe in a subgroup of patients a prophylactic dose of anticoagulation during pregnancy might 
result in more net benefit. 
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Part I Menorrhagia and bleeding disorders
Menorrhagia is a common gynaecologic problem in women of reproductive age, accounting for a 
considerable proportion of gynaecology referrals. Although a variety of gynaecologic, endocrine, or 
other systemic causes may be responsible, an underlying aetiology is identified in only 50% of cases.1 
Underlying bleeding disorders may play a role in women with menorrhagia. 
 Chapter 1 summarized the evidence for timing of haemostatic testing during the menstrual cycle 
in women with a suspected bleeding disorder. Studies that determined the cyclic variation of platelet 
function, von Willebrand factor, factor VIII, factor IX, factor XI, factor XIII, d-dimer, PAI-I, tPA, alpha-
2-antiplasmin and fibrinogen during normal menstrual cycle without hormonal contraceptives were 
systematically reviewed. In total, 1046 studies were identified of which 30 studies (25 longitudinal and 
5 cross-sectional studies) were included. Overall, most of the studies found no cyclic variation in von 
Willebrand factor, FVIII, FXI, FXIII, fibrinolytic factors (PAI, t-PA, uPA, d-dimer and α2-antiplasmin) and 
fibrinogen.  However, in studies where these variables showed any variation, they reached the lowest 
levels during menstrual and early follicular phase. This was most evident  for von Willebrand, Factor 
FVIII and platelet function tests. We concluded that the most sensitive timing for haemostatic testing 
during menstrual cycle seems to be menstrual and early follicular phase.
Chapter 2 reported the work-up of menorrhagia in routine gynaecological practice, with a special 
interest in haemostatic evaluation, and the outcome of individualized treatment in our centre. A 
retrospective medical chart review of consecutive patients referred for menorrhagia to the University 
Medical Centre of Groningen between January 2006 and January 2007 was performed. In April 2008, 
all women were contacted for a structured telephone interview evaluating the effectiveness of their 
therapy. In total, 112 patients were included, with a median age of 42 years. Twenty-nine percent 
were anaemic (hemoglobin <12.0 g/dL). Seventy-one (63%) had unexplained menorrhagia. Only two 
patients had haemostatic evaluation; Von Willebrand’s disease was excluded in both. Forty percent 
(29/71) needed two or more different therapies, 17% (12/71) needed three different therapies and two 
patients needed a total of seven different therapies. Eight patients underwent a hysterectomy, six of 
them after endometrial ablation. Most patients (80%) were successfully treated medically or surgically 
and were satisfied with their therapy during follow-up. Eleven patients declined therapy and accepted 
their heavy periods. In conclusion, haemostatic evaluation in women with unexplained menorrhagia is 
uncommon in gynaecological practice in our centre. Although most of the patients were satisfied with 
their treatment, a significant number required hysterectomy and another important proportion had to 
accept their menorrhagia. Therefore we hypothesized that the identification of haemostatic disorders 
might improve care for these women.
To follow up on these findings, Chapter 3 addressed the prevalence of bleeding disorders and 
symptoms in women with menorrhagia, with and without gynaecological abnormalities. Hundred-
and-two consecutive patients referred for menorrhagia between March 2007 and December 2010 
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were included. All underwent gynaecologic evaluation. Menorrhagia was confirmed by a pictorial 
bleeding assessment chart score above 100. Patients and controls (28 healthy volunteers without 
menorrhagia) had haemostatic testing in the 1st week after menstruation. Forty-six percent of 
patients were anaemic, 61% had low ferritin. Twenty-six percent of patients had endometrial polyps 
or submucosal uterine myoma, sufficient to explain menorrhagia. An underlying bleeding disorder 
was found in 29% vs 11% (p=0.04) of the patients vs controls, and in 31% vs 27% of the women 
with unexplained vs explained menorrhagia (p=0.75). We diagnosed 6 cases of VWD, 4 cases of FXI 
deficiency and one FVII deficiency. The only abnormalities found in controls were platelet aggregation 
defects (11% vs 23% in patients). Patients had a significantly longer aPTT compared to controls (26.5 
vs 25.0 sec; p=0.001) caused by lower median levels of FXI (100 vs 124 IU/dL; p<0.001). Although non-
menorrhagia bleeding symptoms were more prevalent in patients than in controls, additional bleeding 
symptoms did not predict for an underlying bleeding disorder. In conclusion, bleeding disorders play 
an equally important role in the aetiology of menorrhagia, in women with and without gynaecological 
abnormalities. A novel finding is the occurrence of low, but not deficient levels of factor XI.
In chapter 4 the gynaecological and obstetrical symptoms in an unselected cohort of women 
with moderate and severe VWD in the Netherlands were assessed, as part of the nation-wide 
‘Willebrand in the Netherlands (WiN) study. 423 women aged ≥16 years were included. Bleeding 
severity was measured using the Tosetto Bleeding Score (BS). Menorrhagia, defined as occurrence 
of ≥2 menorrhagia symptoms, was reported by 81%. Of all VWD women, 78% received any kind of 
treatment for menorrhagia and 20% underwent a hysterectomy predominantly because of severe 
menstrual bleeding. Over half of the women reported more blood loss than expected with a normal 
delivery. In 52% of reported pregnancy losses curettage was needed because of bleeding. Mean 
number of live births was 1.9, which is comparable with the general Dutch population. We concluded 
that women with moderate or severe VWD frequently have menorrhagia in need of treatment, with 
20% of the VWD women undergoing a hysterectomy. Bleeding complications occurred in over 50% 
of the women after childbirth or pregnancy loss. Progeny seems not to be affected in women with 
moderate or severe VWD.
Part II Bleeding issues in obstetrics
Low-molecular-weight heparins (LMWH) are the most commonly used anticoagulant during 
pregnancy for the treatment and prevention of venous thrombo-embolism (VTE). However, the size 
of the associated risk of postpartum haemorrhage (PPH) is unknown. Moreover, hypersensitivity skin 
reactions due to the use of LMWH are frequently seen, but are probably underreported in the literature. 
Chapter 5 and 6 addressed these complications of LMWHs during pregnancy. Chapter 5 assessed the 
bleeding risk of therapeutic dosage of LMWH, also in relation to time between last dose LMWH and 
delivery. In this study, we prospectively followed 88 pregnant women between 1999 and 2009 who 
used therapeutic anticoagulation. Controls were pregnant women without LMWH, matched 1:4 for 
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parity, mode of delivery, age, gestational age and delivery date. PPH was defined as >500 ml blood loss 
for vaginal delivery (severe PPH in vaginal delivery as >1000 ml) and >1000 ml for caesarean section 
(CS). Women were divided into subgroups by the interval between last dose of LMWH and delivery 
(<12, 12-24hrs, >24hrs). Risk of PPH after vaginal delivery was 30% and 18% for LMWH-users and non-
users, respectively (OR 1.9, 95%CI 1.1-3.5). Risk of severe PPH after vaginal delivery was not different 
(5.6 vs 5.0%; OR 1.1; 0.4-3.6). Risk of PPH after CS was 12% in LMWH-users and 4% in non-users (OR 
2.9; 0.5-19.4). Both events of LMWH-users occurred after emergency CS. The risk of PPH associated 
with delivery within 24 hours after last dose of LMWH was 1.2 fold higher (95%CI 0.4-3.6) compared 
to a larger interval. We concluded that therapeutic dosage of LMWH carries an increased risk of PPH 
after vaginal delivery. The interval between last dose of LMWH and delivery does not influence the risk 
of PPH. Chapter 6 evaluated, in the same cohort, the incidence of hypersensitivity skin reactions due 
to the use of LMWH in pregnancy, and the subsequent management of anticoagulation. All women 
were started on nadroparin and switched to another preparation when hypersensitivity skin reactions 
occurred. We included 135 pregnancies in 88 women. Overall, in 52 of 135 pregnancies (39%), women 
switched at least once to another anticoagulant due to the development of hypersensitivity skin 
reactions. Switching to another preparation of LMWH was effective in 77% of the cases. In 23% of 
the cases skin reactions recurred and another switch had to be made.  In a subgroup of women, 
it is necessary to ultimately switch to VKA or fondaparinux. Chapter 7 describes ten patients who 
used fondaparinux during 12 pregnancies between 2003 and 2010 because of hypersensitivity 
skin reactions. All women were followed prospectively. They initially used LMWH but developed 
hypersensitivity skin reactions. Two patients used fondaparinux during two pregnancies, both started 
in the 1st trimester of the 2nd pregnancy. In all other pregnancies, fondaparinux was started in the 
2nd or 3rd trimester. Fondaparinux was not associated with skin reactions or other side-effects. None 
of the 13 infants had congenital abnormalities or neonatal bleeding. Concluding, fondaparinux seems 
to be an alternative treatment for women who had allergic skin reactions to LMWH. Given the limited 
data, we do not recommend the use of fondaparinux in the 1st trimester. 
Chapter 8 evaluated the reproductive choices and obstetrical experiences in the current generation 
of carriers of haemophilia in our Haemophilia Centre in the north of the Netherlands, a largely secular 
country with liberal abortion laws and a unique tradition of home births. We performed a retrospective 
survey among haemophilia carriers. We sent a questionnaire to 74 carriers of whom 65 were available, 
and 75% responded. Median age was 41 (range 20–83) years. Of the 49 women, 46 experienced 120 
pregnancies: 25 resulted in fetal loss, two in pregnancy termination (one for haemophilia) and 93 in 
live births. No woman had chosen not to start a family. Mean number of children was 2.0, 2.4 vs. 1.8 
in women with and without sons with haemophilia (P = 0.008), respectively. Twenty women (20 of 
46) were unaware of their carriership during 1st pregnancy; they were younger at 1st pregnancy than 
known carriers (25 vs 29 years, P = 0.03). Twenty-three percent reported bleeding complications during 
the first delivery. Overall, 10% vs. 3% of deliveries were complicated by a primary and secondary PPH, 
respectively. In our Haemophilia Centre, carrier state has not influenced reproductive choices in the 
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past, other than older age at first pregnancy. Carriers of haemophilia have an increased risk of primary 
PPH.
 Thrombin-activatable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase, activated by thrombin, 
mainly in complex with thrombomodulin, and by plasmin that inhibits tissue plasminogen activator-
induced fibrinolysis.  Through this inhibition of fibrinolysis, high TAFI levels might enhance the 
development of thrombosis, and consequently placental thrombosis, which can be a cause of fetal 
loss.  On the other hand,  fetal loss may be also induced by apoptosis of trophoblasts due to high levels 
of fibrin degradation products.  Consequently, high TAFI levels, which inhibits fibrinolysis and gives 
accordingly less fibrin degradation products, could  also  reduce this risk, especially in women with 
thrombophilia who generate more thrombin. In chapter 9 this hypothesis was tested in women from 
4 family cohorts, originally designed to estimate the risk of venous thromboembolism, associated with 
either hereditary deficiencies of antithrombin, protein C or protein S, prothrombin 20210A, factor V 
Leiden, elevated factor VIII levels or hyperhomocysteinemia. In these women, the fetal loss rate was 
retrospectively assessed. We compared women with high TAFI levels (> 75th percentile, i.e. 115 U/dl) 
to women with normal TAFI levels. Of 1557 women, 843 (probands and relatives) were evaluable of 
whom 213 had high TAFI levels. Women with high TAFI levels and women with normal TAFI levels were 
comparable for age at time of first pregnancy (24 versus 24 years) and mean number of pregnancies 
(2.9 versus 3.0). Thrombophilic defects were equally distributed, excepted for high FVIII levels (48.1% 
versus 34.9%; p < 0.001). Fetal loss rates were lower in women with high TAFI levels. Total fetal loss 
rates were 22.5% vs 27.9% (odds ratio 0.72; 95 % CI, 0.49-1.07); early fetal loss rates 19.2% vs 24.9% 
(0.71; 0.48-1.05); total recurrent fetal loss rates 3.8% vs 7.9% (0.43; 0.19-0.96); and recurrent early 
fetal loss rates 2.8% vs 7.0% (0.38; 0.15-0.92). Our data provides evidence that high TAFI levels may 
protect against early and recurrent early fetal loss in women from families with thrombophilia. 
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Dit proefschrift gaat over stollingsstoornissen bij verschillende problemen in de gynaecologie en 
verloskunde. Ik heb zowel naar verhoogde bloedingsneiging, als naar problemen van trombose gekeken. 
De verschillende studies werden uitgevoerd bij vrouwen met menstruatieproblemen, vrouwen die 
bloedverdunners gebruikten tijdens de zwangerschap, vrouwen die zelf een bloedingsziekte hadden 
of die dit door konden geven aan hun kinderen en vrouwen met herhaalde miskramen. Met de 
resultaten van dit proefschrift kunnen patiënten beter geïnformeerd worden en in een aantal situaties 
ook beter behandeld worden. 
Deel 1 Menorragie en stollingsstoornisssen
 In deel 1 van dit proefschrift worden de verschillende aspecten van menorragisch bloedverlies 
en stollingsstoornissen beschreven. Menorragisch bloedverlies is hevig menstrueel bloedverlies, 
overeenkomend met meer dan 80 ml bloedverlies per menstruele cyclus, wat o.a. kan leiden tot 
bloedarmoede en een verminderde kwaliteit van leven. Ongeveer 10% van de vrouwen heeft last 
van hevige menstruaties, een deel van deze vrouwen wordt tenminste eenmaal door de huisarts voor 
een consult naar de gynaecoloog verwezen. Er zijn vele mogelijke oorzaken van hevig menstrueel 
bloedverlies, zoals een verstoring van de hormoonbalans, myomen (vleesbomen) en poliepen in de 
baarmoeder. De helft van de gevallen wordt echter maar verklaard door één van deze afwijkingen. 
Een andere oorzaak die in de laatste decennia steeds vaker gediagnosticeerd wordt zijn onderliggende 
bloedstollingsstoornissen. Bloedstolling is een buitengewoon complex proces waarbij vooral de 
bloedplaatjes en een groot aantal eiwitten in het bloed, de zogenaamde stollingsfactoren, betrokken 
zijn. Falen van de bloedstolling leidt tot een verhoogde bloedingsneiging, waarbij mensen langer 
bloeden dan normaal. 
 Onderliggende bloedstollingsstoornissen die tot nu toe beschreven zijn bij vrouwen met een hevige 
menstruatie zijn o.a. de ziekte van Von Willebrand, plaatjesaggregatiestoornissen en een verlaagde 
waarde van één van de stollingsfactoren. De ziekte van Von Willebrand is de meest voorkomende 
erfelijke bloedingsziekte. In de algemene populatie is 1 op de 1000 individuen aangedaan.  Van deze 
erfelijke afwijking in de bloedstolling bestaan verschillende typen en de mate van ernst kan variëren. De 
oorzaak is een verlaagd gehalte aan het stollingseiwit Von Willebrand Factor (VWF) of een abnormaal 
functionerend VWF. De ziekte komt voornamelijk tot uiting door slijmvliesbloedingen (vooral neus- en 
tandvleesbloedingen). Er bestaat een verhoogd risico op nabloedingen bij het trekken van kiezen, 
operaties en trauma’s. Bij vrouwelijke patiënten kan het leiden tot hevige bloedingen tijdens de 
menstruatie of na een bevalling. Een andere bloedstollingsstoornis is een plaatjesaggregatiestoornis. 
Hierbij is er een stoornis in het samenplakken van bloedplaatjes, wat nodig is om een goed stolsel te 
kunnen vormen. Een stoornis in deze onderlinge hechting kan leiden tot o.a. slijmvliesbloedingen, 
maar ook tot hevige menstruaties. 
 In hoofdstuk 1 wordt een systematisch overzicht gegeven van alle relevante onderzoeken die in 
de afgelopen 30 jaren stollingsfactoren gedurende de natuurlijke menstruele cyclus hebben gemeten. 
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In totaal werden 1046 studies gevonden, waarvan uiteindelijk 30 studies relevant bleken te zijn. De 
meeste studies lieten geen verandering zien van de verschillende stollingsfactoren als Von Willebrand 
factor, factor VIII, factor XI, factor XIII, fibrinolytische factoren en fibrinogeen gedurende de menstruele 
cyclus. Enkele studies lieten wel een cyclische verandering zien. Deze studies lieten een verlaging van 
factor VIII en Von Willebrand factor zien gedurende de eerste helft van de menstruele cyclus, oftewel 
de eerste 2 weken na de eerste dag van de menstruatie. Concluderend lijkt de beste timing voor 
stollingsonderzoek tijdens de menstruele cyclus de eerste helft te zijn, omdat je dan de meeste kans 
hebt dat je een verlaagde waarde van een stollingsfactor vindt. 
Eerder uitgevoerd onderzoek liet zien dat stollingsstoornissen mogelijk de oorzaak kunnen zijn van 
hevige menstruaties. Derhalve hebben wij in hoofdstuk 2 bestudeerd hoe vaak er in de klinische praktijk 
gedacht wordt aan onderliggende stollingsstoornissen bij vrouwen met hevige menstruaties en hoe 
vaak aanvullend stollingsonderzoek wordt verricht. Wij hebben in 2007 terugkijkend alle patiënten met 
hevige menstruaties onderzocht die in 2006 werden verwezen naar de polikliniek gynaecologie van 
het UMCG. Er bleek bij slechts 2 van de 102 patiënten aanvullend stollingsonderzoek te zijn verricht, 
beide patiënten hadden geen stollingsstoornis. In april 2008 werden alle 102 patiënten telefonisch 
benaderd voor een interview over de ingestelde therapie. De meeste patiënten (80%) werden succesvol 
behandeld en waren tevreden met de ingestelde behandeling. Echter, 40% hiervan bleek twee of meer 
behandelingen nodig te hebben gehad. De baarmoeder werd bij 8 patiënten verwijderd, bij 6 patiënten 
werd dit verricht nadat het baarmoederslijmvlies al was verwijderd. Elf patiënten werden niet meer 
behandeld en accepteerden de hevige menstruaties.  Concluderend is een groot deel van de patiënten 
tevreden met de ingestelde therapie, een deel echter pas nadat ze een baarmoederverwijdering 
hadden ondergaan. Een ander deel accepteerde de hevige menstruaties. Op basis van deze gegevens 
veronderstelden wij dat er ruimte was voor het optimaliseren van de behandeling voor deze patiënten, 
mogelijk door het identificeren van onderliggende stollingsstoornissen.
Daaropvolgend hebben wij een studie opgezet om het voorkomen van onderliggende 
stollingsstoornissen bij vrouwen met hevige menstruaties te onderzoeken. Daarvoor hebben wij in 
2007 de M(enstruatie)-poli opgezet in het UMCG. Alle patiënten die doorverwezen werden met hevige 
menstruaties, kregen voorafgaand aan het polikliniekbezoek een vragenlijst thuis gestuurd met o.a. 
vragen over de menstruatie en symptomen die kunnen passen bij een verhoogde bloedingsneiging. 
Hierbij gaat het om symptomen als hevige menstruaties vanaf de eerste menstruatie (=menarche), 
voorkomen van bloedneuzen, nabloedingen na operaties of bevallingen. Tijdens het polikliniekbezoek 
werd bij al deze patiënten gynaecologisch onderzoek verricht naar onderliggende gynaecologische 
afwijkingen zoals vleesbomen of poliepen, die ook kunnen zorgen voor hevige menstruaties. In 
hoofdstuk 3 worden de resultaten van deze studie beschreven. In totaal werden 102 patiënten 
geïncludeerd. Aanvullend werden ook 28 gezonde vrijwilligsters (= controlegroep) met normaal 
menstrueel bloedverlies gevraagd om mee te doen. Bij zowel de vrijwilligsters als de patiënten werd 
stollingsonderzoek verricht in de eerste week na de menstruatie. In 26% van de patiënten werd 
een onderliggende gynaecologische oorzaak (vleesboom of poliep) gevonden als oorzaak voor de 
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hevige menstruaties. Bij 46% van de patiënten bleek sprake van bloedarmoede. Een onderliggende 
stollingsstoornis werd bij 29% van de patiënten en 11% van de controles gevonden. We vonden bij 
6 patiënten de ziekte van Von Willebrand (VWD), 4 patiënten hadden een verlaagde factor XI en één 
patiënt had een verlaagde factor VII spiegel. Bij de gezonde controles werden alleen stoornissen 
in de functie van de bloedplaatjes gevonden. Verder werd bij de patiënten een significant langere 
aptt (=stollingstijd) gevonden, waarschijnlijk doordat de patiënten gemiddeld een significant lagere 
FXI spiegel hadden. Het hebben van een verhoogde bloedingsneiging op basis van symptomen, 
bijv. bloedneuzen, bleek in onze patiëntengroep geen voorspeller te zijn voor een onderliggende 
stollingsstoornis. Concluderend spelen onderliggende stollingsstoornissen een belangrijke rol 
bij vrouwen met hevige menstruaties, dus adviseren wij bij deze patiënten een onderliggende 
stollingsstoornis overwogen moet worden als mogelijke oorzaak.   Von Willebrand ziekte (VWD) is 
een erfelijke stollingsafwijking die even vaak voorkomt bij mannen als bij vrouwen. Echter bij vrouwen 
met VWD geeft de ziekte eerder klachten door vrouwspecifieke symptomen als hevig menstrueel 
bloedverlies en bloedingen bij de bevalling. 
 In hoofdstuk 4 zijn de gynaecologische en obstetrische klachten bij vrouwen met matig-ernstige 
of ernstige VWD bestudeerd. Deze studie is een onderdeel van het grote Willebrand in Nederland 
(WiN) onderzoek.  De studie omvatte 432 vrouwen, ruim 80% van hen had last (gehad) van hevige 
menstruaties. Bijna al deze vrouwen gebruikten of hebben eerder hormonale anticonceptiva 
(hormoon therapie, de pil of Mirena) gebruikt om de hoeveelheid menstrueel bloedverlies te doen 
verminderen. Tevens had 20% van de vrouwen een baarmoederverwijdering ondergaan en bij de 
vrouwen boven de 40 jaar was dit zelfs 28%. Een baarmoederverwijdering werd vaker gecompliceerd 
door een bloeding als de diagnose VWD ten tijde van de operatie nog niet bekend was. Ook daarom 
is het erg belangrijk dat gynaecologen onderliggende stollingsafwijkingen in overweging nemen 
bij vrouwen met menorragisch bloedverlies. Verder zijn er voor patiënten met een onderliggende 
stollingsstoornis andere aanvullende behandelopties beschikbaar die de bloedstolling activeren. 
Desmopressine en tranexaminezuur zijn medicamenten die de bloedstolling beïnvloeden waarmee 
de hoeveelheid bloedverlies tijdens de menstruatie verminderd. Verder had meer dan de helft van de 
vrouwen met VWD overmatig bloedverlies tijdens de bevalling. Dit werd gedefinieerd als meer dan 
de verwachte hoeveelheid bloedverlies. De vrouwen met VWD bleken ook vaker een bloedtransfusie 
nodig te hebben in vergelijking met de algemene populatie. Het gemiddeld aantal levendgeborenen 
was 1.9 per vrouw, dit is vergelijkbaar met de algemene populatie. Dit suggereert dat vrouwen met de 
ziekte van Von Willebrand, ondanks de bloedingsproblemen, net zo veel kinderen krijgen als andere 
vrouwen.  
Deel 2 Bloedingsproblemen in de verloskunde 
In deel 2 van dit proefschrift worden o.a. de verschillende complicaties van het gebruik van 
bloedverdunners in de vorm van laag moleculair gewicht heparines (LMWH) in de zwangerschap 
beschreven. LMWH is het middel van 1e keus bij zowel behandeling als preventie van veneuze trombo-
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embolieën tijdens de zwangerschap. Het risico op een bloeding na de bevalling hierbij is echter niet 
goed bekend. Tevens hebben patiënten vaak last van allergische huidreacties als gevolg van het 
dagelijks spuiten van de LMWH. 
 In hoofdstuk 5 en 6 beschrijven wij de complicaties van het gebruik van bloedverdunners tijdens 
de zwangerschap. In hoofdstuk 5 wordt het risico op een bloeding na de bevalling onderzocht bij 
vrouwen die tijdens de zwangerschap een hoge dosering bloedverdunners gebruikten. Verder 
onderzochten wij of het tijdstip waarop de laatste gift van de bloedverdunner was gegeven invloed 
had op de hoeveelheid bloedverlies. Voor dit onderzoek hebben wij alle vrouwen die tussen 1999 en 
2009 in het UMCG bloedverdunners kregen tijdens de zwangerschap geïncludeerd. Deze vrouwen 
werden zowel op de afdeling verloskunde als ook op de afdeling stolling gezien. Daarnaast hebben we 
een controle groep geïncludeerd. Dit waren vrouwen die geen bloedverdunners gebruikten, maar die 
in dezelfde periode in het UMCG zijn bevallen. Een bloeding na de bevalling (PPH) werd gedefinieerd 
als meer dan 500 ml voor een vaginale bevalling en als meer dan 1000 ml voor een keizersnede. Een 
ernstige PPH werd gedefinieerd als meer dan 1000 ml na een vaginale bevalling. Het risico op een 
PPH bleek 1.9 hoger voor vrouwen die bloedverdunners gebruikten rond een vaginale bevalling. Het 
risico op een ernstige PPH na een vaginale bevalling bleek niet verhoogd te zijn tijdens het gebruik van 
bloedverdunners. Het risico op een PPH na een keizersnede was 12% in de groep die bloedverdunners 
gebruikten vergeleken met  4% in de controle groep. Alle bloedingen werden echter gerapporteerd 
in de groep die een spoed-keizersnede ondergingen. Het risico op een PPH was niet verder verhoogd 
indien patiënten binnen 24 uur na de laatste gift LMWH bevielen.
 In hoofdstuk 6 wordt in hetzelfde cohort de incidentie van allergische huidreacties als gevolg van 
het gebruik van bloedverdunners tijdens de zwangerschap bestudeerd. Alle vrouwen startten met 
nadroparine, een bloedverdunner in de vorm van een LMWH, en switchten naar een ander middel als 
zij een allergische huidreactie ontwikkelden. We includeerden hiervoor 135 zwangerschappen van 88 
vrouwen. In 52 van de 135 zwangerschappen (39%) moesten de vrouwen tenminste een keer switchen 
naar een ander preparaat i.vm. een allergische huidreactie. Het switchen was effectief in 77% van de 
gevallen. Derhalve concludeerden wij dat allergische huidreacties vaak voorkomen bij het gebruik van 
LMWH in de zwangerschap, maar het switchen naar een ander middel lijkt hierbij zinvol. 
 In hoofdstuk 7 beschrijven we 12 zwangerschappen waarin fondaparinux als bloedverdunner 
werd gegeven in de zwangerschap. Fondaparinux is een alternatief antistollingsmiddel dat gebruikt 
werd indien patiënten allergische huidreacties hadden op meerdere LMWH preparaten. Er is  nog 
weinig ervaring met dit middel bij zwangere vrouwen. Fondaparinux gaf in deze zwangerschappen 
geen allergische huidreacties. Ook werden geen aangeboren afwijkingen en bloedingen bij de 
pasgeborene gerapporteerd. Fondaparinux lijkt een goede alternatieve antistollingsbehandeling in de 
zwangerschap, echter gezien de beperkte ervaring  adviseren wij nog steeds om dit middel niet te 
geven in de eerste drie maanden van de zwangerschap. 
 Hemofilie is een zeldzame geslachtsgebonden erfelijke bloedingsziekte. Vrouwen uit families 
waarin hemofilie voorkomt en die via de vrouwelijke lijn verwant zijn aan een hemofilie patiënt 
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hebben a priori een verhoogde kans om draagster te zijn. Draagsters kunnen een verhoogd risico 
op bloedingen hebben. Verder hebben zij 50% kans dat als zij een zoon krijgen, die zoon hemofilie 
heeft.  Er zijn twee typen hemofilie. Bij hemofilie A is er sprake van een tekort aan stollingsfactor VIII 
en bij hemofilie B is er sprake van een tekort aan stollingsfactor IX. In hoofdstuk 8 evalueren wij de 
verloskundige ervaringen in de huidige generatie draagsters hemofilie A en B. Hiervoor benaderden 
wij alle draagster hemofilie A en B (n=74) die bekend waren in onze kliniek, 75% van de draagsters 
respondeerden. De mediane leeftijd was 41 jaar. 46 van de 49 draagsters waren ooit zwanger geweest 
met in totaal 120 zwangerschappen. Het gemiddeld aantal kinderen was 2.0. De draagsters met een 
zoon met hemofilie hadden gemiddeld minder kinderen dan de draagsters zonder een kind met 
hemofilie (1.8 in vergelijking met 2.4). Twee vrouwen besloten om de zwangerschap af te breken, 
één vanwege hemofilie. In totaal bleken 20 draagsters tijdens de eerste zwangerschap niet op de 
hoogte te zijn van hun draagsterschap. Zij waren dan ook jonger tijdens hun eerste zwangerschap in 
vergelijking met draagsters die dit wel wisten. (25 in vergelijking met 29 jaar) In 23% van de gevallen 
werd de bevalling van het eerste kind gecompliceerd door een bloeding na de bevalling. Bij 10% van 
alle bevallingen trad de bloeding binnen de eerste 24 uur en in 3% meer dan 24 uur na de bevalling op. 
Wij concludeerden dat draagsters van hemofilie even veel kinderen lijken te krijgen als de algemene 
populatie, de leeftijd  ten tijde van het eerste zwangerschap lijkt alleen hoger te zijn. Verder hebben 
draagsters een verhoogd risico op een bloeding na de bevalling. 
 Trombine-geactiveerde fibrinolyse remmer (TAFI) is een stollingseiwit dat de fibrinolyse remt. 
Fibrinolyse is het proces waarbij een bloedstolsel langzaam wordt afgebroken.  Omdat TAFI de 
fibrinolyse remt, kan dit leiden tot trombose en daardoor ook tot  trombose in de placenta wat weer 
kan leiden tot een miskraam. In hoofdstuk 9 wordt het risico op (herhaalde) miskraam bij vrouwen 
met een hoge TAFI spiegel beschreven. Deze vrouwen zijn afkomstig uit een grote groep van families 
met een verhoogd trombose risico vanwege een erfelijke of verworven stollingsafwijking. Dit kon 
een deficiëntie van antitrombine, proteïne C of proteïne S, protrombine G20210A mutatie, factor V 
Leiden, hoge factor VIII spiegels of hyperhomocysteïnemie zijn. De miskramen werden terugkijkend 
onderzocht. We  vergeleken vrouwen met een hoge TAFI spiegel (> 115 U/dl) met vrouwen met een 
normale TAFI spiegel. Er konden 843 vrouwen mee doen in deze studie. In totaal hadden 213 vrouwen 
een verhoogde TAFI spiegel. Het gemiddeld aantal zwangerschappen was vergelijkbaar in beide 
groepen. Echter het aantal miskramen was lager in de groep vrouwen met hoge TAFI spiegels (22.5 
versus 27.9 %). Ook het aantal vrouwen met een herhaalde miskraam (>2) was significant lager in de 
groep vrouwen met een hoge TAFI spiegel (3.8 versus 7.9%).  Concluderend, in tegenstelling met wat 
we hadden verwacht, beschermen hoge TAFI spiegels dus mogelijk tegen een vroege en een herhaalde 
vroege miskraam.  
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